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Abstract 
Lifelong infection by human herpesviruses have established their ubiquity in almost all 
communities and almost all species. Varicella Zoster Virus (VZV), an alphaherpesvirus 
within this family, is the causative agent of chickenpox (varicella) and shingles (herpes 
zoster). VZV is capable of influencing the host immune system through evasion of immune 
recognition and subversion of the immune response. This modulation is predicated upon 
the susceptibility of immune cells to VZV infection, in particular dendritic cells (DCs) and T 
lymphocytes which are presumed to facilitate the widespread dissemination of VZV 
throughout the host. However, the underdeveloped knowledge regarding the susceptibility 
of other immune cells has likely contributed to our limited understanding of the full 
capacities for VZV to evade the immune system. Human monocytes and macrophages are 
integral to the recognition and resolution of viral infections. In particular, human monocytes 
are highly abundant in circulation and generate site-specific DCs and macrophages in 
many tissues. There has been little consensus regarding the susceptibility of these cells to 
VZV infection and the impact infection may have on these innate immune cells.  
This study is the first to comprehensively identify the productive VZV infection of human 
monocytes and macrophages. Monocytes in particular were observed to harbour infectious 
virus in the nucleus and along the cell-surface of VZV infected cells by electron microscopy. 
VZV infected monocytes were also able to transfer infectious virus to permissive fibroblasts, 
suggesting that monocytes may be a source of viral dissemination in vivo. Furthermore, 
monocyte-derived macrophages were generated and demonstrated to also be susceptible 
to productive VZV infection. These results provided a useful means to interrogate the 
impacts of VZV infection on human monocytes and macrophages.  
In-depth characterisation of monocytes and macrophages by flow cytometry revealed the 
alteration of cell-surface immune molecules following VZV infection and exposure to VZV. 
These analyses revealed the novel selective downregulation of multiple immune markers 
that reflected the potential functional impact of VZV infection in these cells. Specifically, 
VZV infection of human monocytes downregulated markers essential in differentiation and 
recognition of microbial ligands. VZV infection of macrophages was associated with 
downregulation of immune markers regulating endocytosis. These cell-surface alterations 
were the basis for further examination into the functional consequences for VZV infection 
of monocytes and macrophages.  
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The susceptibility of both monocytes and macrophages to VZV infection was also 
associated with multiple functional modulations. VZV infected monocytes exhibited 
diminishing viability as differentiation of VZV infected monocytes did not generate viable 
macrophages. This result suggests that the renewal of monocyte-derived cells may be 
compromised during VZV infection. Monocytes and macrophages were also unable to 
endocytose environmental antigen suggesting an impact of VZV on the antigen 
presentation pathway. Further investigation into inflammatory cytokine release 
demonstrated that VZV infection of monocytes significantly limited the release of 
inflammatory interleukin 1-beta (IL-1β) and IL-18, whereas release of tumour necrosis factor 
(TNF) was unchanged. These results clearly demonstrate that VZV infection of human 
monocytes and macrophages induces functional changes with far-reaching implications 
for these cells in their recognition and response to viral infections.  
Overall, this study highlights the susceptibility of a highly abundant and dynamic system of 
innate immune cells to VZV infection and provides novel identification of multiple strategies 
through which VZV is able to control the immune system.  
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1. Introduction 
Through hundreds of millions of years of co-evolution with humans and animals, and the 
establishment of lifelong infection, herpesviruses have obtained extensive global 
prevalence and at least one herpesvirus can be found within almost all species (1). One 
such herpesvirus, Varicella Zoster Virus (VZV), is a ubiquitous alphaherpesvirus 
characterised by its highly infectious nature and lifelong infection (2). Primary varicella 
infection (chickenpox) is disseminated throughout the host via infection of circulating 
immune cells (3) and can spread to the peripheral nervous system (4) where it establishes 
lifelong latency. Reactivation of VZV from latency causes herpes zoster (shingles) which is 
associated with intense neuropathic pain, that can last for months to years following 
resolution of disease (5). The aetiology of VZV disease is predicated upon extensive viral 
modulation of the immune response to infection, and these mechanisms have been 
demonstrated to aid in persistence of the virus, dissemination throughout the host, and 
establishment of lifelong latency (6-8). Expanding our understanding of how VZV infects 
and evades the host immune system will provide unique insight into the underlying 
mechanisms controlling infection.  
1.1. Herpesviridae 
The Herpesviridae family comprises over 130 viruses which can infect a vast range of 
species (9). All members share a linear double-stranded DNA (dsDNA) genome 125-290 
kilobase pairs (kbp) in size surrounded by a proteinaceous layer known as the tegument, 
and a lipid envelope studded with membrane-bound viral proteins (9, 10). All herpesviruses 
undertake three distinct phases of infection: lytic infection, latent infection, and reactivation 
(11). This family of viruses is subdivided into three sub-families, Alphaherpesvirinae, 
Betaherpesvirinae, and Gammaherpesvirinae (12), of which, nine herpesviruses have 
humans as a natural host. Human alphaherpesviruses comprise Herpes simplex virus type 
1 and 2 (HSV-1; HSV-2), and VZV, and can be characterised by their latent infection of 
neuronal ganglia (13). Human betaherpesviruses include Human cytomegalovirus (HCMV), 
Human herpesvirus 6A and 6B (HHV-6A; HHV-6B), and Human herpesvirus 7 (HHV-7), and 
typically undertake latent infection of reticuloendothelial and myeloid progenitor cells (14, 
15) and salivary glands (16). Gammaherpesviruses comprise Epstein-Barr virus (EBV) and 
Kaposi’s sarcoma-associated herpesvirus (KSHV), which generally target lymphoid cells, 
such as T and B cells, as sites for latent infection (17, 18). 
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1.2. Varicella Zoster Virus 
1.2.1. VZV Pathogenesis & Clinical Manifestations 
Clinical studies have provided valuable insights into the transmission and dissemination of 
VZV in vivo, however, as VZV is a human-restricted pathogen, the field currently lacks a 
small animal model which replicates all stages of infection (19, 20). However, some animal 
models have contributed a considerable amount to our understanding of VZV 
pathogenesis. One such model utilises the engraftment of human tissues, such as skin and 
dorsal root ganglia (DRG), in humanised mice with severe combined immunodeficiency 
mutations (SCID) known as the SCIDhu model (21-27). Earlier studies utilised mousepox 
infection as a guide for the pathogenesis of VZV disease (28). As such, the current model 
of VZV pathogenesis is the culmination of in vivo clinical studies, small animal models, and 
in vitro experimentation.  
Varicella 
Primary VZV infection is contracted through exposure to highly infectious vesicular fluid 
from cutaneous lesions of people undergoing acute VZV infection, either by direct contact, 
or inhalation of aerosolised particles (29, 30). It was originally believed that infectious 
respiratory droplets facilitate transmission of the virus (31, 32). However, viral titres are 
relatively low prior to rash onset whereas high viral titres are typically observed immediately 
following appearance of the rash suggesting primary transmission through infectious 
particles from varicella (reviewed in 3). Infection of the upper respiratory tract is mediated 
by replication of the virus in the epithelial mucosa prior to accessing the lymphoid tissue of 
the tonsils and lymph node (33) (Figure 1.1). As dendritic cells (DCs) have been 
demonstrated to be susceptible to VZV infection in vitro, it is postulated that respiratory 
DCs at the site of infection are the first immune cells to undergo infection and facilitate 
spread of the virus to other immune cells, predominantly T cells (23, 34-37). This then 
results in the first phase of viraemia, which is thought to be facilitated by the susceptibility 
of multiple circulating immune cells to infection, including T cells, B cells, and more recently 
natural killer (NK) cells (23, 38-40). This concept is further supported by detailed analyses 
of VZV infected T cells, demonstrating the remodelling of T cells which would allow them 
to mediate spread of VZV to the skin (7). These events, among other immunomodulatory 
effects of VZV infection (Section 1.4.3), are presumed to occur within an incubation period 
of 14-21 days during which time there is no detectable symptoms of VZV disease (41).  
Figure 1.1: Pathogenesis of Varicella Zoster Virus. Initial infection is mediated by inhalation 
of highly infectious particles from patients undergoing acute varicella infection. (A) Inoculation 
of the respiratory epithelial mucosa results in infection of site-specific DCs. (B) Infected DCs 
traffic to lymph nodes where they encounter T cells and transmit infectious virus. (C) Infected 
T cells have been suggested to migrate haematogenously and facilitate viral infection of the 
skin and the sensory neurons of the dorsal root ganglia (DRG) to mediate latent infection. (D) 
Viral infection of the skin results in the characteristic varicella rash, as neurons from ending 
nerve terminals in the skin are productively infected. (E) Retrograde axonal spread of VZV to 
the DRG in combination with the suggested direct T cell trafficking of the VZV, results in lifelong 
latent infection. (F) Throughout the lifetime of the latently infected host, VZV has the potential to 
reactivate, resulting in anterograde spread of the virus to the dermatome the latently infected 
ganglia innervates, resulting in the characterstic herpes zoster rash.
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During this time, VZV is thought to spread to multiple organs, such as the liver and spleen 
(42-44), and undergo replication prior to a second round of viraemia and symptomology 
within one to two weeks of initial infection (45).  
Acute varicella sometimes presents with initial symptoms of fever and malaise (46), which 
rapidly develops into the characteristic chickenpox rash. This rash is maximally distributed 
across the trunk and consists of small, maculopapular and pruritic lesions (47). Within 12-
72 hours of rash onset, these lesions will form pustules, from which infectious virus may be 
spread (47). After 7-14 days from lesion onset, the rash resolves as the lesions crust over 
and are shed by sloughing (48). Although complications from acute infection are rare, the 
most common complications predominantly involve secondary bacterial infections and 
pneumonias which can lead to life-threatening infections (45). In rarer cases, vasculopathy, 
myelopathy, and neuropathies may result from acute infection (reviewed in 49, 50).  
At some stage during primary infection, the virus gains access to the sensory neurons in 
the dorsal root ganglia (DRG) and enters a latent infectious state (4, 51). This is thought to 
be facilitated by retrograde axonal transport of virions through nerve terminals ending in 
the afflicted skin (52-54), and also contributed to by direct haematogenous transmission 
by infected immune cells infiltrating the ganglia (27, 51) (Figure 1.1). 
Herpes Zoster 
VZV latency is established in the DRG during primary varicella infection. Herpes zoster is a 
dermatomal neuro-cutaneous disease which results from the reactivation of VZV from its 
latent state in sensory ganglia (41). Although incidence of herpes zoster is understood to 
correlate with increasing age, it is thought that VZV may reactivate sub-clinically over the 
lifetime of the host and remain under immune control without evident disease (47). It is well 
established that VZV reactivation is the result of diminishing VZV-specific T cell mediated 
immunity (55, 56), and not as a result of decreasing anti-VZV antibody titres (57, 58). Herpes 
zoster prodrome includes mild fever, malaise and progresses to a regional and dermatome-
restricted vesicular rash (46) associated with burning and itching pain (49). Similar to 
varicella infection, the herpes zoster rash is often pruritic and progresses from papular to 
vesicular lesions within 3-5 days, prior to crusting after 7-10 days (59, 60). Disseminated 
herpes zoster, characterised by multiple lesions in adjacent or non-primary dermatomes, 
can sometimes occur in patients with immunosuppression (48). However, in most patients, 
amelioration of skin lesions and complete resolution of disease typically occur within 4-6 
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weeks. Other than disseminated disease, most complications of herpes zoster infection are 
associated with severe neuropathies and ophthalmic complications that may also arise 
from primary varicella infection, although the subsequent risk of developing post-herpetic 
neuralgia (PHN) is unique to herpes zoster (61, 62).  
Post-Herpetic Neuralgia  
The most common complication following reactivation to herpes zoster is post-herpetic 
neuralgia (PHN) and incidence increases dramatically with age, as 80% of all cases occur 
in those aged 50 years or older (62-64). PHN is a severe neuropathic pain that persists 
months to years following resolution of the herpes zoster rash, however the underlying 
mechanism of pain is poorly understood (65). Three non-conflicting theories have been 
proposed to explain the mechanisms responsible for PHN: a) ganglionic neurons have 
altered excitability following reactivated infection and are firing aberrantly (66), b) there 
exists persistent productive VZV infection in latently infected ganglia (66-68), and, c) viral 
gene and/or protein synthesis in the absence of replicative virus may be disrupting neuronal 
physiology (69). Interestingly, antiviral treatment has shown to be effective in reducing 
acute symptoms of herpes zoster and subsequent risk of PHN if administered within 72 
hours (70). Although, further studies have provided little evidence to support changes in 
incidence, severity, or duration of chronic PHN with antiviral treatment outside of this time 
period (71, 72).  
1.2.2. Epidemiology 
Primary varicella infection results in lifelong latent infection, which has the potential to 
develop into herpes zoster later in life. The highly infectious nature of VZV during primary 
and reactivated infection, in combination with one-third of latently infected individuals 
reactivating over their lifetime, has firmly established the worldwide distribution of VZV (30, 
64). Although no strict seasonal distribution or association with climate have been 
recognised, more than 90% of children in temperate climates are VZV seropositive by the 
age of 10 (73). The proportion of seropositive individuals is however lesser in tropical and 
subtropical areas (74). Those at risk of life-threatening acute VZV infection are generally 
patients without underlying immunity, such as immunodeficient or immunosuppressed 
individuals, although seronegative adults, pregnant women, young infants from 
seronegative mothers, and unborn children exposed to maternal varicella also are at high 
risk (75, 76). Prior to the implementation of VZV vaccination, acute infection was associated 
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with 8 deaths and 1500 hospitalisations per year in Australia (77, 78) The causal 
complications associated with hospitalisation generally include bacterial infections of the 
skin and respiratory tract, as well as rarer incidence of cerebellitis and encephalitis (79). 
The adoption of varicella vaccination strategies has resulted in high coverage in children 
and adolescents (80), and has reduced the rate of disease in some areas by more than 
70% (81) (Section 1.2.3).  
Although current data may be limited by underreporting of mild disease, reactivation of VZV 
from latency causes herpes zoster and has an incidence of 4-4.5 per 1000 person-years, 
with the vast majority of herpes zoster cases occurring in individuals over 50 years of age 
(63, 64, 82). Of these patients, between 3-6% of herpes zoster cases result in 
hospitalisation (82, 83). Incidence of PHN from herpes zoster is dependent upon age (82). 
10-18% of those aged over 50 years and 33% of those aged over 80 years generally 
develop PHN, whereas PHN is rare in patients under 30 years of age (62-64, 84). The 
funding allocated to managing primary VZV infection and treatment of patients undergoing 
reactivation to herpes zoster and PHN has contributed to a heavy socio-economic burden 
on the healthcare system (85). As incidence of VZV disease has been observed to increase 
with age, this burden is also expected to increase over time as the result of an ageing 
population (86). 
1.2.3. Vaccination  
Varicella 
The first successfully developed vaccine protective against primary varicella infection was 
derived from an attenuated clinical isolate in 1974 (87). Serial propagation of the ‘Oka’ strain 
through cells of human and guinea pig origin resulted in attenuation, although the molecular 
mechanism(s) underpinning this process are incompletely understood (88). This strain has 
contributed to multiple live attenuated vaccines, such as Varivax (Merck) and Varilrix 
(GlaxoSmithKline), as well as a vaccine for herpes zoster, Zostavax (Merck) (89). 
Vaccination in Australia is nationally scheduled at 18 months of age (90) and has been 
demonstrated to protect 70-90% of vaccinated individuals from infection and is 
accompanied by 90-100% reduction in severity of disease (91, 92). Vaccination is not 
recommended in immunodeficient or immunosuppressed individuals due to the risks of 
developing herpes zoster post-vaccination, rather passive immunity via immunoglobulins 
directed against VZV is suggested (93, 94). Although the risk is low, breakthrough VZV 
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disease, characterised by wild-type infection of vaccinated individuals, does occur (95). 
This is generally attributed to external influences which impede the adequate induction of 
immunity, such as asthma, prolonged steroidal usage, and errors in administration (96, 97). 
Herpes Zoster 
Reactivation to herpes zoster is presumably attributed to waning of VZV-specific T cell 
mediated immunity (98) and not as the result of decreasing anti-VZV antibody titres (57, 
58). Therefore, for successful implementation of a herpes zoster vaccine, there must be a 
strong induction of adaptive T cell responses following vaccination. The currently available 
vaccine in Australia is a live attenuated concentration of the Oka strain, Zostavax (Merck), 
and is scheduled for individuals over 70 years of age (90). Zostavax has been demonstrated 
to reduce incidence of disease by 65% in 50-59 years old, by 50% in 60-69 years old, and 
by <40% in 70+ years old individuals (99, 100). The decrease in protection is associated 
with a rapid decline in the induced cell-mediated immunity, which is critical in controlling 
reactivation (101). A recently developed, novel subunit vaccine, Shingrix (GlaxoSmithKline) 
has been licensed in the United States, and is associated with a 90% reduction in risk of 
developing herpes zoster in those aged 60 years and older (64, 102, 103). This subunit 
vaccine is comprised of surface VZV glycoprotein E (gE) in combination with an adjuvant 
acting as a toll-like receptor 4 (TLR4) agonist and increasing antigen retention in DC 
populations (104, 105). To date, Shingrix is yet to be licensed for administration in Australia. 
1.2.4. VZV Genome Structure and Organisation 
The genomic organisation of VZV constitutes four independent structural components: a 
dsDNA-containing core, a contiguous nucleocapsid, a matrix of viral proteins known as the 
tegument, and an outer envelope studded with viral proteins (9) (Figure 1.2). The 125 kbp 
dsDNA genome is comprised of a 105 kbp unique long (UL) region, a unique short (US) 
region of 5 kbp with internal repeats (IR) and terminal repeat (TR) regions (106-108). In 
comparison to other herpesviruses, the VZV genome is remarkably genetically stable in 
culture (109, 110). The VZV genome encodes genes from at least 71 independent open 
reading frames (ORFs) with three regions, ORF62, ORF63, and ORF64, duplicated at 
ORF70, ORF71, and ORF69, respectively (41, 111). It has been demonstrated that nearly 
two-thirds of VZV ORFs are required for viral replication in vitro and nearly 40% of the viral 
genome are conserved across all herpesviruses (41, 112).  
 
Figure 1.2: VZV virion organisation. (A) Schematic representation of the VZV virion. The VZV 
genome is a 129 kbp dsDNA contained within a viral nucleocapsid. Surrounding the 
nucleocapsids is fibrous layer of viral tegument proteins, that contains multiple immediate-early 
proteins and viral kinases. The genome and tegument are contained within a viral envelope that 
is studded with multiple distinct viral glycoproteins. These glycoproteins are distributed within 
the viral envelope to facilitate viral entry into new cells. (B) Scanning electron microscopy (SEM) 
of VZV virions (arrows) on the surface of infected human foreskin fibroblasts (HFF). (C) SEM 
of non-enveloped VZV virions (arrows) measuring between 180-200 nm within the nucleus of 
infected HFF. Images acquired by Jarrod J. Kennedy with assistance from the Australian Centre 
for Microscopy and Microanalysis, University of Sydney. 
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The fibrous tegument layer contains several putative viral proteins (reviewed in 113), 
although consensus indicates proteins derived from immediately-early (IE) genes ORF4, 
ORF62, and ORF63 are present (114), in conjunction with viral kinases encoded by ORF47 
and ORF66 (25, 115). The VZV genome encodes nine viral glycoproteins, gK, gN, gC, gB, 
gH, gM, gL, gI, and, gE (116). Multiple distinct glycoproteins are distributed within the viral 
envelope to facilitate viral entry into new cells (117). A fully enveloped VZV virion measures 
approximately 180-200 nm in diameter (118).  
1.3. VZV Life Cycle 
Infection with VZV progresses through three clinically distinct phases of disease (119). 
Primary varicella is characterised by productive infection, extensive gene expression and 
infectious virus production (41). Latent infection, established during primary varicella, is 
generally associated with a decline in viral genome copies and undetectable levels of 
infectious virus (41). Reactivation of latent VZV to result in herpes zoster is characterised 
by an increase in viral genome copies and transportation of the virus from the site of latency 
to the skin (119). 
1.3.1. Viral Entry 
The VZV entry process is incompletely understood, however it has been reported to involve 
a combination of fusion between virions and the plasma membranes of target cells, and, 
endocytosis of complete virions (120-122). Viral entry is presumed to be initially mediated 
by cell-surface heparan sulfate moieties, non-specifically binding negatively charged viral 
glycoproteins, such as gB (123). This low-affinity interaction is thought to allow subsequent 
specific and more stable interactions between viral entry ligands and cognate entry 
receptors to occur (124). Unlike HSV-1 entry, which utilises binding of gD to multiple 
independent entry receptors (125), VZV does not encode a functional gD homolog, nor 
specific viral entry ligand (126). Many putative cellular entry receptors have been reported. 
The cation-independent mannose 6-phosphate receptor (MPRCI) has been previously 
suggested to mediate viral entry through interaction with N-linked oligosaccharides 
moieties in viral glycoproteins gB, gE, gH and gI (127). Treatment of permissive cells with 
mannose 6-phosphate (M6P) prior to exposure to cell-free VZV (CF-VZV) inhibited infection, 
however, these cells remain susceptible to infection with cell-associated VZV (CA-VZV) 
(128, 129). Another putative VZV entry receptor, insulin-degrading enzyme (IDE), was 
reported to interact with VZV gE to mediate entry (130). Although, further assessment of 
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this interaction revealed IDE associates with immature forms of gE within the endoplasmic 
reticulum alone, suggesting that IDE is unlikely to mediate viral entry (131). Viral entry 
through gB interaction with myelin-associated glycoprotein (MAG) has also been 
speculated, however expression of this receptor is general restricted to neuronal cells (120). 
In relation to these studies, there has yet to be a putative entry receptor that has been 
demonstrated to be essential for viral entry into all permissive cell types (116). Once stable 
binding of the virion to the target cell is established, VZV utilises a combination of gB, gH, 
and gL as core proteins for fusion with the plasma membrane (132). VZV virions are 
subsequently uncoated and viral nucleocapsids enter the host cell nucleus at nuclear pores 
allowing for injection of viral genomes (133). After entry into the nucleus, tegument proteins 
are free to initiate viral protein transcription (2, 134).  
1.3.2. Viral Gene Expression and Replication 
VZV gene expression and replication uses a combination of host and viral machinery for 
transcription and translation (133). As VZV infection is highly cell associated and 
asynchronous, there is limited understanding as to the exact nature and timing of VZV gene 
expression (135) and much of our knowledge is reinforced by our understanding of HSV-1 
replication and gene expression (11). Entry of VZV allows for the uncoating of enveloped 
virions into the cytoplasm, and the trafficking of the nucleocapsid and tegument into the 
nucleus (116). During this stage of infection, viral gene expression is initiated in a highly 
regulated temporal cascade of immediate-early (IE), early (E), and late (L) gene products 
(136). 
Within the first few hours of VZV infection, IE gene products present within the tegument 
utilise host machinery to initiate viral gene expression in the absence of any prior de novo 
protein synthesis (115, 136). Tegument proteins include protein products from VZV ORF4, 
ORF62 (IE62), and ORF63 (IE63), which are homologs of HSV-1 tegument proteins infected 
cell protein 27 (ICP27), ICP4, and ICP22 (2, 137). IE61, the VZV homolog of HSV-1 ICP0, is 
not a tegument protein, however VZV IE61 is detectable within 1 hour post-infection (hpi) 
(115). The major viral transactivator, IE62, is localised within the nucleus during early 
infection, but sequestered in the cytoplasm when co-expressed with ORF66 in later stages 
of infection (138). The changing localisation of this protein during infection is presumed to 
mediate the multiple effects of IE62 (2). Multiple IE and E genes are transactivated through 
IE62 activity, and expression of IE62 is essential for cell-to-cell spread of VZV in vitro and 
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during in vivo models of VZV pathogenesis (139, 140). IE63 similarly interacts with IE62 to 
induce transcription of viral glycoproteins and the cellular RNA polymerase (141). 
Furthermore, as discussed in a later section, ORF63 expression is demonstrated to mediate 
anti-apoptotic effects in productively infected cells (142, 143) (Section 1.4.3). ORF4 
expression is localised to the cytoplasm of infected cells, although nuclear co-expression 
with IE62 is observed (144), and ORF4 is essential for viral gene expression (145).  
It is generally thought that VZV early protein expression peaks within 5-7 hpi, however, 
multiple early proteins are observed within the first few hours of VZV infection (115, 136). 
The vast majority of VZV early genes encode viral enzymes and transcription factors which 
mediate VZV DNA replication (138). Among these proteins, ORF28 and ORF16 encode the 
large subunit and small subunits of the viral DNA polymerase, respectively and are 
necessary for viral DNA replication (2, 111). Furthermore, multiple early genes are required 
for productive infection, including ORF29 as the single-stranded DNA binding protein, and 
ORF51 as the origin binding protein (146, 147). In concert with these proteins, expression 
of essential viral protein kinases including, thymidine kinase ORF36 and serine/threonine 
kinases ORF47 and ORF66 are required for viral replication (148, 149). Interestingly, ORF47 
is present within the virion capsid and tegument and is essential for infection of skin, DCs, 
and T cells (25, 150-152). Furthermore, activity of ORF47 mediates the inhibition of 
interferon regulatory factor (IRF) 3 to permit viral protein synthesis (153-155) (Section 1.4.3). 
ORF66 similarly mediates immunomodulatory effects by targeting MHC class I expression 
(156, 157) (Section 1.4.3), while also regulating the activity of IE62 (138). ORF47 and ORF66 
can form a regulatory complex with host cellular factors to mediate the activity of viral 
transcription factors and other viral proteins leading to the synthesis of VZV late proteins 
(25, 158-160).  
Late viral products are present between 9-12 hpi (115) and contribute to the generation of 
newly synthesised virions and machinery necessary for viral egress (161). Late viral gene 
expression requires expression of both IE and E gene products, and encodes for a majority 
of structural components including nucleocapsid proteins, tegument proteins, and viral 
glycoproteins (2, 136). Protein products of VZV ORF21 and ORF40 constitute the viral 
nucleocapsid, which is formed around the scaffolding proteins from products of VZV 
ORF33.5 (162-164). VZV encodes nine viral glycoproteins, several of which share homology 
with HSV-1 glycoproteins (116, 165). 
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VZV gE is the most abundant viral glycoprotein and is primarily responsible for regulation 
of cell-to-cell contact and membrane fusion between infected cells and neighbouring 
susceptible cells (122, 166-169). Interestingly, despite being classified as a late viral gene 
product, VZV gE can be detected within 4 hpi in human epithelial lung fibroblasts (HELFs) 
(115). Furthermore VZV gE forms heterodimers with VZV gI (170) and VZV gH (171). 
Although VZV gI is dispensable for viral infection of certain cell types (172) it is well 
established that VZV gI is essential for viral replication and spread within neuronal cells (8, 
173). VZV gB is the second most abundant viral glycoprotein, and in combination with other 
viral envelope glycoproteins gB, gE, gH, gI, and gK, is a major target for neutralising 
antibodies (174, 175). Furthermore, the role of VZV gB by interacting with heparan sulfate 
and MAG to mediate viral binding and entry has previously been established (123, 176, 
177), and discussed (Section 1.3.1). VZV gH is the third most abundant viral glycoprotein 
(2) and neutralisation of VZV gH is associated with inhibition of viral spread and 
transportation of virions (26, 121, 178). The role of VZV gH as a fusogen has been firmly 
established, and cell-to-cell spread of the virus in culture is suggested to require the 
endocytic capacity of VZV gH (179, 180). Co-expression of VZV gH with VZV gL as a 
chaperone protein similarly facilitates spread of the virus and formation of syncytia (122, 
179). Multiple viral glycoproteins are associated with cell-to-cell spread evidenced by the 
requirement of VZV gM and gN heterodimers for viral growth and spread, although these 
glycoproteins are not essential for virion formation (180, 181). In contrast, both VZV gC and 
gK are essential for viral replication (24, 182). Interestingly, VZV gC expression is limited 
within the first 48 hours of infection during which time all other viral glycoproteins are 
adequately expressed, and gC expression is not required for viral entry into susceptible 
cells (24, 112, 183-185). 
1.3.3. Viral Egress 
Viral nucleocapsids form around 9 hpi as they accumulate adjacent to the nuclear border 
(186) and fully formed virions are observable after 9-12 hpi (115). During in vitro culture 
there is a distinct absence of fully assembled virions (183), however, the highly infectious 
nature of vesicular fluids and aerosolised infectious particles released from patients with 
primary VZV infection demonstrates that virion packaging and assembly occurs efficiently 
in vivo (187). The steps through which VZV virions undergo envelopment has not yet been 
fully elucidated, although studies of HSV-1 infection have yielded suitable models of this 
process (188, 189). As the nucleocapsid crosses the nuclear membrane, primary 
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envelopment and subsequent de-envelopment occur as the nucleocapsid is delivered into 
the cytoplasm (190). Viral glycoproteins, which are processed in the trans-Golgi network 
(TGN), are expressed on the cell-surface and consequently recycled to the cisternae of the 
TGN (191). Tegument proteins then adhere to the glycoprotein tails on the cytosolic surface 
of the cisternae allowing the nucleocapsid to invaginate the cisternae, and undergo a 
secondary envelopment within a TGN-derived vesicle (192). Vesicles containing fully 
enveloped virions are then targeted to lysosomal compartments for degradation or directed 
to late endosomes for cell membrane fusion and externalisation of virus (193). Although 
some glycoproteins are collected from the secondary envelopment of virions from the TGN, 
selected glycoproteins are obtained via budding from the surface of infected cells (26, 121, 
194). These glycoproteins are thought to mediate syncytia formation with neighbouring 
uninfected cells, and allow for further infection of other cells following virion egress. 
Surprisingly, in tissue culture settings, VZV remains highly cell-associated and no infectious 
virus is released from infected cells, which differs greatly from what is observed during in 
vivo infection (190, 195).  
1.3.4. Latent VZV Infection  
Primary varicella infection leads to the establishment of lifelong latency in sensory neurons 
of the DRG and trigeminal ganglia (TG) (196, 197). Interestingly, VZV DNA has been 
observed in other peripheral sensory ganglia (198, 199) and autonomic ganglia (200, 201), 
although it is not known if the virus can reactivate from these sites, or if they mediate 
persistence of VZV genomes alone (202). As such, latently infected neurons in the DRG and 
TG are the only sites demonstrated to mediate VZV reactivation. VZV DNA in latently 
infected ganglia is maintained at low levels in comparison to productive infection, and VZV 
protein expression is rare (203-205). Any observed gene products may also represent early 
stages of subclinical reactivation, rather than an underlying constitutive protein expression 
(206, 207). VZV encodes a range of transcripts that are expressed at low levels during latent 
infection, as well as a number of viral microRNAs (181, 187, 208, 209). RNA transcripts 
from a wide variety of VZV ORFs are detectable at low levels in latently infected ganglia, 
including RNA from ORF4, ORF18, ORF21, ORF 29, ORF62, ORF63 and ORF66 (196, 210-
217). More recently, transcription of VZV ORF11, ORF40, ORF41, ORF43, ORF57, and 
ORF68 were also detectable in these sites (218, 219). Although expression was relatively 
low in comparison to productive infection, VZV ORF63 was the most abundantly expressed 
viral transcript, which may indicate ORF63 is important in maintaining latent infection (219, 
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220). Recently, a VZV latency associated transcript (VLT) was identified in human TG 
neurons from post-mortem human ganglia, which runs anti-sense to VZV ORF61 (181). Low 
co-expression of ORF63 RNA was also detectable in these sites although not all TG 
neurons were transcriptionally active, even if they harboured latent VZV DNA (205). 
1.3.5. Reactivation of VZV  
The lifetime risk of reactivation of latent VZV to herpes zoster is between 25-30%, and 
increases to 50% for individuals over the age of 80 (82). As previously mentioned, it is 
believed development of herpes zoster is attributable to the decline in VZV-specific T cell 
immunity and not due to waning anti-VZV antibody titres (57, 58, 98). Reactivation to herpes 
zoster is characterised by productive VZV infection, the full cascade of viral gene 
expression, and transportation of infectious virus from the sensory ganglia to the skin (2). 
Anterograde trafficking of VZV to the nerve terminals in the dermis is supported by 
presence of VZV proteins and inclusion bodies at these sites (221). Patients experiencing 
herpes zoster may shed infectious virus from pruritic lesions formed on the onset of 
symptomatic disease, and VZV DNA is detectable in saliva and blood of these patients 
(222, 223), which can last up to 6 months post-infection (224). 
1.4. VZV and the Immune System 
It is presumed that following primary VZV infection, susceptible immune cells become 
targets of VZV infection (3). Through these interactions, VZV is able to suppress the 
essential functions that control viral infection and disseminate within the host (Section 
1.4.3). Moreover, it is thought that following the establishment of latency VZV may 
reactivate sub-clinically but remain under immune control (47). Thus, the immune response 
necessitates controlling infection, whilst also countering the viral subversion of these 
effects, and inducing a memory response capable of controlling reactivation.  
1.4.1. Immune Response during Varicella 
Innate Immune Response 
The innate immune response is a predominantly non-specific attempt to control infection 
until adaptive responses are induced (225). This response largely consists of the actions of 
site-specific DCs, NK cells, and cells of the monocyte and macrophage axis (226, 227). 
Biopsies taken from VZV skin lesions have revealed a notable influx of plasmacytoid DCs 
(pDCs) as the proportions of skin-resident Langerhans cells (LCs) decreased (227, 228). 
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These findings likely represent two anti-viral mechanisms at play: the trafficking of antigen-
laden DCs to lymphoid tissue to initiate T cell priming, and, the recruitment of key immune 
cells, such as pDCs, which have been demonstrated to be a potent source of interferon 
alpha (IFN-α) (229). The activity of pDC-mediated IFN-α is supported by inflammatory 
cytokine production in infected epithelial cells in the skin (36). Cytokine secretion is 
predicted to be important in controlling infection, as elevated levels of interleukin-2 (IL-2), 
tumour necrosis factor (TNF), and IFN-γ have all been found in the serum of patients with 
primary varicella (230). This is further reinforced by reports of more severe varicella in 
patients with less IFN-α (231), although IFN-γ is suggested to be more potent in controlling 
VZV infection (232). The additive effects of IFN-α and IFN-β are also observed to 
synergistically inhibit VZV replication (233), which may be sourced from activated NK cells 
(234) and T cells (235). The action of IFN-α and IFN-β at nerve endings has been reported 
to prevent the retrograde axonal transport of alphaherpesviruses (236). Although this may 
confer some protection to VZV exposed nerve terminals, sensory neurons of the DRG are 
ultimately infected.  
The release of cytotoxic granulysin from NK cells in vivo has also been demonstrated to 
block VZV replication (237). This finding contributes to reports identifying the significant 
role NK cells play in response to VZV infection, as patients with NK cell deficiencies are 
reported to have severe, and often fatal, varicella infections (238-241). Recently, it was 
reported that NK cells are permissive to productive VZV infection (40) and there is evidence 
to support that VZV infection functionally disarms NK cells (T. Campbell, personal 
communication).  
Concomitant with the infiltration of pDCs in the skin, CD14+ monocyte migration has also 
been observed in varicella lesions (227). Exposure of these cells to IFN-α resulted in 
upregulation of DC-like maturation markers, and enhanced antigen presentation; 
monocytes have previously been demonstrated to contribute as professional antigen 
presenting cells (APC) (242). Exposure of monocytes to VZV infection also induced TLR2 
and nuclear factor-kappa B- (NF-κB)-dependent secretion of IL-6 (243). This report also 
suggests that VZV is recognised by TLR2 binding to viral glycoproteins. Sensing of VZV 
through pattern recognition receptors (PRRs) such as TLR3, which binds dsDNA, has also 
been suggested, as severe VZV disease is observed in patients with deficiencies in TLR3 
functioning (244). Furthermore, severe VZV disease is observed in patients with inborn RNA 
polymerase III (POL III) errors (245). POL III recognises AT-rich regions of dsDNA (246), and 
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unlike the low AT content of HSV-1 and HSV-2, 70-80% of the VZV genome is AT-rich 
(245). VZV may be further recognised by stimulator of interferon genes (STING), as 
infection-limiting STING-dependent secretion of IFN-λ is observed during VZV infection of 
keratinocytes (247).  
Relatedly, recognition of VZV through the inflammasome pathways, multiprotein 
complexes that stimulate the expression of inflammatory genes (248), has been previously 
reported, as IL-1β was released following productive infection of THP-1 cells (249). This 
finding is further corroborated by examining human skin infected in a SCIDhu mouse 
model, which upregulated expression of nucleotide-binding oligomerization domain, 
leucine rich repeat and pyrin domain containing 3 (NLRP3) (249). NLRP3 is essential to the 
recognition of pathogens and this study suggested that inflammasome formation may 
occur in response to VZV infection in vivo. This is not, however, the first suggestion that 
alphaherpesviruses are recognised by the intrinsic immune system. There are extensive 
reports detailing how promyelocytic leukemia (PML) cages restrict HSV-1 nucleocapsid 
formation, and the subversion of this process by viral proteins (250, 251). Although studies 
have identified a similar process restricting VZV nucleocapsids (252), VZV does not encode 
functional homologs of the HSV-1 gene products used to combat this system (253).  
Adaptive Immune Response 
The humoral response to primary varicella develops within three days of rash onset with 
the production of VZV-specific IgM, IgG, and IgA (254, 255), with antibody titres peaking 
within four weeks (256). The effector function of this antibody response has been 
associated with complement-dependent neutralisation, mainly directed towards the highly 
immunogenic viral glycoproteins gE, as well as gB, gC, and gH (132, 257). The magnitude 
of VZV-specific B cell responses however, does not correlate with improved resolution of 
infection (258, 259), and severe disease VZV is not evident in patients with B cell 
deficiencies (260). Therefore, the B cell response is thought to be less pivotal in controlling 
primary varicella infection.  
In direct contrast, the high magnitude of the adaptive T cell response to VZV is associated 
with prevention of severe disease and cessation of viraemia, with early expansion of T cells 
correlating with milder symptomology (261, 262). VZV-specific T cells develop within the  
1-3 days of rash onset and are maintained at low frequencies (0.1-0.3%) in circulation (56). 
The absence of VZV-specific T cells during the delayed incubation period may reflect the 
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capacity of VZV to modulate the MHC class I and II antigen presentation pathways  
(156, 157, 263) (Section 1.4.3). The relative abundance of VZV-specific CD8+ T cells in 
comparison to CD4+ T cells has also been reported to be equivalent (259), although 
associated studies using a more restricted group of viral antigens for T cell stimulation have 
reported greater responsiveness of CD4+ T cells following stimulation (reviewed in 264). T 
cell antigen specificity is broad and characterised by recognition of highly immunogenic 
viral glycoproteins gB and gE, as well as multiple IE gene products (259, 265-267). The 
magnitude of T cell responses following exposure to gE has contributed to the development 
of a novel subunit vaccine for herpes zoster (102).  
The role for T cells in controlling varicella and herpes zoster is highlighted in individuals 
with T cell deficiencies, such as those with human immunodeficiency virus type 1 (HIV-1) 
infection (268). In these cases, severe manifestations of varicella are common (268) as is 
an increased incidence in herpes zoster (269), while HIV-1 specific anti-retroviral therapy 
ameliorates this condition (270). VZV-specific T cell activation generates TH1-like cytokines, 
including release of IL-2, IFN-γ, TNF, and IL-10 (235, 261, 271-273). Cytotoxic  
T lymphocyte (CTL) activity is predominantly mediated by CD8+ T cells in a MHC  
class I-restricted mechanism, although this cytokine milieu has also been demonstrated to 
induce cytolytic CD4+ T cells recognising VZV infected cells through MHC class II  
(259, 274-279).  
1.4.2. Immune Response during Latency and Herpes Zoster  
The establishment of immune memory responses during primary VZV exposure and 
following immunisation is expected to confer protection against further disease (280) with 
an ongoing immune response during latency predicted to continually disrupt reactivation 
of endogenous VZV (281). Interestingly, strong cell-mediated immunity (CMI) at onset of 
herpes zoster is correlated with reduced severity of disease, whereas robust humoral 
responses were conversely associated with more severe disease and increase incidence 
of PHN (282). Immune cell infiltration into herpes zoster lesions is comprised of responding 
T cells and DCs, and is associated with secretion of IFN-α (228, 283-285). Interestingly, the 
phenotype of CD4+ T cells during reactivation comprised features of cellular anergy, such 
as increased expression of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and 
programmed cell death protein 1 (PD-1) (273). These features are reduced following 
resolution of infection, and may be adequate markers for early detection of reactivation.  
  36 
At the level of the DRG, immune cell infiltration is observed, attributed in part to the actions 
of CXCL10 secreted from neurons (286). Recruitment of cytolytic CD8+ T cells, CD4+ T cells, 
and NK cells has been observed in the DRG of herpes zoster patients (287), as have B cells 
and macrophages (288). VZV infection of DRG in SCIDhu models of infection have 
demonstrated an abundance of IFN-α, IL-1α, IL-6, CXCL10, and transforming growth factor 
beta (TGF-β) (289). Although the exact sources of these cytokines within the DRG is 
unknown, they may potentiate from surrounding satellite glial cells (SGC) (290, 291). These 
cells share many properties of conventional APCs and macrophages, whilst also physically 
supporting the neuronal architecture, and mediating inflammatory responses (290-292). 
Through the combination of in situ neuronal protection, control mediated by infiltrating 
immune cells, and the actions of the peripherally-distributed memory response, 
reactivation to herpes zoster can be effectively controlled within two weeks  
post-reactivation in an otherwise healthy individual (293).  
1.4.3. Immune Evasion Mechanisms  
Primary varicella involves the infection of multiple susceptible immune cells that facilitates 
widespread dissemination of the virus throughout the host (Section 1.4.4). Although the 
immune response is intended to control infection, this also affords multiple opportunities 
for subversion of the host response by VZV. The virus has evolved multiple 
immunomodulatory mechanisms to evade detection by the immune system, whilst 
simultaneously aiding dissemination within the host (293). These include the modulation of 
cell-surface MHC class I and II, interference in the NF-κB and apoptotic pathways, and 
modifications to DC and NK cell maturation.  
Several studies have demonstrated the reduction of cell-surface MHC class I expression 
within VZV infected cells. VZV infection was demonstrated to downregulate expression of 
MHC class I in human foreskin fibroblasts (HFF) and T cells, attributed to defects in post-
translational processing (156, 294). Furthermore, the viral kinase activity of VZV ORF66 was 
shown to play a key role in modulating cell-surface MHC class I expression (157). In the 
presence of exogenous IFN-γ stimulation, VZV inhibited the expected increase in  
cell-surface MHC class II expression on infected HFF (263). Further analysis of this result 
demonstrated a VZV-mediated transcriptional block in human leukocyte antigen DR (HLA-
DR), class II major histocompatibility complex transactivator (CIITA), and interferon 
regulatory factor 1 (IRF-1). These findings suggest that following VZV infection, significant 
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modulation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) 
signalling pathway occurs (reviewed in 293, 295). In human keratinocytes, VZV infection 
mediates the downregulation of MHC class I, MHC class II and intracellular adhesion 
molecule 1 (ICAM-1) (296). Downregulation of ICAM-1 is thought to impair adhesion of T 
cells to APCs, which is facilitated in part by ICAM-1 (297). Overall, VZV encoded modulation 
of MHC class I and MHC class II expression across a variety of susceptible cells may allow 
for the virus to evade immune recognition and elimination.  
Apoptosis in the context of viral infection has long been postulated to be a balancing act 
between viral anti-apoptotic mechanisms and the necessity of the infected host cell to 
undergo programmed cell death (PCD) to restrict viral replication and spread (298-300). 
VZV infection of HFF and human sensory ganglionic neurons in vitro revealed a neuronal-
specific protection from apoptosis during productive VZV infection (6). Transient 
transfection of ORF63 was also observed to be protective against apoptosis induced by 
nerve growth factor (NGF) withdrawal (143). Furthermore, neural stem cells exhibit 
protection from apoptosis during VZV infection (301), and neurons from the DRG of herpes 
zoster patients lacked cleaved casapase-3 (CC3), the terminal effector of apoptosis (287). 
Another comparative study between VZV infected HFF and human neurons from embryonic 
stem cells reported the upregulation of anti-apoptotic gene transcripts in neurons while 
pro-apoptotic gene transcripts were upregulated in HFF (302). In SCIDhu mouse models of 
infection, blocking of VZV ORF66 expression was associated with decreased T cell survival, 
supporting a role for this kinase in mediating inhibition of apoptosis (160). More recently, it 
was demonstrated that expression of ORF63 conferred a protective response against 
staurosporine (STS)-induced apoptosis in human neuronal and keratinocyte cell lines (142). 
It is thought that the virus-mediated prolonged survival of post-mitotic neurons in which 
VZV establishes a lifelong latent infection is mutually beneficial (6). Furthermore, VZV 
ORF12 has been demonstrated to have an anti-apoptotic effect through enhanced 
phosphorylation of extracellular signal-regulated kinase 1 and 2 (ERK1/2), stimulation of 
activator protein 1 (AP-1), and activation of the phosphatidylinositol 3-kinase (PI3K) and 
Akt pathways (303, 304). 
As DCs possess potent antigen presentation abilities, they have long been considered a 
prime target for modulation by viruses endeavouring to delay and evade the immune 
response (305, 306). In an extensively studied model of human monocyte derived dendritic 
cells (MDDC), immature MDDCs were inoculated with VZV in vitro and shown to be 
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productively infected with VZV (34). Subsequently MDDCs were capable of transmitting 
infection to autologous CD3+ T lymphocytes, further implicating DCs in the dissemination 
of virus from initial sites of replication to regional lymph nodes (34). In later studies using 
this model, mature MDDCs were similarly observed to be productively infected with VZV 
and this led to the selective downregulation of key immune molecules such as MHC class 
I, CD80, CD83 and CD86 (37). Infected mature MDDCs also exhibited dampened 
stimulation of allogenic T lymphocytes, further implicating virally infected DCs as inefficient 
activators of naïve lymphocytes (34, 37). In the context of in vivo skin infection, VZV was 
demonstrated to modulate DC number and function. A detailed immunofluorescence 
analysis of VZV infected human skin revealed a diminished frequency of LCs, paired with a 
significant infiltration of pDCs into the skin (228). These cells were demonstrated to be 
virally infected in vivo, and as such, have been the subject of further study in vitro. The 
response of pDC to VZV infection was characterised and revealed that VZV infection in vitro 
prevented pDCs producing IFN-α (228, 229). IFN-α is a potent inhibitor of VZV replication 
in vitro, and treatment with IFN-α is associated with reduced severity of VZV disease (231). 
Additionally, secretion of IFN-α from neighbouring uninfected cells in skin infection was 
blocked by VZV in SCIDhu models of infection suggesting this response limits spread of 
VZV in the dermis infection (36).  
In a series of experiments, microarray analyses were performed on cells infected with  
wild-type (WT), vaccine, and small-plaque mutants of VZV to identify cellular and viral 
modifications at the molecular level in VZV infected T cells, epidermal cells, and HFF (22, 
307). It was revealed that a large proportion of modulated genes following VZV infection 
were regulated through the NF-κB signal transduction pathway. As p50 and p65 are key 
mediators of NF-κB signal transduction, it was observed that these proteins were not 
degraded, but sequestered, in the cytoplasm (308). Degradation of cellular inhibitor of 
kappa B alpha (IκBα), which is essential for nuclear accumulation of p50/p65, was not 
induced in these cells, although phosphorylation of IκBα did occur (308). This phenotype 
was also recapitulated in immature MDDCs productively infected with VZV, suggesting the 
induction of essential anti-viral responses is impaired in these cells (309). Furthermore, 
using an NF-kB reporter system, it was demonstrated that the E3 ubiquitin ligase domain 
of VZV ORF61 is capable of inhibiting NF-kB signalling (309). In combination, the capacity 
for VZV to sequester components of the NF-κB pathway is suggested to be a mechanism 
to limit the host defence. 
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Furthering the trend of signalling cascade modulation, VZV also employs many strategies 
to inhibit type I interferon signalling. VZV IE62 has been implicated in blocking IRF3 
phosphorylation during embryonic lung fibroblast infection (153). VZV ORF47 also mediates 
an atypical phosphorylation of IRF3, and ORF61 has degradative effects on phosphorylated 
IRF3 (153-155). VZV IE63 has also been shown to reduce levels of phosphorylated 
elongation initiation factor 2α (eIF-2α), a key antiviral factor activated by IFN-α (310, 311). 
It has been proposed that the above described methods of immune evasion may account 
for the 14-21 day incubation period of primary varicella, during which time patients are 
asymptomatic (41). It is apparent that the susceptibility of innate and adaptive immune cells 
to VZV infection intrinsically mediates the immune evasion strategies VZV undertakes.  
1.4.4. Immune Cell Tropism 
With regard to the diversity of mechanisms VZV utilises to suppress and evade the immune 
response, these strategies may involve direct infection of specific immune cell subsets, as 
well as subversion of immune control by regulation of neighbouring exposed cells. Tropism 
of VZV for CD4+ and CD8+ T cells has long been associated with a model of viral 
transmission and dissemination, implicating multiple immune cells and key immune organs 
including the tonsils and lymph nodes (7, 21, 23, 24, 35, 36, 312). More recently, it was 
identified that rather than preferentially infecting skin-homing T cells, the virus remodels 
infected T cells to produce skin-homing markers (7). Similarly, the potential for VZV to infect 
human DCs has been studied comprehensively, implicating DC transmission of virus to T 
cells during primary infection (34, 37, 228). In further studies, VZV has been shown to infect 
MDDCs in vitro, as well as Langerhans cells and plasmacytoid DCs in vivo (37, 228). 
However, given the prolonged viraemia of primary varicella in vivo, it remains to be seen 
the true extent of interactions the virus may have with the host immune system. Recently, 
it has been established that in vitro exposure of human NK cells to VZV results in productive 
infection and modulates the expression of NK cell maturation markers (40). Therefore, the 
discovery of novel permissive populations potentiates the discovery of further immune 
evasion strategies VZV undertakes and broadens our understanding of viral pathogenesis.  
Infection of Monocytes and Macrophages by VZV 
Viraemia is associated with both primary and reactivated VZV and as such interactions 
between VZV and mononuclear cells (MNC) have been documented (extensively reviewed 
in 3, 313-315). VZV DNA was observed in many MNC cell subsets (primarily T lymphocytes) 
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although little focus was drawn on VZV in the context of the monocyte-macrophage axis 
(316-320).  
In an investigation of MNC from children with primary varicella, VZV was detected from B 
and T lymphocytes but not from adherent macrophages (321). Similar studies tested VZV 
gE expression, indicating that both CD4+ and CD8+ populations expressed VZV gE 
comparable to the CD4– and CD8– populations, which were assumed to be monocytes 
(318). In an attempt to further characterize peripheral blood mononuclear cells (PBMC) 
infection in patients with clinical varicella, one group magnetically isolated patient CD14+ 
monocytes and identified VZV ORF62 and VZV gB transcripts by quantitative  
reverse-transcriptase PCR (qRT-PCR) (38). As the same study observed comparable viral 
DNA copies in both T and B lymphocytes and monocytes, these findings suggest that MNC 
populations during the acute viremic phase of varicella may harbour replicative virus (38).  
Despite the focus on VZV-MNC interactions there are a minority of investigations that have 
focused exclusively on monocyte infection in vitro. Early studies employed non-specific 
monocyte isolation methods such as adherence and peroxidase or α-naphthyl butyrate 
staining (322, 323). These studies utilised a cell-free inoculum (CF-VZV) and neither 
reported productive VZV infection of monocytes. The first study indicated only surface 
antigen staining following inoculation, however, extensive virion formation was observed in 
monocytes cultured for seven days prior to infection (322). It was suggested that this culture 
period generated monocyte-derived macrophages (MD-MΦ). Using electron microscopy 
(EM), viral particles were observed in the nucleus and cytoplasm of these exposed 
MD-MΦ, however morphologically complete particles were rarely detected (322). In a 
further study, VZV antigen detection on inoculated monocytes was comparable to control 
epithelial cell infection and VZV antigen was not detected on monocytes or epithelial cells 
following inoculation with UV-irradiated CF-VZV (323). When VZV exposed monocytes were 
collected and used as an inoculum for an infectious centre assay (ICA), few infectious 
centres were observed compared to the large number observed when the monocytes were, 
again, cultured for seven days prior to infection (323). Thus, the differentiation of monocytes 
to macrophages in vitro appears to play an important role in VZV replication. 
In a further series of reports, Köenig and associates utilised magnetic isolation kits to 
extract monocytes from fresh PBMC (39, 324). Using CF-VZV, viral transcription was 
identified in VZV exposed monocytes, as well as in B and T lymphocytes, yet 
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immunofluorescence assays (IFA) were not undertaken on monocyte populations (324).  
A following report from this group also investigated apoptosis of monocytes following VZV 
infection, demonstrating that 12% of VZV exposed monocytes expressed VZV gE by IFA 
(39). It was also observed that 18% of VZV exposed monocytes displayed annexin V 
staining compared to undetectable staining in mock infected monocytes, although 
combination staining of VZV gE with annexin V was not undertaken. Similarly, on average 
25% of VZV exposed monocytes exhibited extensive fragmentation and loss of DNA 
compared to 0.2% of unexposed monocytes (39). This provided the first evidence of any 
functional characterisation following VZV exposure to monocytes. In a recent study, a 
human acute monocytic leukemia cell line (THP-1) was characterised following VZV 
infection, with EM analysis indicating de novo virion production (249). Although there is a 
clear absence of definitive literature detailing the susceptibility of monocytes to VZV 
infection, the scientific community is currently of the opinion that these cells are readily and 
productively infected by VZV. For example, an investigation into TLR2 and CD14 signalling 
following VZV infection neglected to characterise monocyte populations following  
cell-associated infection (243). It is apparent that the knowledge gained from these reports 
over the past decades is proportionally robust to the technology utilised in acquiring it. 
Therefore it is of the utmost importance that a comprehensive characterisation of VZV 
infection of monocytes be undertaken with the most current methods available.  
Infection of Monocytes and Macrophages by Human Herpesviruses 
HSV-1 infection was initially described as abortive in human monocytes (325), although 
multiple studies have previously demonstrated HSV-1 infection of monocyte cell lines  
THP-1 cells and human leukemic monocytic lymphoma ‘U937’ cells (326, 327). However, 
these studies conflictingly report the extent to which THP-1 cells are permissive to HSV-1 
infection, as one such study identified <5% of HSV-1 infected THP-1 cells, with the second 
study reporting >80% of HSV-1 infected THP-1 cells. Regardless, HSV-1 infection of  
THP-1 cells was not demonstrated to be productive in either of these reports (326, 327). 
Exposure of HSV-1 to THP-1 cells was however characterised by potent downregulation 
of TLR2 and TLR4, suggested to impair the host response to fungal infection, and exposure 
was associated with the induction of apoptosis (328, 329). Infection of primary human 
monocytes by HSV-1 is equally contentious. HSV-1 infection of monocytes was first shown 
to be abortive as empty viral capsids in the nucleus of exposed cells were observed by EM 
(325). This study, among others, reported the enhanced susceptibility of monocytes to 
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HSV-1 following differentiation of monocytes into macrophages prior to infection (325, 330). 
This idea is corroborated by an increase in viral infection of U937 cells following phorbol 
12-myristate 13-acetate (PMA) treatment to generate macrophage-like cells (331). More 
recently, exposure of PBMC isolated monocytes to HSV-1 preparations resulted in <3% of 
cells with demonstrable viral antigen expression (332). This proportion of HSV-1 infected 
cells decreased within 48 hours, suggesting that infection was abortive, as evidenced in 
previous studies.  
The interactions between HCMV and the myeloid lineage have been extensively studied, 
with a particular focus on the monocyte-macrophage axis (reviewed in 333). Although 
CD34+ haematopoietic cells (HPCs), including monocytes, are not supportive of a fully 
productive infection (334-337) bone-marrow derived CD34+ HPCs are sources of latent viral 
infection (338, 339). As a result, this reservoir constitutively seeds latently infected 
monocytes into the periphery (340, 341). Furthermore, HCMV infection of monocytes is 
associated with far-reaching modulation of the host cell to facilitate this dissemination 
(342). HCMV infected monocytes undertake greatly increased transendothelial migration 
and higher motility than uninfected monocytes (343, 344). Monocytes are therefore 
promulgated as the ‘trojan horses’ of HCMV infection, with evidence supporting the 
dissemination of infection haematogenously (345-347). Although monocytes are known to 
undergo spontaneous apoptosis in circulation (348), regulation of apoptotic proteins by 
HCMV results in prolonged survival through multiple, independent pathways (349-351). 
HCMV infection also drives the differentiation of infected monocytes into macrophages 
(351-354). In this state, macrophages can support full productive infection, characterised 
by viral gene expression and release of progeny virions (346, 347, 355). 
HHV-6 infection of immune cells has also been previously reported, as the virus appears 
tropic for T cells, monocytes and macrophages (356). Infection of immature MDDCs results 
in the upregulation of multiple maturation markers accompanied with a decrease in antigen 
presentation capacities. Furthermore, HHV-6 DNA has been detected in the PBMC of 
patients with acute infection, and monocytes and macrophages are reported to harbour 
latently infected virus (357-359).  
Human monocytes are susceptible to EBV infection through expression of CD21 (360), 
although CD21 is only expressed on approximately 20% of circulating classical monocytes 
(361). The limited number of EBV-susceptible monocytes is further corroborated by 
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observations of EBV virions in the nucleus of 20% of exposed monocytes within 1 hour of 
infection, although these cells did progress to IE, E, and L gene expression within 40 hpi 
(362, 363). Exposure of PBMC to EBV enhanced the survival and maturation of monocytes 
in these cultures, although this effect was suggested to be a response to paracrine IFN-α 
from B cells and NK cells exposed to the virus (364, 365). In relation, THP-1 cells were 
described to support EBV infection in parallel with primary monocytes, and the full cascade 
of temporal gene expression was observed in these cells through IFA and transcriptional 
analyses (366).  
Monocytes have been demonstrated to support productive infection by KSHV in vivo and 
in vitro and are thought to contribute to the dissemination of KSHV throughout the host 
(367-369). This is further supported by the evidence of productively infected immune cells, 
and in particular monocytes, in lesions of KSHV patients (369). In parallel, THP-1 cells are 
susceptible to KSHV infection and support both lytic and latent infection (370, 371). 
Furthermore, CD34+ progenitors are observed to support KSHV infection, potentiating the 
release of infected monocytes into the bloodstream, akin to HCMV infection of CD34+ cells 
(372). Although there is not a conserved entry receptor across KSHV-tropic cells, DC-SIGN 
has been implicated in viral entry in both macrophages and DCs (373, 374). KSHV infection 
of primary monocytes induces the regulation of inflammatory cytokine production, 
including IL-1 and IL-6, and mediates an increase of programme death-ligand 1 (PD-L1) 
suggested to impair T cell responses to KSHV infection (375). Infection of monocytes is 
also demonstrated to induce differentiation of these cells into macrophages, which similarly 
support viral replication, and polarisation into tumour-associated macrophages (TAMs) 
(376). Interestingly, co-infection of monocytes with HIV increases replication of HIV and 
likely induces reactivation of HIV from chronically infected cells (377).  
Monocytes and macrophages are susceptible to infection by many members of the 
Herpesviridae family, although there is little consensus regarding the true nature of VZV 
infection of these cells. Understanding the impact that VZV infection has on these 
populations of myeloid cells may provide further insight into the pathogenesis of VZV and 
the full extent of immune control that VZV can undertake.  
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1.5. Mononuclear Phagocyte System 
The mononuclear phagocyte system (MPS) is comprised of monocytes, macrophages, and 
DCs (378, 379). The MPS functions to maintain homeostasis under the steady state and 
responds rapidly following infection and non-infectious injury. Monocytes and 
macrophages in particular are involved in pathogen sensing and defence against infection, 
and contribute to the initiation and resolution of inflammation (reviewed in 380). As there is 
difficulty surrounding ontogenic studies of this system in humans, much of what is known 
has been garnered from animal models. 
1.5.1. Monocytes 
Monocytes mature from common monocyte progenitor cells (cMoP) in the bone marrow 
(BM) through tightly regulated differentiation of haematopoietic stem cells (HSC) in a 
process termed ‘definitive haematopoiesis’ (381). Once in circulation, human monocytes 
form three populations based on expression of CD14 and CD16, whereas murine 
monocytes are identified by Ly6C (human CD14 counterpart), CCR2, and CX3CR1 (Table 
1.1) (382-386). It is important to note that murine monocyte expression of CCR2 and 
CX3CR1 is not equivalent to expression of CD16 on human monocytes and should not be 
considered as such (386). However, although all human and murine monocytes express 
CX3CR1, CCR2 expression on human monocytes is inversely correlated with CD16 
expression (387). 
Table 1.1 – Human and murine monocyte subsets 
 
Subset Human Murine  Proportion*  
 
Classical 
 
CD14+ CD16– 
 
Ly6Chi CCR2+ CX3CR1int 
 
≈ 85% 
 
 
Intermediate 
 
 
CD14+ CD16+ 
 
 
– 
 
 
≈ 15%a 
 
 
Non-classical 
 
 
CD14lo CD16+ 
 
 
Ly6Clo CCR2– CX3CR1hi  
 
 
≈ 15%a 
 
* Proportion of circulating monocytes 
a Shared proportion between intermediate and non-classical human monocytes only 
It was predicted that circulating human classical monocytes in the steady-state constitute 
precursors for intermediate and non-classical monocytes, similar to murine and rodent 
classical monocytes (388). More recently, a model of sequential ontogeny of human 
monocytes through in-vivo deuterium-labelling was investigated (348). It was observed that 
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in the BM, a proliferative pool of HSC exists from which cMoPS are generated. These 
monocyte progenitors then serve as precursors to classical monocytes alone, which then 
enter the circulation within 1-2 days of generation. In circulation, classical monocytes 
predominantly extravasate or undergo cell death and only 1% serve as precursors to 
intermediate (CD14+CD16+) monocyte populations. All observed intermediate monocytes 
acted as precursors for non-classical (CD14loCD16+) monocytes (348) (Figure 1.3). This 
model of sequential ontogeny contests an alternate theory of parallel ontogeny, whereby 
each subset would have required a BM progenitor however only classical monocytes have 
been observed in the BM. Classical monocytes therefore serve as precursors to 
intermediate and non-classical monocyte subsets.  
Monocytes Under Steady-State 
The previously accepted paradigm of circulating monocytes serving as reservoirs to 
replenish tissue macrophage and DC populations was demonstrated by early in vitro 
experiments (389, 390). More recently, there has been a conceptual revolution to reflect the 
self-renewal capacities of tissue-resident macrophages (trMΦ) and the capacity of tissue-
emigrating monocytes to retain monocyte phenotypes. Indeed, many trMΦ have been 
shown by fate-mapping experiments to be independently maintained through self-renewal 
during the steady state (391). Regardless, circulating classical monocytes have been 
observed to constitutively emigrate to lymphoid and non-lymphoid tissues and, where local 
niches permit, replenish monocyte-derived cells at these sites (242). For example, MDDCs 
replenish local DC populations in murine skin (392) and intestinal mucosa (393). 
Furthermore, adoptive transfer experiments revealed the capacity of classical monocytes 
to replenish specific reservoirs of trMΦ during the steady state (386). The role of non-
classical monocytes has largely been in patrolling endothelial vascular integrity (394), 
although adoptively transferred murine non-classical monocytes have also been observed 
to accumulate in the liver, lung, and spleen to replenish monocyte-derived macrophages 
(MD-MΦ) (386, 395).  
This work reflects the independent capabilities of classical and non-classical murine 
monocytes subsets, similarly demonstrated by the functional restriction placed on human 
monocytes. Human classical monocytes are predisposed to generate MDDCs and MD-MΦ 
in vitro, whereas intermediate and non-classical monocytes appear restricted to MD-MΦ 
formation alone (384).  
Figure 1.3: Ontogeny and persistence of monocytes and macrophages. During 
embryogenesis, macrophage precursors derived from yolk sac (YS) and fetal liver (FL) 
progenitors seed multiple areas to generate tissue-resident macrophages (trMΦ). In the bone 
marrow, common myeloid progenitor cells generate classical monocytes, which are seeded into 
circulation. In the circulation classical monocytes sequentially differentiate into intermediate 
monocytes although the vast majority migrate into tissues. Circulatory intermediate monocytes 
serve as precursors to non-classical monocytes which patrol the vasculature. Under the steady 
state, monocytes will migrate to draining lymph nodes to facilitate antigen presentation, undergo 
spontaneous apoptosis, or generate monocyte-derived MΦ. During inflammation, monocytes, 
MD-MΦ, and trMΦ will respond to local environmental signals to mediate inflammatory or 
anti-inflammatory responses. Following resolution of inflammation, trMΦ may self-replenish tissue 
macrophage populations. In certain contexts, MD-MΦ can contribute to a mixed population 
of MD-MΦ and trMΦ, or entirely replenish the tissue niche. Abbreviations: PL placenta, 
FL fetal liver, YS yolk sac, cMoP common myeloid progenitor, DLN draining lymph node, 
MD-MΦ monocyte-derived macrophage, trMΦ tissue-resident macrophage. 
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Human monocytes therefore represent a potential source for renewal of trMΦ and tissue-
specific DCs under the steady state, with human classical monocytes representing the 
most functionally diverse subset undertaking these actions. Furthermore, the capacity of 
monocytes to function independently of seeding monocyte-derived cells is increasingly 
apparent. Monocytes are capable of uptaking environmental antigen and migrating to 
draining lymph nodes while retaining a monocyte phenotype to assist in presentation of 
antigen from non-lymphoid organs (242). More specifically, CD14+ monocytes have been 
observed in varicella lesions and were suggested to have enhanced APC capacities (227). 
These studies reveal both the evidence for monocytes as professional APCs and their 
activity during VZV infection. The constitutive emigration of monocytes during the steady-
state, and the functional capabilities outside of circulation can however shift dramatically 
following inflammation. 
Monocytes During Inflammation 
Tissue alteration as a result of inflammation, injury, or infection generally results in migration 
of monocytes to distal sites, however the molecular mechanisms behind this process are 
not currently well understood. The chemokines controlling migration, the subsets recruited, 
and the immune modulatory effects of infiltrating monocytes, appear to vary widely and are 
intrinsically linked to the source of injury.  
For example, Listeria monocytogenes infection in mice results in CCR2 dependent release 
of monocytes from the BM (396). In contrast, non-infectious injury, such as atherosclerosis, 
utilises both CCR2 and CXCL1 in monocyte migration but only CXCL1 is essential (397). In 
West Nile Virus (WNV) infection, CCR2 is necessary for protective monocyte infiltration, as 
CCR2-/- mice exhibit a reduction in infiltrating monocytes and increased mortality attributed 
to enhanced encephalitis (398). Dengue virus (DENV) infection in CCR2-/- mice however, 
leads to attenuation of disease suggesting monocytes contribute to tissue damage (399). 
These studies highlight both the disease-specific contexts of monocyte recruitment and 
also the differing roles inflammatory monocytes play during these disease events. 
Furthermore, accumulation of monocyte-derived TNF and iNOS producing DCs (TiP-DCs) 
in Influenza A Virus (IAV) infection is thought to contribute to the lethality of infection (400). 
Although, IAV infected CCR2–/– mice exhibit a reduction in TiP-DCs without a reduction in 
mortality (400). Interestingly, treatment of IAV-infected CCR2–/– mice with pioglitazone  
re-establishes the infiltrating monocytes and subsequent TiP-DC populations, and restores 
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viral clearance but not tissue damage. The influence of infiltrating monocytes is therefore 
inherently linked to the highly specific niches generated by the local environment during 
infection. This study also links the influence of CCR2-mediated migration on the 
subsequent functional capacity of the infiltrating monocytes. The plasticity of infiltrating 
monocytes to highly-specific niches during migration and infection is evident across a 
range of tissue injury and infectious models (reviewed in 401, 402).  
1.5.2. Macrophages 
It has been a central dogma that all monocytes generate tissue-resident macrophage 
populations, and therefore macrophages were BM derived (389). However, a majority of 
trMΦ are now known to be embryonically derived prior to the appearance of BM derived 
monocytes (403). During embryonic development, tissue macrophages can be seeded 
through embryonic precursors in two distinct phases of haematopoiesis. ‘Primitive 
haematopoiesis’ from the yolk sac (YS) at embryonic day (E) 7.0 generates tissue 
macrophages and erythrocytes which can seed brain microglia, pancreatic macrophages, 
and certain reservoirs of epidermal LCs (404). Cells of the late stage fetal liver (FL) at E10.5 
generate HSC from which the remaining tissue-macrophage populations are seeded in 
parallel with HSC differentiation from the adult spleen BM (Figure 1.3) (380, 405). It is 
important to note however, that the information regarding macrophage ontogeny is 
restricted to the murine setting as little is known of the origin of human macrophages.  
Macrophage Generation and Nomenclature  
Fate-mapping experiments in numerous murine models have revealed the embryonic 
origins of microglia (brain), Kupffer cells (liver), alveolar macrophages (lung), red pulp 
macrophages (spleen), Langerhans cells (skin), and peritoneal macrophages (Figure 1.3) 
(388, 391, 406-410). Interestingly, embryonic development does not necessitate 
independence from BM-derived cells for repopulation. For example, steady-state 
monocytes are observed replenishing LCs, brain microglia, and lamina propria 
macrophages during experimental depletion studies (407, 411-413) even though these 
populations also have the capacity to self-renew (388, 391, 414). There appears to be no 
universally applicable strategy to replenish tissue macrophages as both organ and 
depletion-specific factors influence the outcome during the steady state (405). 
Although there is distinction between infiltrating monocyte-derived macrophages (MD-MΦ) 
and trMΦs, both subsets converge in their responses to tissue-specific signals governing 
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differentiation and local signals providing phenotypic variation (415). Both trMΦ and 
monocytes entering tissues during inflammation will encounter local signals that govern 
their differentiation or polarisation and are broadly characterised as either inflammatory or 
homeostatic. Inflammatory phenotypes are broadly driven by TH1-like cytokines such as 
granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-γ, lipopolysaccharide 
(LPS), or through TLR engagement, to produce TNF, IL-1, IL-6, and nitric oxide (NO) to 
promote an anti-microbial state (reviewed in 380). Homeostatic MΦs however are driven 
by Th2-like cytokines, including macrophage colony-stimulating factor (M-CSF), IL-4, and 
IL-13, and promote wound healing and tissue repair through the actions of TGF-β and 
vascular endothelial growth factor (VEGF) (402). Until recently these distinct trMΦ and  
MD-MΦ phenotypes were referred to as M1 ‘inflammatory’ and M2 ‘anti-inflammatory’ 
macrophages, although this has been subject to revision (416). As the M1/M2 nomenclature 
refers to two extremes of a continuum of macrophage specialisation and function, it is 
prudent to identify the specific phenotype of the macrophages being studied and, in 
particular, identify the ontogenic origin if applicable, or method of generation in the context 
of macrophages produced in vitro (416, 417). 
Macrophage Plasticity 
Both trMΦ and MD-MΦ rapidly alter their phenotype and function when stimuli are 
introduced in vitro and in vivo. Specifically, ontogenically distinct YS, FL, and BM derived 
macrophages are observed to develop into alveolar macrophages in the alveolar niche, 
regardless of ontogenic origin (418). Plasticity and heterogeneity within macrophage 
populations allows for swift responses and resolutions to danger. During resolution, trMΦs 
may require re-expansion if resident MΦ populations are lost. This results in a dynamic 
relationship, whereby infiltrating monocytes and MD-MΦs may replenish the entire 
population following total losses of trMΦ (388, 391), or alternatively form ‘macrophage 
chimaera’ populations comprised of both trMΦs and newly differentiated MD-MΦ from 
infiltrating classical monocytes (419). In certain cases, trMΦs may entirely self-renew in an 
effort to reduce the inflammatory effects and pathological contributions of infiltrated MD-
MΦ (420).  
Nevertheless, cells of the MPS represent a highly plastic and intrinsically dynamic system 
which influence nearly every level of the immune response. In sterile and microbial 
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inflammation, they form highly variable arrangements that permit the discovery of novel 
strategies the immune system undertakes to combat infection.  
 
1.6. Objectives 
Tropism for immune cells is a hallmark of most human herpesviruses and contributions to 
this field have demonstrated the vast immunomodulatory behaviour of these viruses. In 
particular, VZV infection of the immune system permits widespread dissemination of the 
virus throughout the host and facilitates pathogenesis. It has been established that the 
susceptibility of T cells and DCs to VZV infection is likely important for VZV dissemination 
as well as for manipulation of host immune cells. However, our underdeveloped 
understanding of VZV infection in other immune cell types has likely contributed to 
previously unrecognised immunomodulatory effects VZV undertakes. Monocytes and 
macrophages are targets for infection by HSV, HCMV, HHV-6, EBV, and KSHV, however 
limited study of monocytes in the context of VZV infection has been undertaken. Previous 
reports have demonstrated that monocytes are susceptible to infection although this 
infection may be abortive. As it stands, conclusive evidence has yet to be presented 
demonstrating the susceptibility of this immune subset to productive VZV infection. The 
abundance of monocytes within circulation allows for rapid and targeted dissemination of 
these cells throughout the host, and represent a potential source for VZV dissemination. 
Monocytes and macrophages represent a highly responsive and potent source for pro- and 
anti-inflammatory signalling integral to the resolution of infection. Infection of this abundant 
and highly migratory population by VZV may present another strategy through which VZV 
is able to subvert and control the immune system to provide a favourable environment for 
viral dissemination and persistence.  
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1.6.1. Aims 
Therefore, the primary aims of this current examination into VZV infection of primary human 
monocytes and macrophages are:  
1) To demonstrate the susceptibility of human monocytes and macrophages to VZV infection, and 
to determine the nature of infection, productive or otherwise, in these primary human cells. 
2) To characterise the immune phenotype of human monocytes and macrophages following 
infection with VZV to identify potential impacts in cellular functioning. 
3) To interrogate the functional capabilities of monocytes and macrophages during VZV infection, 
in an attempt to:  
a. Recognise the potential for VZV to utilise the monocyte-macrophage axis for viral 
dissemination. 
b. Identify the capability for VZV to further modulate host recognition of viral infection 
through infection of monocytes and macrophage. 
c. Elucidate novel strategies VZV undertakes to subvert the inflammatory response of 
monocytes and macrophages to viral infection. 
Chapter Two
Materials and Methods
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2. Materials and Methods 
2.1. Media and Supplements 
Reagent Usage 
 
DMEM 
 
Dulbecco’s Modified Eagle Medium (DMEM) with L-glutamate, 4.5 g/L 
glucose, non-essential amino acids, inorganic salts and vitamins, and 
without sodium pyruvate (Lonza). Supplemented with 10% (v/v) fetal 
calf serum (FCS) (Serana) and 50 IU/mL penicillin/streptomycin 
(pen/strep) (Gibco). Stored at 4˚C. 
 
FCS 
 
Fetal calf serum (Serana) stored at -80˚C as supplied. Stored at -30˚C in 
50 mL aliquots.  
 
GM-CSF  
 
Human granulocyte macrophage-colony stimulating factor (GM-MCSF) 
(Miltenyi Biotec). Supplied as powdered stock and diluted to 1000 
IU/mL in 1X PBS. Stored at -30˚C. 
 
M-CSF  
 
Human macrophage-colony stimulating factor (M-CSF) research grade 
(Miltenyi Biotec) supplied as powdered stock and diluted to 20 ng/µL in 
1X PBS. Stored at -30˚C.  
 
Pen/strep 
 
Penicillin 10,000 IU/mL and streptomycin 10,000 µg/mL (Gibco). 
Supplied at 100X stock and stored at -30˚C in 5 mL aliquots.  
 
RPMI-1640 
 
Roswell Park Memorial Institute 1640 Medium (RPMI-1640) with  
L-glutamate, 4.5 g/L glucose, non-essential amino acids, inorganic salts 
and vitamins, and without sodium pyruvate (Lonza). Supplemented with 
10% (v/v) fetal calf serum (FCS) (Serana) and 50 IU/mL pen/strep 
(Gibco). In certain experiments, media was supplemented with 25 
ng/mL M-CSF, or, 400 IU/mL GM-CSF.  
 
RPMI-1640 
without serum 
 
RPMI-1640 medium without serum and supplemented with 50 IU/mL 
pen/strep. Stored at 4˚C. 
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2.2. Buffers 
Buffer Usage 
 
BD Permeability 
Buffer 
 
BD Permeability Buffer was prepared from 1:10 dilution of BD 
Perm/Wash Concentrate (BD Biosciences) in distilled H2O (dH2O). 
Stored at 4˚C. 
 
Cell Dissociation 
Buffer 
 
Cell dissociation buffer, Enzyme-free (Gibco) as supplied. Stored at 4˚C. 
Macrophages were incubated in warmed buffer for 15 minutes at 37˚C 
under 5% CO2. 
 
Citrate Buffer  
 
40 mM sodium citrate, 10 mM KCl, 135 mM NaCl in dH2O, pH 3.0. 
Buffer stored at 4˚C and allowed to equilibrate to room temperature (RT) 
prior to use. 
 
BD Cytofix 
Fixation Buffer  
 
BD Cytofix Fixation Buffer (BD Biosciences) used as supplied. Stored 
at 4˚C.  
 
BD Permeability 
Solution 
 
BD Cytofix/Cytoperm Buffer (BD Biosciences) used as supplied. Stored 
at 4˚C. 
 
FACS Buffer 
 
Fluorescence-Activated Cell Sorting (FACS) Buffer was prepared by 
supplementing 1X PBS (Lonza) with 1% (v/v) FCS and 2mM EDTA, pH 
8.0. Stored at 4˚C. 
 
Freezing Solution  
 
Freezing solution was prepared by diluting 10% (v/v) dimethyl sulfoxide 
(DMSO) (Sigma Aldrich) in FCS. Stored at 4˚C. 
 
MACS Buffer 
 
Magnetic-Activated Cell Sorting (MACS) Buffer was prepared by 
supplementing 1X PBS with 0.22 µm-filtered solution of 10% bovine 
serum albumin (BSA) (Sigma Aldrich) and 0.5 M EDTA to a final 
concentration of 0.5% BSA and 2 mM EDTA, pH 8.0. Stored at 4˚C. 
 
Normal Donkey 
Serum 
 
Normal donkey serum (NDS) containing 0.01% (w/v) thimerosal (Sigma 
Aldrich). Stock serum stored at -30˚C in 1 mL aliquots and diluted as 
required in 1X PBS. 
 
PBS 
 
Dulbecco’s Phosphate Buffered Saline (PBS) without Ca++ or Mg++ 
(Lonza). Stored at RT. 
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2.3. Solutions and Reagents 
Reagent Usage 
 
BSA 
 
Bovine serum albumin (BSA) (Sigma Aldrich) stock powder diluted as 
necessary in PBS. Stored at 4˚C 
 
CD14 Microbeads 
 
CD14-conjugated magnetic beads (Miltenyi Biotec). Used as supplied. 
Stored at 4˚C. 
 
CFSE  
 
Carboxyl fluorescein succinimidyl (CFSE) (Invitrogen). Lyophilised stock 
reconstituted to 5 mM in DMSO. Stored at -30˚C. 
 
Compensation 
beads  
 
Anti-mouse Ig, or anti-rat Ig, negative control compensation particles 
set (BD Biosciences). Used as supplied. Stored at 4˚C. 
 
CTV 
 
CellTrace Violet Dye (ThermoFisher Scientific). Lyophilised stock 
reconstituted to 5 mM in DMSO. Stored at -30˚C. 
 
DAPI 
 
Prolong Gold antifade reagent with 4’6-diamidino-2-phenylindole 
dihydrochloride (DAPI) (Invitrogen). Stored at -30˚C protected from light. 
 
DMSO  
 
Dimethyl sulfoxide minimum 99.5% (Sigma Aldrich). Used as supplied. 
Stored at RT protected from light. 
 
Ficoll-Hypaque 
 
Ficoll Paque Plus (GE Healthcare). Used as supplied. Stored at RT 
protected from light. 
 
Staurosporine 
 
Staurosporine from Streptomyces sp. (Sigma Aldrich). Lyophilised 
stock reconstituted in DMSO and stored at -30˚C in 100 µL aliquots. 
 
Triton X 
 
Triton X-100 (Sigma Aldrich). Stored at RT. 
 
Fc receptor 
blocking solution  
 
Human TruStain FcX (Fc Receptor Blocking Solution) (BioLegend). 
Stored at 4˚C.  
 
Trypsin/EDTA 
 
Trypsin-EDTA (0.5%) containing 2 g/mL sodium EDTA and 8.5 g/L 
sodium chloride, no phenol red (Gibco). Diluted 1:10 in 1X PBS. 
Stored at -30˚C in 50 mL aliquots.  
 
Live/dead dye  
 
Zombie-NIR Fixable Viability Dye (BioLegend). Lyophilised stock 
reconstituted in 100 µL DMSO and stored at -30˚C. Diluted at 1:1000 
in 1X PBS when required. Stored at -30˚C after dilution 
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2.4. Antibodies 
Antibodies used in flow cytometry are listed below and recommended isotype antibodies 
were obtained from the same suppliers. All stored at 4˚C protected from light. VZV gE:gI 
was conjugated in-house to R-PE and DyLight488 using Lynx Rapid Conjugation Kit  
(Bio-Rad).  
Specificity Clone Supplier Usage 
  
CD14 
 
MΦP-9 
 
BD Biosciences 
 
Flow Cytometry 
 
CD16 
 
3G8 
 
BD Biosciences 
 
Flow Cytometry 
 
CD11b 
 
ICRF44 
 
BioLegend 
 
Flow Cytometry 
 
CD71 
 
M-A712 
 
BD Biosciences 
 
Flow Cytometry 
 
MR 
 
19.2 
 
BD Biosciences 
 
Flow Cytometry 
 
CD163 
 
GHI/62 
 
BD Biosciences 
 
Flow Cytometry 
 
HLA-ABC 
 
W6/32 
 
BioLegend 
 
Flow Cytometry 
 
HLA-DR 
 
G46-6 
 
BD Biosciences 
 
Flow Cytometry 
 
M-CSFR 
 
94D2-IE4 
 
BD Biosciences 
 
Flow Cytometry 
 
GM-CSFR 
 
hGM-CSFR-M1 
 
BD Biosciences 
 
Flow Cytometry 
 
Cleaved 
 
caspase-3 
 
C92605 
 
BD Biosciences 
 
Flow Cytometry 
 
VZV gE:gI 
 
SG1 
 
Meridian Life Sciences 
 
Flow Cytometry 
 
VZV IE62 
 
IE62 
 
Meridian Life Sciences 
 
Immunofluorescence Assays (IFA) 
 
VZV gE 
 
vN-20 
 
Meridian Life Sciences 
 
IFA, Infectious Centre Assays (ICA) 
 
VZV pORF29 
 
Polyclonal 
 
Kindly provided by  
 
IFA, ICA 
  Prof. Paul Kinchington,  
  University of Pittsburgh  
 
2.5. Kits 
All kits were stored at 4˚C or -30˚C and performed according to manufacturer instructions.  
Commercial Name Supplier  Description 
Human TNF-alpha ELISA Kit ElisaKit.com Detection of TNF secretion 
Human IL-1-beta ELISA Kit ElisaKit.com Detection of IL-1β secretion 
IL-18 Human ELISA Kit ThermoFisher Scientific Detection of IL-18 secretion 
Lynx Rapid Dy488 Conjugation Kit Bio-Rad In-house Ab-conjugation kit 
Lynx Rapid R-PE Conjugation Kit Bio-Rad In-house Ab-conjugation kit 
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2.6. Cell Culture 
2.6.1. Cells  
Human Foreskin Fibroblast 
Human foreskin fibroblast (HFF) cells were acquired from the America Type Tissue Culture 
(ATCC) and were originally harvested from surgically removed foreskin tissue (421). HFFs 
were cultured in DMEM supplemented with 10% FCS and 50 IU/mL penicillin streptomycin. 
Cells were passaged up to 30 times in 37˚C with 5% CO2. 
2.6.2. Harvesting and Splitting of Cells 
Once monolayer cultures were 80-100% confluent, cell media was aspirated and cells were 
washed with warmed 1X PBS (Lonza) prior to incubation with warmed trypsin/EDTA (Life 
Technologies) at 37˚C for 5 minutes. Cell media washed along inside of flask to collect 
detached cells in suspension, which were split at required dilutions into fresh tissue culture 
flasks (BD Biosciences). For suspension cultures, once cell density reached greater than 
5x105 per mL, cell suspension was collected and centrifuged at 840 x g for 5 minutes. 
Media supernatant was aspirated and replaced with fresh media following splitting of 
culture into fresh tissue culture flasks as above.  
2.6.3. Freezing and Resuscitation 
For freezing, cells were harvested as previously described and collected in media. Cell 
suspensions were centrifuged at 452 x g for 5 minutes prior to aspiration of media 
supernatant. Cell pellets were resuspended in freezing solution (10% DMSO in FCS) and 
immediately stored at -80˚C in 1.5 mL cryovials (Greiner Bio-one) at appropriate cell 
densities. For resuscitation, cell aliquots were removed from -80˚C and immediately 
defrosted at 37˚C prior to transfer to a 15 mL Falcon tube (BD Biosciences) for the addition 
of warmed media. Cell suspensions were centrifuged at 452 x g for 5 minutes and pellets 
resuspended in appropriate volume of media and seeded at required densities in tissue 
culture flasks.  
2.7. Human Blood Processing and Culture 
2.7.1. Peripheral Blood Mononuclear Cell (PBMC) Collection 
Human blood buffy coats (Australian Red Cross Blood Service) were obtained with ethics 
approval from the University of Sydney. Buffy coats were aspirated and mixed 1:4 with 1X 
PBS. Blood was underlayed with Ficoll-Hypaque (GE Healthcare) and separated by density 
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gradient sedimentation through centrifugation at 652 x g without brake for 20 minutes at 
RT. The intermediate phase containing peripheral blood mononuclear cells (PBMC) was 
removed and washed twice in 1X PBS. 
2.7.2. Monocyte Extraction and Culture 
Prior to extraction, PBMCs were washed twice in 1X MACS buffer and resuspended at 
1x108 cells/mL in 1X MACS buffer. PBMCs were incubated with desired volume of CD14 
microbeads (Miltenyi Biotec) for 20 minutes at 4˚C and washed with 1X MACS buffer. 
QuadroMACS™ Separator (Miltenyi Biotec) was pre-chilled and LS separation column 
(Miltenyi Biotec) with attached 20 µM pre-separation filter (Miltenyi Biotec) was added to 
magnet. PBMCs were washed in 1X MACS buffer before adding to column following three 
washes with 1X MACS buffer. CD14+ monocytes were eluted in 1X MACS buffer and kept 
on ice. When required, monocytes were cultured for infection at 106 cells/mL in RPMI-1640 
(Lonza) supplemented with 10% FCS and 50 IU/mL penicillin streptomycin.  
2.7.3. Macrophage Differentiation and Culture 
Following elution, freshly isolated CD14+ monocytes were counted and seeded into 6 well 
plates (BD Biosciences) in RPMI-1640 without serum and containing 50 IU/mL penicillin 
streptomycin. Monocytes were incubated for 2 hours at 37˚C with 5% CO2 to facilitate 
adherence. Media was then aspirated to remove non-adherent cells, and remaining 
adherent cells were supplemented with RPMI-1640 media supplemented with 10% FCS, 
50 IU/mL penicillin streptomycin and either 20 ng/mL M-CSF (Miltenyi Biotec), or 400 IU 
GM-CSF (Miltenyi Biotec). Monocytes were allowed to differentiate for five days at 37˚C 
with 5% CO2 with a media change after three days.  
Macrophage Harvesting  
Prior to harvesting, macrophages were visualised for characteristic morphology by light 
microscopy (Zeiss). Cell media was aspirated and cells washed in PBS prior to a 15-30-
minute incubation with Cell Dissociation Buffer (ThermoFisher Scientific) at 37˚C with 5% 
CO2. Detached macrophages were gently agitated via pipetting and collected for use.  
2.8. Viral Infection 
2.8.1. Virus Strains  
A clinical isolate, VZV-S, was utilised in all experiments involving viral infection, and was 
kindly provided by Prof. Ann Arvin, Stanford University. 
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2.8.2. Viral Propagation  
Viruses were propagated in HFF cell cultures and were monitored for cytopathic effect 
(CPE) daily. When 70-85% of the monolayer showing visible CPE, the virally infected cells 
were harvested for splitting as previously described and seeded onto confluent monolayers 
of uninfected cells of the same type. 
2.8.3. Cell-dye Labelling of Inoculum 
Prior to being used for infection, uninfected (mock) and VZV infected HFF were harvested 
as previously described and centrifuged at 452 x g for 5 minutes. Supernatant was 
aspirated and cell pellets resuspended in 1 mL 1X PBS for labelling. 
CFSE Labelling 
For CFSE labelling, a 1:1000 dilution of CFSE (ThermoFisher Scientific) was generated in 
1X PBS. Up to 1x106 cells were incubated with diluted CFSE for 15 minutes at RT and then 
5X volume of media was added for a further 5-minute incubation at RT. Cells were 
centrifuged at 452 x g for 5 minutes and media aspirated. Labelled cells were then 
resuspended in appropriate media and incubated for 5 minutes at RT prior to use.  
Cell Trace Violet (CTV) Labelling  
For CTV labelling, a 1:1000 dilution of CTV (ThermoFisher Scientific) was generated in 1X 
PBS. Up to 1x106 cells were incubated with diluted CTV for 15 minutes at RT and then 5X 
volume of media was added for a further 5-minute incubation at RT. Cells were centrifuged 
at 452 x g for 5 minutes and media aspirated. Labelled cells were then resuspended in 
appropriate media and incubated for 5 minutes at RT prior to use.  
2.8.4. Cell-associated Infection 
Cultures of uninfected (mock) and VZV infected cells were harvested as previously 
described and counted prior to CFSE or CTV labelling as above. Mock or VZV infected cells 
were inoculated at specified ratios of cell-dye labelled inoculum cell to target cell, 1:2 for 
infection of monocyte, and 1:5 for infection of macrophages. For infection of monocytes, 
tissue culture plates containing labelled HFF inoculum and target monocytes were 
‘spinoculated’ by centrifugation at 200 x g for 15 minutes at RT to facilitate contact. 
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2.8.5. Storage of Cell Supernatants  
To assess the production of soluble mediators, cytokines, or supernatants for infectious 
virus, supernatants were aspirated and centrifuged at 425 x g for 5 minutes at RT to remove 
particulate cell matter. In certain experiments, supernatants were 0.22 µm-filtered prior to 
storage. Supernatants were stored immediately at -80˚C in 1-1.5 mL aliquots.  
2.9. Flow Cytometry  
2.9.1. Cell-surface & Intracellular Immunostaining 
Cells were washed in PBS prior to incubation with cell viability dye. 1:100 live/dead dye 
(BioLegend) was added to cells for 15 minutes at RT protected from light. Cells were then 
washed with chilled FACS wash. For immunostaining of primary monocytes and 
macrophages, cells were then incubated with Fc receptor blocking solution Human 
TruStain FcX™ (BioLegend) for 10 minutes at RT according to manufacturer instructions. 
Cells were incubated in suspension with required antibody cocktails (or matching isotype 
controls) for 30 minutes at 4˚C. Cells in antibody suspension were washed twice with FACS 
wash. For cell-surface staining, cells were then fixed by incubation in BD Cytofix™ Fixation 
Buffer (BD Biosciences) for 20 minutes at 4 ˚C according to manufacturer instructions, and 
then washed FACS wash as above. For intracellular cleaved caspase-3 staining, cells were 
first immunostained with antibodies for cell-surface markers as above, prior to incubation 
with BD Permeabilisation Solution (BD Biosciences) for 20 minutes at 4˚C according to 
manufacturer instructions. Cells were then washed twice in BD Perm/Wash Buffer (1:10 in 
dH2O). Antibodies specific to cleaved caspase-3 were added for incubation overnight at 
4˚C. Cells were then washed three times in BD Perm/Wash (1:10 in dH2O). All samples were 
fixed as described above before being run on a flow cytometer, and stained cells were 
stored protected from light at 4˚C prior to data acquisition.  
2.9.2. Data Acquisition 
Flow cytometry data was obtained on a BD LSRFortessa X-20 (BD Biosciences) running 
BD FACSDiva™ v8.0.1 (BD Biosciences). Compensation controls were utilised where 
applicable and generated by incubating individual antibodies with compensation beads 
(BD Biosciences) for 30 minutes at 4˚C prior to washing and fixing as above.  
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2.9.3. Fluorescence Activated Cell Sorting (FACS)  
Cells requiring sorting via FACS were prepared as above with minor modifications. 
Following antibody incubation, cells were washed in FACS wash twice and deposited into 
FACS tubes with cell strainer snap caps (Corning). Cells were sorted with a BD FACSAria™ 
IIu and separated based on an experimental basis (e.g. to remove labelled inoculum, to 
isolate VZV antigen positive cells). Cells were eluted into FACS wash and kept on ice until 
further use. 
2.9.4. Conventional and Dimensionality Reducing Analysis 
All data analysis was performed in FlowJo vX (FlowJo LLC) and raw data underwent 
compensation. Almost all analyses followed a gating strategy isolating single cells and 
excluding cells staining positive for viability dye. Conventional analyses utilised core 
workflows of FlowJo software. Dimensionality reducing analysis was performed following 
protocols previously published from our laboratory (40). For visualisation of high-
dimensionality datasets, the Barnes-Hut implementation of t-distributed stochastic 
nearest-neighbour embedding (tSNE) was employed (422). Equal numbers of cells for tSNE 
analysis were collected while preserving underlying phenotypic architecture with the 
‘DownSample’ plugin in Flowjo. Cells were then exported and concatenated into one ‘.fcs’ 
fie for tSNE analysis with the ‘TSne’ plugin using the following setting: Iteration 1000, 
Perplexity 30, Eta 200, Theta 0.5. Concatenated samples post-tSNE analysis were 
separated and analysed in FlowJo. Heatmaps were generated with a custom R script (423) 
that utilised exported CSV-Channel values from FlowJo. Globally scaled colourised maps 
were generated with packages ggplot2, colourRamps, ggthemes and scales in R.  
2.10. Immunofluorescence (IFA) Staining  
2.10.1. Generating cell spots and coverslips 
For generation of cell spots, cells were harvested as previously described (Section 2.6) and 
washed in 1X PBS before a volume of 1X PBS was added equal to the size of the cell pellet. 
Cell suspensions were spotted onto glass microscope slides (ProSciTech) and allowed to 
dry for 10-15 minutes at RT. Cell spots were encircled using a wax pen (Dako) and 
incubated with BD Cytofix™ Fixation Buffer (BD Biosciences) at RT for 15 minutes. Cells 
were washed in 1X PBS and stored in 1X PBS inside coplin jars. Cells cultured on glass 
coverslips (Menzel Gläser) were washed twice with 1X PBS and incubated with BD 
Cytofix™ Fixation Buffer for 20 minutes at 4˚C. Fixation reagent was removed and cells 
  62 
washed twice with 1X PBS. Coverslips in plates were stored in PBS at 4˚C prior to 
immunofluorescent staining.  
2.10.2. Cell Spot & Coverslip Staining 
Cells on coverslips or glass slides were stored in 1X PBS prior to staining. PBS was 
removed and cells were permeabilised with 0.1% Triton X (Sigma Aldrich) in 1X PBS for 10 
minutes before washing twice in 1X PBS. Cells were incubated with 20% normal donkey 
serum (NDS) (Sigma Aldrich) diluted in 1X PBS for 30 minutes as an antibody blocking 
solution. Blocking solution was aspirated and cells were incubated with primary or 
matching isotype control antibodies in 10% NDS (in 1X PBS) for 1 hour at RT or 37˚C, and 
protected from light. Cells were washed with 1X PBS for 5 minutes before incubation with 
secondary antibodies in 10% NDS (in 1X PBS) for 30 minutes at RT or 37˚C and protected 
from light. Cells were then washed in 1X PBS for 5 minutes before application of 3 µL DAPI 
anti-fade reagent (Invitrogen) and either mounting of glass coverslips over cell spots, or, 
mounting cell-coated coverslips onto glass slides. Slides were allowed to cure overnight at 
RT and all slides were sealed with nail polish once set. Slides were stored at 4˚C prior to 
imaging.  
2.10.3. Image Acquisition 
Images were acquired with a Zeiss Axioplane 2 Imaging upright Fluorescence and 
Deconvolution Microscope with a Zeiss AxioCam HRm digital monochrome CCD camera 
and attached Zeiss ApoTome.2 (Zeiss). Images were acquired and processed using Zen 
2012 Imaging Software (Zeiss). Access to microscopy facility was through the Bosch 
Advanced Microscopy Facility  
2.11. Backscatter Electron Microscopy (BSEM) 
All materials used in electron microscopy were sourced from Sigma Aldrich, unless 
previously indicated, or indicated otherwise.  
2.11.1. Infection, Harvesting, and Metal Exposure 
Specimen preparation for electron microscopy was performed by the Australian Centre for 
Microscopy and Microanalysis (ACMM) at University of Sydney. 2x106 monocytes were 
infected as previously described with mock- and VZV infected HFF at a ratio of one HFF to 
two monocytes. In parallel monocytes without HFF were cultured, as well as cultures of 
VZV infected HFF. All samples were collected after 24 hours culture at 37˚C with 5% CO2. 
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Samples were pelleted at 652 x g, aspirated, and fixed in 2.5% glutaraldehyde (ProSciTech) 
in 1X PBS for 1 hour at 4˚C. Samples were then provided to the ACMM to undergo 
preparation for serial block face scanning electron microscopy. Samples were pelleted 
again and washed five times in cold cacodylate buffer containing 2 mM calcium chloride 
(Sigma Aldrich) for 3 minutes. Samples were then incubated for an hour on ice in a solution 
containing 3% potassium ferrocyanide in 0.3 M cacodylate buffer supplemented with 4 mM 
calcium chloride combined with an equal solution of 4% aqueous osmium tetroxide. 
Samples were washed five times in ddH2O for 3 minutes at RT. Immediately following this, 
samples were incubated for 20 minutes at RT in a 0.22 µm-filtered solution of 0.1 g 
thiocarbohydrazide dissolved in 10 mL ddH2O. Samples were washed five times in ddH20 
for 3 minutes at RT and placed in 2% osmium tetroxide in double distilled H20 (ddH20) for 
30 minutes at RT. Samples were washed five times in ddH20 for 3 minutes at RT and then 
placed in 1% uranyl acetate (aqueous) overnight at 4˚C.  
2.11.2. En-bloc Staining and Sectioning 
Samples were washed five times in ddH20 for 3 minutes at RT after overnight incubation. A 
lead aspartate solution was prepared by dissolving 0.066 g lead nitrate in 10 mL of an 
aspartic acid stock solution (0.998 g L-aspartic acid in 250 mL of ddH2O) and adjusting pH 
to 5.5 with 1 N KOH. Samples were incubated in lead aspartate solution for 30 minutes in 
a 60˚C oven. Samples were washed five times in ddH20 for 3 minutes at RT and dehydrated 
in ice-cold solutions of freshly prepared 20%, 50%, 70%, 90%, 100%, 100% ethanol 
(anhydrous) for 5 minutes each at RT, before placing in anhydrous ice-cold acetone for 10 
minutes at RT. Samples were transferred to RT acetone for 10 minutes. Samples were then 
placed into increasingly concentrated ratios of Durcupan ACM resin (prepared following 
manufacturer’s instructions) to acetone as follows: 25%, 50%, and 75% 
(Durcupan:acetone) for 2 hours each. Samples were then placed in 100% Durcupan ACM 
resin overnight, and then into fresh 100% Durcupan ACM resin for 2 hours. Samples were 
mounted into fresh resin and placed in a 60˚C oven for 48 hours prior to sectioning. Resin-
embedded samples were then mounted and precision sectioned for SEM imaging. 
Sections were mounted onto grids for imaging by the ACMM on a SIGMA VP HD (Zeiss) 
scanning electron microscope.  
2.12. Cell-free Virus Release Assay 
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Monocytes and macrophages cells were infected with mock or virally-infected inoculum 
HFF and co-cultured as above. At 48 hours post inoculation, cell media from mock and 
VZV infected monocytes and macrophages was removed and clarified by centrifugation at 
652 x g for 5 minutes. Supernatants were then filtered through 0.45 µm filters (Millipore) 
and inoculated without dilution onto previously seeded monolayers of 1x105 HFF adhered 
to coverslips. Fibroblasts were examined for the presence of plaques and CPE daily, until 
harvesting after 5 days and staining for IFA as described previously (Section 2.10).  
2.13. Cell Viability Assay 
Monocytes were mock and VZV infected as described previously (Section 2.8). At 24 and 
48 h post-infection (hpi), monocytes were harvested and immunostained for cell-surface 
VZV gE:gI, in combination, with intracellular staining for cleaved caspase-3 (Section 2.9). 
In some experiments, prior to collection for immunostaining, monocytes were treated with 
0.5 µM staurosporine (Sigma Aldrich) for four hours. Following treatment, cells were 
immediate collected for flow cytometry.  
2.14. Infectious Centre Assay 
HFFs were seeded onto glass coverslips (Menzel Gläser) at a density of 1x105 cells per 
coverslip in 24-well plates, one day prior to the addition of inoculating monocytes. Target 
monocytes were infected with mock or VZV infected CFSE-labelled HFF for 24 hours. 
Monocytes were then isolated by FACS sorted as previously described, to exclude the 
infected HFF inoculum (Section 2.9.3). FACS isolated monocytes were washed in PBS and 
inoculated onto previously seed HFF cultures at a ratio of one monocyte to five HFF (1:5). 
In some experiments, prior to inoculation, monocytes were incubated with 1 mL citrate 
buffer for 1 minute at RT. Citrate-treated monocytes were washed in media twice following 
incubation. 24-well plates containing monocyte-inoculated HFF on coverslips were 
centrifuged at 200 x g for 15 minutes at RT to facilitate contact and cultured for five days 
at 37˚C with 5% CO2. After five days, fibroblast monolayers were examined for plaque 
formation through IFA as previously described (Section 2.10). 
2.15. Dextran Endocytosis  
To assess endocytosis, monocytes and macrophages were mock and VZV infected as 
previously described (Section 2.8) with a CTV-labelled HFF. At 24 hpi, monocytes in 
suspension were collected, counted, and seeded at 1x106 per mL into flat 96 well plates 
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(BD Biosciences). For macrophage infection and endocytosis, monocytes were 
differentiated in 12 well plates (BD Biosciences) with M-CSF or GM-CSF as previously 
described (Section 2.7.3) prior to infection. For endocytosis, fresh media was added to 
plates and dextran-FITC (40,000 MW; Sigma Aldrich) was added for 1 hour at 37˚C under 
5% CO2, or, at 4˚C. Following incubation, macrophage media was aspirated, whereas 
monocytes were centrifuged at 652 x g for 5 minutes to pellet cells, and supernatant was 
aspirated. Cells were washed three times in cold 1X PBS prior to immunostaining for flow 
cytometry as previously described (Section 2.9). The levels of endocytosed dextran were 
established by comparing the expression of FITC following incubation at 4˚C, which 
mediates surface binding of dextran, and at 37˚C, which facilitates surface binding and 
entry of dextran. The MFI of dextran at 4˚C was subtracted from the MFI of dextran at 37˚C 
to generate MFI of ‘internalised dextran’. The MFI of internalised dextran was normalised 
to respective mock infected cells at each timepoint.  
2.16. Enzyme-Linked Immunosorbent Assay (ELISA)  
Sandwich ELISAs were performed using commercial kits (R&D Systems, Elisakit.com) and 
following manufacturer instructions. Standard protein samples were reconstituted using 
provided diluent, and 1:2 serial dilutions were performed following manufacturer 
concentration specifications. Samples were diluted as required in kit-supplied diluent. 
Samples and standard dilution series were added to ELISA plate for two hours incubation 
at RT and plates were sealed with adhesive strips. Samples and standard dilution series 
were aspirated and plate wells were washed three times with supplied washing buffer at 
appropriate dilution. Conjugate solution containing appropriate capture antibodies were 
added to plate wells for 2 hours at RT and covered with an adhesive strip. All wells were 
washed as previously in washing buffer, prior to addition of freshly prepared substrate 
solution containing hydrogen peroxide and 3,3’,5,5’-tetramethylbenzadine. Wells were 
incubated for 10-20 minutes at RT protected from light before addition of ‘Stop Solution’ 
containing 2 M sulfuric acid and thorough mixing. ELISA kit-specific absorbance was 
measured, with reference wavelength absorbance measured when specified, using a Tecan 
Infinite M1000Pro Plate Reader (Tecan) and Tecan i-Control Software (Tecan). The lower 
limit of qualification specific to each commercial ELISA kit utilised is listed below. 
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Commercial Name Supplier  Analytical Sensitivity 
Human TNF-alpha ELISA Kit ElisaKit.com < 5 pg/mL  
Human IL-1-beta ELISA Kit ElisaKit.com < 1 pg/mL 
IL-18 Human ELISA Kit ThermoFisher Scientific 6.25 pg/mL 
 
2.17. Cytokine Secretion Assays 
To measure the concentration of cytokines which did not require exogenous stimulation for 
production or secretion, supernatants were collected as previously described (Section 
2.12) and ELISAs were performed as previously described (Section 2.16). To measure the 
production of cytokines requiring exogenous stimulation, cells underwent stimulation as 
follows. For treatment of monocytes with LPS, monocytes were collected and 300,000-
600,000 cells were resuspended at 106 per mL in fresh RPMI-1640 supplemented with 10% 
FCS and 50 IU/mL penicillin streptomycin. Monocytes were then incubated with 100 ng/mL 
lipopolysaccharide (LPS) from Escherichia coli 055:B5 (Sigma Aldrich) for 3 hours at 37˚C 
under 5% CO2. Supernatants from treated cells were collected, clarified by centrifugation 
at 652 x g for 5 minutes, and stored at -80˚C. In certain experiments, LPS-treated cells were 
further treated with nigericin (Ngn). Following LPS treatment, cells were incubated with 10 
µM Ngn (Sigma Aldrich) for 30 minutes at 37˚C under 5% CO2. Supernatants from treated 
cells were collected, clarified by centrifugation at 652 x g for 5 minutes, and stored at -
80˚C. Supernatants were then collected and used in ELISAs (Section 2.16). For assessment 
of cytokine secretion from HFF, 1x105 HFF were seeded into plates one day prior to 
infection. HFF were then inoculated with mock or VZV infected HFF at a ratio of 1:2. At 24 
hpi, the media of mock and VZV infected HFF cultures was replaced with fresh DMEM 
supplemented with 10% FCS and 50 IU/mL penicillin streptomycin. Stimulation of HFF with 
LPS and Ngn, and handling of supernatants, followed as described above.  
2.18. Statistical Analyses 
All statistical analyses were performed as stated using GraphPad Prism versions 6 and 7 
(GraphPad Inc).  
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3. Infection of Human Monocytes and Macrophages by VZV  
3.1. Introduction 
It has been previously documented that multiple immune cell types are susceptible to VZV 
infection. A number of studies have focused on the permissive nature of peripheral blood 
mononuclear cells (PBMC) to VZV infection during acute varicella and reactivation to herpes 
zoster (38, 68, 316, 318, 424). Furthermore, it has been identified that human  
T lymphocytes, DCs, and NK cells in vitro, are susceptible to VZV infection, and these 
reports have led to the discovery of many immunoevasive strategies VZV is capable of 
undertaking (23, 35, 40, 228). However, subpopulations of PBMC such as monocytes, have 
been relatively understudied. This gap in knowledge has resulted in conflicting reports and 
poor consensus regarding the role of monocytes and macrophages during VZV infection 
(243, 323, 425) 
In our laboratory we have previously employed the widely accepted model of monocyte-
derived dendritic cells (MDDC) to address the susceptibility of human DCs to VZV infection. 
Specifically, we demonstrated that immature and LPS-matured MDDC are permissive to 
productive VZV infection (34, 37). These studies also provided evidence that DCs are able 
to transmit infectious VZV to T cells, and that the capacity of VZV infected DCs to stimulate 
T cells is reduced (34). The MDDC model utilised stepwise differentiation of the  
MDDC-precursor CD14+ monocytes, although the susceptibility of human monocytes to 
VZV infection was not investigated.  
Few studies have investigated the susceptibility of monocytes to VZV infection, with VZV 
infection of monocytes in vitro initially reported to be abortive (322, 323). Further 
investigations observed the presence of VZV antigen on the surface of monocytes exposed 
to VZV in vitro, suggesting these cells may support VZV infection (39, 324). More recently, 
human monocytes were exposed to VZV infected cells in vitro however, this study did not 
report the proportion of VZV infected cells (243). To date, no study has directly 
demonstrated the susceptibility of human monocytes to productive VZV infection. Human 
monocytes play an integral role in immune surveillance and pathogen clearance in vivo 
(402) and, as previous literature extensively describes the direct infection of circulating 
immune cells by VZV (Section 1.4.4), it is necessary to characterise the influence VZV 
infection may have on this dynamic population of immune cells.  
  69 
Circulating monocytes also have the capacity to enter non-lymphoid organs under  
steady-state conditions to replenish local niches of tissue-resident macrophages (trMΦ) 
and DCs (386, 426). Certain reservoirs of trMΦ are seeded upon birth and are maintained 
independently of migratory monocytes (Section 1.5.2). During microbial inflammation, 
migrating circulatory monocytes are able to replenish skin-resident Langerhans cells and 
dermal DCs with inflammatory DC populations (427, 428). Differentiation of circulating 
monocytes into site-specific MDDCs and monocyte-derived macrophages (MD-MΦ) allows 
for functional specialisation through exposure to local stimuli (388). Interestingly, extended 
culture of human monocytes has been demonstrated to yield macrophages that are 
susceptible to VZV infection (322, 323). However, the susceptibility of MD-MΦ derived 
through signalling pathways commonly utilised in vivo to generate MD-MΦ, has yet to be 
performed. Consequently, it is important to consider the impact of viral infection on fully 
differentiated subsets of monocyte-derived cells as well as the capacity of viral infection to 
influence the differentiation and polarisation process.  
To this end, freshly isolated human CD14+ monocytes from blood donor PBMC were 
assessed through multiple virological and immunological based approaches to directly 
characterise their susceptibility to productive VZV infection. Furthermore, CD14+ MD-MΦ 
were generated to likewise investigate their susceptibility to VZV infection. This chapter 
aims to investigate the previously understudied monocyte-macrophage axis and elucidate 
the susceptibility of these important immune cells to VZV infection. 
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3.2. Results 
3.2.1. VZV infection of human CD14+ monocytes. 
Isolation of monocytes from human PBMC. 
To obtain PBMC from human blood, the widely accepted method of human blood 
fractionation through Ficoll-Hypaque Plus gradient centrifugation was undertaken (429) 
(Section 2.7.1). Isolating human monocytes from PBMC can be achieved through 
adherence of monocytes to glass, repeated high-density gradient separation,  
antibody-labelled magnetic bead separation, or a combination thereof (323, 324, 430). As 
human monocytes comprise approximately 10-30% of PBMC, CD14 magnetic bead 
selection was utilised to enrich monocytes to on average >95% of isolated cells (Section 
2.7.2) (Figure 3.1A). PBMCs and isolated cell fractions were then immunostained for 
expression of CD14 and CD16 (Section 2.9). Flow cytometric analysis for CD14 and CD16 
demonstrated the separation of human monocytes into three distinct subsets: classical 
(CD14++CD16–), intermediate (CD14+CD16+), and non-classical (CD14loCD16++) monocytes 
(384) (Figure 3.1B). In comparison to PBMC, CD14 selection enhanced the proportion of 
classical monocytes from approximately 10% of total cells to 90-95%. In addition, CD14 
selection increased the proportion of CD14+ intermediate monocytes from approximately 
0.5% to 5% of total cells and did not result in the collection of non-classical monocytes 
(Figure 3.1B). Negative fractions from CD14 isolation comprised a small proportion of 
classical monocytes, confirming that MACS separation isolates the majority of classical 
monocytes from PBMC (Figure 3.1B). Analysis of surface CD11b, a pan-monocyte marker, 
revealed classical and intermediate monocytes exhibit comparatively greater surface 
CD11b in contrast to non-classical monocytes, although non-classical monocytes retain 
higher surface CD11b than non-monocyte subsets of PBMC (Figure 3.1C). Thus, CD14 
selection enhanced the proportions of classical and intermediate monocytes from PBMC 
and as such, this technique provides a direct method to isolate monocytes for VZV 
infection.  
Monocytes exhibit surface VZV antigen following co-culture with VZV infected HFF. 
Propagation of VZV in vitro results in highly cell-associated virus which necessitates lengthy 
and time-consuming methods to generate cell-free preparations (431). Cell-free VZV  
(CF-VZV) generation typically results in low viral titres which are often contaminated with 
cellular and viral debris (432). 
Figure 3.1: Acquisition and comparison of monocytes isolated from human peripheral 
blood. Human peripheral blood mononuclear cells (PBMC) were collected from donated blood 
buffy coats using ficoll-density gradient centrifugation. Monocytes were enriched by anti-CD14+ 
microbeads bead selection. (A) PBMC prior to isolation, CD14+ fraction, and CD14– fraction 
cells were examined by flow cytometry for monocytes (boxed) as a proportion of total single 
cells. (B) Proportions of total single cells were stratified into classical (CD14+CD16–), 
intermediate (Inter: CD14+CD16+), non-classical (NC: CD14loCD16+) monocytes, and other 
non-monocyte subsets. (C)  Analysis of CD11b expression in classical (blue), intermediate 
(yellow), non-classical (red) monocytes, and non-monocyte populations (black). Representative 
of n=3 biologically independent donors.
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As such, a cell-associated model of infection is the most common approach to infect cells 
in vitro with VZV. Human foreskin fibroblasts (HFF) are highly permissive to VZV and are 
commonly used to transmit VZV to other cell types in a cell-associated manner (34, 35, 40). 
This current investigation utilised a low-passage VZV clinical isolate, strain S (VZV), which 
was propagated in low-passage HFF (Section 2.8.2). Prior to infection, mock and VZV 
infected HFF inoculum were labelled with CFSE as previously published, to allow their 
exclusion from subsequent analysis (142, 173, 433) (Section 2.8.3).  
Human CD14+ monocytes were co-cultured with labelled mock or VZV infected HFF at a 
ratio of 1 HFF to 2 monocytes in a cell-associated infection (Section 2.8.4). At 24, 48, and 
72 hours post infection (hpi), non-adherent cells were collected and examined by flow 
cytometry for expression of VZV antigen, a complex of glycoproteins E and I (gE:gI) which 
is expressed late in the virus replicative cycle (115). Monocytes were first gated based on 
size followed by gating on viable cells as determined by live/dead dye (Figure 3.2A). 
Monocytes were further identified by pan-monocyte marker CD11b (Figure 3.1C) and the 
absence of CFSE (Figure 3.2A). VZV gE:gI was readily detected on monocytes co-cultured 
with VZV infected HFF in multiple independent biological replicates (Figure 3.2B-C). On 
average, VZV gE:gI was detected on the surface of 24.6% monocytes at 24 hpi (n=33), 
27.1% at 48 hpi (n=29), and 29.2% at 72 hpi (n=5), with a range between 7-62% across all 
timepoints (Figure 3.2C). VZV gE:gI was not detected on the surface of monocytes  
co-cultured with mock infected HFF (Figure 3.2B). These results indicate that co-culture of 
human CD14+ monocytes with VZV infected HFF results in the expression of surface VZV 
gE:gI on monocytes at multiple timepoints. 
All classes of VZV gene products are observable in VZV co-cultured monocytes. 
In order to determine whether monocytes were fully permissive to VZV infection, these cells 
were examined for expression of the three temporally distinct VZV gene classes, namely, 
immediate early (IE), early (E) and late (L) viral gene products (136). Immunofluorescence 
assays (IFA) were undertaken to identify the expression and sub-cellular localisation of 
immediate early protein 62 (IE62), early protein from open reading frame 29 (pORF29) and 
late glycoprotein E (gE) in VZV co-cultured monocytes. Monocytes were isolated and  
co-cultured with CFSE-labelled mock or VZV infected HFF as described above to provide 
a reliable means to readily distinguish inoculating cells from monocytes.  
 
AB
Figure 3.2: Infection of isolated human CD14+ monocytes with VZV. Human PBMC were 
collected from donated blood buffy coats and CD14+ monocytes were isolated via anti-CD14 
microbead isolation. Isolated CD14+ monocytes were co-cultured with mock or VZV infected 
CFSE-labelled HFF for 24-72 hours. (A) Monocytes were gated on by size and viability, and 
excluded CFSE-labelled HFF inoculum through assessment of CFSE and monocyte marker 
CD11b. (B) Monocytes were analysed for cell-surface expression of late VZV antigen gE:gI. 
Representative dot-plots indicate mock or VZV co-cultured monocytes. (C) VZV infected 
monocytes exhibited surface VZV gE:gI. Bars indicate mean proportion at 24 hpi (n=33), 48 hpi 
(n=29), and 72 hpi (n=5) . 
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At 48 hpi, non-adherent monocytes were spotted onto glass microscope slides prior to  
immunofluorescent staining with specific antibodies against IE62, pORF29, or gE (Section 
2.9). Isotype control antibodies were also included to establish staining specificity. Analysis 
of mock co-cultured monocytes showed no observable viral antigen expression (Figure 
3.3). In VZV co-cultured monocytes, VZV antigen staining was readily observable with 
antibodies specific for VZV IE62, ORF29 and gE (Figure 3.3A-C). IE62 showed diffuse 
staining throughout the nucleus and cytoplasm, consistent with what has been reported 
during late VZV infection (Figure 3.3A) (115, 434). pORF29 staining was observed as 
punctae within the nucleus of infected monocytes, similarly consistent with reported 
literature (Figure 3.3B) (115). Diffuse plasma-membrane localisation of gE was observed 
consistent with late-stage VZV infection (Figure 3.3C) (115, 435). DAPI staining in each 
population was consistent with nuclear binding. No specific staining was detectable with 
respective isotype antibody staining (Figure 3.3). In parallel to mock and VZV co-cultured 
monocytes, CD14+ monocytes alone were cultured and immunostained for VZV antigens 
and no viral antigen was observed as expected (data not shown). Analogous results were 
obtained from five independent blood donors. Based on the expression and localisation of 
the three kinetic classes of VZV antigens, in conjunction with flow cytometry data, these 
results suggest that human CD14+ monocytes are productively infected with VZV.  
Detection of VZV virions by backscattered scanning electron microscopy (BSEM) in 
VZV infected HFF and human monocytes. 
To determine whether virions could be visualised in VZV infected monocytes, cells were 
subject to backscattered scanning electron microscopy (BSEM). Monocytes were mock 
and VZV infected as previously described, and VZV infected HFF were cultured in parallel. 
At 24 hpi, all cells were collected and fixed in glutaraldehyde for BSEM processing  
(Section 2.11). Observation of VZV infected HFF and monocyte co-cultures revealed the 
disparate morphology of each cell type. Human monocytes were easily identifiable by small 
and circular morphology in contrast to the larger comparative size of HFF (Figure 3.4A). 
Mock infected monocytes displayed the expected ultrastructures, including observable 
mitochondria, endoplasmic reticulum, and golgi apparatus, as did VZV infected monocytes 
(Figure 3.4B).  
 
 
Figure 3.3: IFA for temporal classes of VZV antigens in mock and VZV infected monocytes. 
CD14+ isolated monocytes were co-cultured with mock or VZV infected HFF for 48 hours. 
Non-adherent monocytes were collected and spotted onto glass microscope slides as cell spots. 
Cell spots were fixed, permeabilised, and immunostained for VZV immediate-early protein IE62 (A), 
early protein pORF29 (B), late glycoprotein gE (C), or with corresponding isotype 
antibodies. Cell spots were counterstained with DAPI (blue) and all secondary antibodies 
conjugated to AF-594 (red). Images taken at 63X magnification and layouts display merged 
images, individual channels, isotype staining, and mock-infected monocytes. Images are 
representative of n=5 independent donors.
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Figure 3.4: Morphology and ultrastructures of mock and VZV infected monocytes and 
HFF by backscattered scanning electron microscopy. Freshly isolated monocytes were 
co-cultured with mock or VZV infected HFF. At 24 hpi, monocytes were collected and fixed in 
glutaraldehyde for backscattered scanning electron microscopy (BSEM) processing. (A) Mono-
cytes and HFF were identified via differential morphologies. (B) Mock infected monocytes (left) 
and VZV infected monocytes (right) displayed similar morphology and consistent ultrastructures. 
Indicated ultrastructures: nucleus (n), heterochromatin (h), euchromatin (e), golgi apparatus (g), 
endoplasmic reticulum (er), mitochondria (m). 
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BSEM of VZV infected HFF provided a useful biological control for the identification of VZV 
virions in a well-documented permissive cell type. In multiple VZV infected HFF, virions 
were readily observable along the cellular periphery (Figure 3.5A). Virions appeared to line 
the outer surface of infected cells (Figure 3.5B), consistent with previous reports of EM in 
VZV infected melanoma cell lines (436). Interestingly, a minority of VZV infected HFF 
exhibited dense heterochromatin distribution throughout the nucleus (Figure 3.5C). This 
may be an indication of VZV replication compartment formation, previously observed by 
IFA for IE gene products (115). VZV nucleocapsids were also observed at multiple sites 
within the nucleus of this particular HFF (Figure 3.5D). This indicates de novo synthesis of 
viral particles and suggests these particles are undergoing export from the nucleus.  
When observing VZV infected monocytes within monocyte and HFF co-cultures by BSEM, 
few monocytes were observable containing readily identifiable virions. Thus, VZV infected 
monocytes underwent FACS sorting to exclude the infecting HFF inoculum, and to isolate 
VZV gE:gI+ monocytes (Section 2.11.2) (Figure 3.2). Resultant VZV gE:gI+ monocytes 
underwent BSEM processing as before. In many VZV gE:gI+ monocytes, virions were 
readily observed along the periphery of infected cells (Figure 3.6A-B and 3.6D). Closer 
examination revealed structures with dense cores, similar to those observed in VZV 
infected HFF (Figure 3.6C and 3.6E). In one particular monocyte, sectioning revealed the 
internal capsid structure of one virion (Figure 3.6F). Previously, detection of VZV virions by 
EM on the surface of primary T cells (35), pluripotent stem cell-derived neurons (437) and 
melanoma cell lines (436) was sufficient to determine productive VZV infection in these 
cells. Multiple VZV gE:gI+ monocytes also harboured viral nucleocapsids within the nucleus 
(Figure 3.7A). These viral structures were approximately 130 nm in size and most exhibited 
densely contrasting core material (Figure 3.7B, arrowheads). Another monocyte assessed 
by BSEM was observed harbouring virions on the surface of the cell in combination with 
the nuclear localised viral nucleocapsids (Figure 3.7C). Multiple distinct virions associated 
with the surface of this VZV gE:gI+ monocytes (Figure 3.7D, arrows) and viral nucleocapsids 
in the nucleus were of the same approximate size as viral nucleocapsids present in other 
monocytes (Figure 3.7E, arrowheads). The presence of virions on the surface of VZV gE:gI+ 
monocytes, and evidence of viral nucleocapsids in the nucleus of infected monocytes 
clearly demonstrates that human monocytes are permissive to fully productive VZV 
infection. 
 
Figure 3.5: Backscattered scanning electron microscopy of VZV infected HFF. VZV infected 
HFF were collected at 24 hpi and fixed in glutaraldehyde for BSEM processing. (A) Representative 
image of VZV infected HFF displaying VZV virions on the outer periphery of the cell membrane. 
(B) Inset of (A) demonstrating virions on outer periphery of cell membrane (arrows). 
(C) Representative image of VZV infected HFF displaying virions along the nuclear periphery. 
(D) Inset of (C) demonstrating virions on periphery of nucleus (arrows)
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Figure 3.6: Virions detectable on the surface of VZV infected monocytes. VZV infected 
monocytes were collected at 24 hpi for FACS sorting. VZV gE:gI+ monocytes were isolated and 
fixed in glutaraldehyde for BSEM processing. (A, D) Representative images of monocytes in 
which VZV virions were observed along the periphery. (B, C) Virions were localised to the external 
cell membrane of gE:gI+ monocytes (arrows). (E, F) Internal capsid structures were observable in 
some virions along the peripheral cell membrane (arrowhead). 
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BFigure 3.7: Viral nucleocapsids present in the nucleus of VZV infected monocytes. VZV 
infected monocytes were collected at 24 hpi for FACS sorting. VZV gE:gI+ monocytes were isolated 
and fixed in glutaraldehyde for BSEM processing. (A) Representative image of monocyte harbouring 
viral nucleocapsids in the nucleus. (B) Higher magnification image of nucleocapsids observed in 
(A) with magnified inset (white box). Arrowheads indicate virions. (C) Representative image of a VZV 
gE:gI monocyte with membrane-associated virions (magnified in D) and viral nucleocapsids in the 
nucleus (magnified in C). (D) Higher magnification image of membrane bound virions observable 
in (C). Arrows indicate membrane associated virions. (E) Higher magnification image of viral 
nucleocapsids observable in (C). Arrowheads indicate virions. 
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3.2.2. Transmission of VZV from monocytes to other permissive cell types in vitro. 
Propagation of VZV in vitro remains highly cell-associated, whereas in vivo dissemination 
is presumed to strike a balance between direct transfer of virus through cell-to-cell spread 
and release of cell-free virus into vesicular lesions (52, 115, 122). Monocytes are highly 
migratory and capable of disseminating widely throughout the host (438, 439). Relatedly, 
HCMV actively utilises the monocyte-macrophage axis for spread within the host (440). 
Therefore the susceptibility of this motile population to VZV infection may present an 
avenue for widespread dissemination, similar to the implied role of VZV infected DCs during 
pathogenesis (34). As such, the capacity for VZV infected monocytes to transfer infectious 
virus was assessed in an infectious centre assay (ICA).  
Infected monocytes are able to transfer VZV to HFF monolayers. 
Monocytes were mock and VZV infected with CFSE-labelled HFF as described previously 
(Section 2.8.3-4). At 24 hpi, monocytes were aspirated and immunostained for CD11b and 
VZV gE:gI for FACS isolation. Given the large number of cells required for subsequent ICA 
experiments, it was not feasible to isolate VZV gE:gI+ monocytes from these cultures. As 
such, monocytes were isolated through FACS sorting by gating on CD11b+ monocytes to 
exclude infecting CFSE-labelled HFF inoculum (Figure 3.2) (Section 2.9.3). During this 
process, monocytes were kept on ice to preserve cellular integrity. Following isolation, 
approximately 2x104 mock and VZV infected monocytes were inoculated onto previously 
seeded monolayers of 1x105 HFF on coverslips for ICA. Following five days incubation, 
coverslips were immunostained for VZV early and late antigens, pORF29 and gE, 
respectively (Section 2.10).  
Five days after VZV infected monocytes were inoculated onto HFF monolayers, many 
distinct viral plaques were readily detected by IFA (Figure 3.8A). Plaques ranged in size and 
number of cells, and all plaques exhibited nuclear pORF29 staining and diffuse gE staining. 
In contrast, no viral antigen staining was detectable following inoculation of mock infected 
monocytes or when isotype antibodies were used (Figure 3.8A). This was observed in seven 
biologically independent blood donors. To mitigate the potential interference of adherent 
infectious virus on the extracellular surface of inoculating monocytes, further experiments 
included citrate buffer treatment of monocytes prior to inoculation of HFF monolayers. 
Monocytes after isolation, but prior to inoculation of HFF monolayers, were treated with a 
low-pH citrate buffer to inactivate adsorbed viral particles (441-443) (Section 2.14).  
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Figure 3.8: Infectious centre assay of isolated mock and VZV infected monocytes (continued). 
Human monocytes were mock or VZV infected with CFSE-labelled HFF. At 24 hpi, monocytes 
were collected and FACS sorted for CD11b+ monocytes. Sorted mock and VZV infected mono-
cytes were seeded onto HFF monolayers at 1:5 (monocyte to HFF) and cultured for 5 days. (A) HFF 
monolayers were fixed and immunostained for early VZV protein ORF29 (green) and late VZV protein 
gE (red), or with respective isotype antibodies. All monolayers were counterstained with DAPI (blue) 
and composite images were taken at 4X magnification.  Images representative of n=7 independent 
experiments. (B) In certain experiments, FACS sorted monocytes prior to seeding were incubated with 
citrate buffer and immunostained for VZV gE or with isotype antibodies. Images are representative 
of n=3 independent experiments. (C) Plaques per inoculated monolayer were enumerated across 
three matched donors. Statistics performed: Paired two-tailed student’s t-test; ns: not significant. 
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Five days after inoculation of citrate-treated VZV infected monocytes onto HFF monolayers, 
plaque formation was readily observed, consistent with inoculation of untreated VZV 
infected monocytes (Figure 3.8B). Inoculation of citrate-treated mock infected monocytes 
did not result in viral plaque formation (Figure 3.8B). Numbers of plaques per inoculated 
HFF monolayer were enumerated in both untreated monocytes and citrate-treated 
monocytes in three experiments with matching blood donors (Figure 3.8C). Citrate treated 
monocytes appeared to generate fewer plaques in comparison to untreated monocytes, 
although this did not reach statistical significance.  
The observed plaque formation following transfer of VZV infected monocytes demonstrates 
the potential of VZV infected monocytes to transmit VZV to HFF through direct  
cell-mediated infection. This result may also imply that VZV infected monocytes potentiate 
the transfer of infectious virus during infection in vivo. 
VZV infected monocytes do not release infectious virus into culture supernatant. 
Propagation of VZV in vitro results in the strict cell-association of newly synthesised virions 
(195) and relies heavily on cell-to-cell transmission of the virus (122). While monocytes were 
capable of transmitting infectious virus directly to HFF, their capacity to release cell-free 
virus following infection had yet to be directly addressed. Therefore, culture supernatants 
from mock and VZV infected monocytes at 24 hpi were assessed for the release of 
infectious VZV. Supernatants were clarified and filtered prior to inoculation onto previously 
seeded HFF monolayers on coverslips (Section 2.12). Five days post-inoculation, 
coverslips were harvested and immunostained for VZV gE or corresponding isotype 
antibodies. In five independent experiments, supernatants from mock and VZV infected 
monocytes did not generate viral plaque formation in HFF monolayers as evidenced by lack 
of VZV antigen detection (Figure 3.9). In all isotype antibody stains no VZV antigen staining 
was observed. Thus, VZV infected monocytes are unable to produce detectable cell-free 
VZV (CF-VZV) which is a common trait associated with in vitro propagation of VZV.  
Summary of monocyte susceptibility to VZV infection. 
In characterising the susceptibility of human monocytes to VZV infection, these results have 
demonstrated the presence of viral gene products within infected cells from each temporal 
class of VZV genes. VZV gE:gI+ monocytes were observed to harbour surface-bound VZV 
virions and viral nucleocapsids were detected in the nucleus of VZV infected monocytes.  
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Figure 3.9: Assessment of VZV infected monocyte supernatant for release of infectious virus 
by plaque assay. Human monocytes were mock or VZV infected. At 24 hpi, culture supernatant was 
collected, clarified, and filtered, prior to inoculation of HFF monolayers. (A-B) Monolayers were 
cultured in the presence of supernatant from mock or VZV infected monocytes for 5 days. 
Coverslips were fixed, permeabilised and immunostained for VZV late protein gE (red) or with 
corresponding isotype antibodies and counterstained with DAPI (blue). Composite images taken 
at 10X magnification and layouts display merged images adjacent to individual channels and 
isotype staining. Images are representative of n=5 independent experiments. 
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Furthermore, in the absence of CF-VZV secretion, VZV infected monocytes were capable 
of transmitting infectious virus to HFF. These results demonstrate for the first time that 
human monocytes are permissive to a full productive VZV infection, as well as capable of 
transmitting VZV to susceptible cells. The ability of VZV to infect this highly abundant 
population of circulating immune cells may have far-reaching implications for the spread 
and resolution of disease, which will be addressed further in Chapters Four and Five.  
3.2.3. Generation of monocyte-derived macrophages in vitro.  
Differentiation of monocyte-derived macrophages. 
The initial reports that described the abortive nature of VZV infection in isolated monocytes 
demonstrated that extended culturing of monocytes for 5-7 days prior to VZV infection, 
generated macrophages that were highly susceptible to VZV infection (322, 425). However, 
in vitro generation of macrophages typically involves stimulation with macrophage-colony 
stimulating factor (M-CSF) or granulocyte macrophage-colony stimulating factor (GM-CSF) 
(385, 444, 445). As such, no study has previously reported the susceptibility of  
M-CSF-derived MΦ (M-MΦ) or GM-CSF-derived MΦ (GM-MΦ) to VZV infection. As it was 
demonstrated that human monocytes support fully productive VZV infection, we sought to 
determine if M-MΦ and GM-MΦ are similarly susceptible to VZV infection.  
It has been a long-held notion that macrophages are represented by their polarisation state, 
namely, M1 (inflammatory), and M2 (anti-inflammatory) (446). The M1/M2 polarisation 
framework through which we view macrophages is not necessarily representative per se of 
all differentiated macrophages; rather these activation states are characterisations of the 
two extremes: M2-like ‘wound healing’ and M1-like ‘inhibitory’ macrophage subsets 
(reviewed in 447). These designations are not reflective of the spectrum of macrophage 
markers that are derived from highly specialised differentiation, and as such, it is difficult 
to commit the unique niches of macrophages into all-encompassing nomenclature. As 
these markers are determined by their cytokine environment, detailed reporting of the 
biological conditions under which MD-MΦ are generated in vitro is strongly recommended 
(416). Phenotyping MD-MΦ generated in vitro also mitigates the presumption of phenotype 
when using any given stimulus. Therefore, prior to assessing the susceptibility of MD-MΦ 
to VZV infection, we sought to generate and phenotype MD-MΦ to serve as a biological 
control for future experiments.  
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Phenotyping human monocyte-derived M-CSF and GM-CSF macrophages.  
Human monocytes were isolated by CD14 magnetic bead separation as detailed previously 
(Section 2.7.1-2) and adhered in serum-free media for 2 hours prior aspiration of  
non-adherent monocytes. Remaining adherent monocytes were cultured with 25 ng/mL  
M-CSF (M-MΦ) or 400 IU/mL GM-CSF (GM-MΦ) for six days (Section 2.7.3). Light 
microscopy was performed on freshly isolated monocytes prior to differentiation, and on 
M-MΦ and GM-MΦ after differentiation. Light microscopy revealed freshly isolated 
monocytes were small in size and rounded in morphology in comparison to M-CSF or GM-
CSF derived cells (Figure 3.10A). M-MΦ comprised a heterogenous population of cells with 
a rounded or elongated morphology (Figure 3.10B). These results corroborate previous 
literature which similarly identified two macrophage subsets following M-CSF 
differentiation (448, 449). GM-MΦ were comprised solely of rounded cells, larger in size in 
comparison to monocytes (Figure 3.10C). Both rounded and elongated macrophages 
exhibited podosome formation and extension around a central nucleus (Figure 3.10B-C, 
arrows), and this morphology was observed for both M-MΦ and GM-MΦ and was 
consistent across multiple independent blood donors.  
To assess M-MΦ and GM-MΦ differentiation by flow cytometry, freshly isolated monocytes 
and MD-MΦ at day six were phenotyped for differentiation-specific macrophage markers, 
CD71 and mannose receptor (MR) (450). After six days differentiation, both M-MΦ and  
GM-MΦ exhibited significantly higher proportions of CD71+ and MR+ cells in comparison 
to freshly isolated monocytes (Figure 3.11A). GM-MΦ constituted higher proportions of 
MR+ cells in comparison to M-MΦ. Given that M-MΦ were observed to comprise a 
heterogenous population of rounded and elongated MD-MΦ morphologies which has been 
previously associated with M1 and M2 macrophage polarisation states respectively (451), 
we sought to further examine the heterogeneity of these cells through flow cytometry. M2-
like macrophages have been reported to express CD14 and CD163 to higher proportions 
than M1-like macrophages (445, 448). Prior to differentiation, almost all freshly isolated 
monocytes were CD14+, however in comparison, significantly fewer M-MΦ (mean 36%) 
retained CD14 expression and CD14 expression was observed to be donor-variable with a 
range between 1-72% (Figure 3.11B). GM-MΦ also had significantly less CD14+ cells than 
either freshly isolated monocytes or M-MΦ (Figure 3.11B). In contrast, M-MΦ had 
significantly higher proportions of CD163+ cells (mean 36%) when compared to freshly 
Figure 3.10: Morphology of human M-CSF-derived and GM-CSF-derived macrophages. 
Human monocytes were adhered for 2 hr in serum-free media. Non-adherent monocytes 
were removed and differentiation media containing either 25 ng/mL M-CSF or 400 IU/mL 
GM-CSF was added for six days (D6). Cultures were imaged by light microscopy to 
identify cell morphology. (A) Light microscopy of isolated monocytes prior to differentiation, 
day six M-CSF treated, and day six GM-CSF treated monocytes at 10X magnification. 
(B) M-CFS macrophages (M-MΦ) under higher magnification. (C) GM-CSF macrophages 
(GM-MΦ) under higher magnification. Images are representative of four independent blood 
donors. Arrows indicate podosome formation around central nuclei of M-MΦ and GM-MΦ. 
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Figure 3.11: Cell-surface immunophenotyping of M-MΦ and GM-MΦ. Human monocytes 
were adhered for 2 hours in serum-free media. Non-adherent cells were removed and 
differentiation media containing either 25 ng/mL M-CSF or 400 IU/mL GM-CSF was added for six 
days. Monocytes prior to differentiation (green), M-MΦ (blue), and GM-MΦ (red) were examined 
by flow cytometry for proportion of MD-MΦ expressing indicated markers. (A) Representative 
contour plots display expression of CD71 (n≥5) and MR (n≥5) in comparison to isotype antibody 
staining (dashed line). Graph depicts proportions of CD71+ and MR+ cells (bar signify means) 
and symbols represent independent donors. (B) Representative contour plots of CD14 (n≥5) and 
CD163 (n≥4) in comparison to isotype antibody staining (dashed line). Graph depicts proportions 
of CD14+ and CD163+ cells (bar signify means) and symbols represent independent donors. 
Statistics performed: ordinary one-way ANOVA with Tukey’s MC; * p<0.05, ** p<0.005, *** 
p<0.0005, **** p<0.00005, ns: not significant. 
CD71 MR
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isolated monocytes (mean 2%), although this phenotype was also donor-variable with a  
range between 1-92%. Fewer CD163+ GM-MΦ (mean 2%) were observable in comparison 
to M-MΦ, although this did not reach statistical significance.  
Taken together, these results demonstrate that both M-CSF and GM-CSF generate MD-
MΦ as evidenced by distinct cell morphology and expression of macrophage markers 
CD71 and MR. Furthermore, M-CSF, but not GM-CSF, generates heterogenous 
populations of MD-MΦ comprising cells of two distinct morphologies and represented by 
the presence of M2-like macrophage markers CD14 and CD163 (Table 3.1). These data 
highlight the varying proportions of M1-like and M2-like M-MΦ, as well as demonstrating 
the inter-donor phenotypic variability of MD-MΦ generated in vitro. These models also 
allow us to assess the susceptibility of MD-MΦ derived from different differentiation 
conditions to VZV infection. 
Table 3.1 – In vitro Monocyte-derived Macrophages 
 
Phenotype Cytokine Morphology Phenotype 
 
M1-like “Inflammatory” 
 
M-CSR or GM-CSF 
 
Rounded 
 
CD71+ MR+ 
CD14lo CD163– 
 
 
M2-like “Wound-healing” 
 
 
M-CSF  
 
 
Elongated 
 
 
CD71+ MR+ 
CD14hi CD163+ 
 
3.2.4. VZV infection of M-MΦ and GM-MΦ.  
Human monocytes were demonstrated to support productive VZV infection. Previous 
reports have also demonstrated that susceptibility of monocyte-derived cells, such as 
MDDC, to VZV infection (34, 37). No previous investigation into the susceptibility of 
monocyte-derived M-MΦ or GM-MΦ has been undertaken, and as such, we sought to 
establish if these cells support VZV infection.  
M-MΦ and GM-MΦ are susceptible to VZV infection. 
Freshly isolated monocytes were cultured with M-CSF or GM-CSF as described previously 
(Section 2.7) to generate M-MΦ and GM-MΦ, respectively. Differentiation was confirmed 
by light microscopy for MD-MΦ morphology and flow cytometry phenotyping after six days, 
which mirrored results previously observed (Figure 3.10-11). After differentiation, M-MΦ 
and GM-MΦ were co-cultured with mock or VZV infected, CFSE-labelled HFF at a ratio of 
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1 HFF to 5 MΦ (1:5) (Section 2.8.3-4). CFSE-labelling of the infecting HFF inoculum allows 
for their exclusion from subsequent analysis. M-MΦ and GM-MΦ were collected at 24 hpi 
and 48 hpi for flow cytometry. MD-MΦ were immunostained with live/dead dye and 
antibodies against CD14 and VZV gE:gI, or respective isotype antibodies. Analysis was 
performed on MD-MΦ gated by size, viability, and to exclude the CFSE-labelled HFF 
inoculum (Figure 3.12A). VZV gE:gI was readily detected by flow cytometry on the surface 
of M-MΦ at 24 and 48 hpi (Figure 3.12B). Surface VZV gE:gI was detected on an average 
of 49% of M-MΦ at 24 hpi (range 16-71%) which significantly increased to 67% of M-MΦ 
at 48 hpi (range 21-94%) (Figure 3.12C). VZV gE:gI was also readily detected on the surface 
of GM-MΦ exposed to VZV infected HFF at 24 and 48 hpi by flow cytometry (Figure 3.12D). 
Surface VZV gE:gI was detected on an average of 40% of GM-MΦ at 24 hpi (range 13-
68%) which significantly increased to 56% of GM-MΦ at 48 hpi (range 6.7-85%) (Figure 
3.12E). As expected, no VZV gE:gI staining was detected on the mock infected M-MΦ or 
G-MΦ. These experiments provide evidence that following co-culture of M-MΦ and GM-
MΦ with VZV infected HFF, surface expression of VZV gE:gI is detectable and increases 
over time. Although VZV infection has been previously reported in MD-MΦ, those studies 
did not attempt differentiation with M-CSF or GM-CSF. As such, our results are the first 
evidence that M-MΦ and GM-MΦ are permissive to VZV infection in vitro.  
CD14 expression on M-MΦ does not influence susceptibility to VZV infection. 
M-CSF differentiation generates a heterogenous population of MD-MΦ with a significant 
proportion of cells expressing M2-like macrophage markers CD14 and CD163. This 
proportion of cells was observed to be highly variable across MD-MΦ generations of 
independent blood donors (range of 1-72%) (Figure 3.11B). We therefore sought to 
examine if susceptibility to VZV infection was preferentially targeted towards or against M2-
like M-MΦ based on the differential expression of CD14. Mock and VZV infected M-MΦ 
were assessed by flow cytometry at 24 hpi to examine the number of VZV gE:gI+ CD14+ M-
MΦ in comparison to the number of VZV gE:gI+ CD14– M-MΦ (Figure 3.12F). When 
enumerated, there was no observable difference in the proportion of VZV gE:gI+ M-MΦ 
when CD14+ and CD14– M-MΦ from matched donors were compared across 7 independent 
experiments (Figure 3.12G). This data suggests that although M-MΦ comprise a 
heterogenous population of CD14+ and CD14– MΦ, there is no observable relationship 
between CD14 expression and susceptibility to VZV infection.  
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Figure 3.12: Assessment of VZV infection of M-MΦ and GM-MΦ by flow cytometry. 
Human monocytes were differentiated in the presence of M-CSF or GM-CSF for six 
days to generate M-MΦ and GM-MΦ respectively. MD-MΦ were co-cultured with mock 
or VZV infected, CFSE-labelled HFF at a ratio and 1:5 (HFF to MΦ). After 24 and 48 hours, 
MD-MΦ were collected for flow cytometric analysis of VZV gE:gI expression. 
(A) Representative plots demonstrate gating of MΦ by size, viability, and to exclude 
the infecting CFSE-labelled inoculum. (B) Representative plots display VZV gE:gI 
expression on mock infected and VZV infected M-MΦ at 24 hpi. (C) Graph displays 
proportion of VZV gE:gI+  M-MΦ at 24 hpi (n=9) and 48 hpi (n=10). Symbols represent 
individual donors. (D) Representative plots display VZV gE:gI expression on mock 
infected and VZV infected GM-MΦ at 24 hpi. (E) Graph displays proportion of VZV gE:gI+  
GM-MΦ at 24 hpi (n=5) and 48 hpi (n=5).  Symbols represent individual donors. (F) Representative 
plot of VZV gE:gI expression on VZV infected CD14+ and CD14– M-MΦ. (G) Proportion of CD14+ 
and CD14– M-MΦ expressing VZV gE:gI at 24 hpi (n=7). Statistics performed: Paired two-tailed 
student’s t-test; ns: not significant, * p < 0.05, *** p < 0.0005, ns: not significant.
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As such, further flow cytometric analyses assessed M-MΦ as a single population of cells, 
without separation into CD14+ and CD14– M-MΦ unless stated. 
M-MΦ and GM-MΦ exhibit de novo VZV protein synthesis. 
It was observed via flow cytometry that human MD-MΦ express cell-surface VZV antigens 
following co-culture with infected HFF. To assess productive infection of MD-MΦ with VZV, 
we sought to detect the presence of de novo VZV pORF29 by IFA. M-MΦ and GM-MΦ 
were generated and mock or VZV infected as before with a CFSE-labelled HFF inoculum. 
MD-MΦ were collected at 48 hpi and stained for IFA with antibodies against intracellular 
VZV pORF29 and counterstaining with DAPI (Section 2.10). MD-MΦ were readily 
discernible from inoculating HFF by morphology. At 48 hpi, punctate pORF29 staining was 
readily observed in the nuclei of multiple VZV infected M-MΦ and GM-MΦ (Figure 3.13A-
B). When isotype antibodies were used, some background fluorescence was observed 
within the cytoplasm of stained cells, however no punctate nuclear antigen staining was 
observed. Analysis of mock infected M-MΦ and GM-MΦ similarly revealed background 
cytoplasmic staining, however no punctate nuclear antigen stained was observed (Figure 
3.13A-B). DAPI staining in each population was consistent with nuclear binding. These 
results demonstrate that VZV infection of M-MΦ and GM-MΦ results in the de novo 
synthesis of nuclear VZV pORF29 further suggesting that M-MΦ and GM-MΦ are 
permissive to productive VZV infection.  
VZV infected M-MΦ and GM-MΦ do not release cell-free virus. 
Culture supernatants from mock and VZV infected M-MΦ and GM-MΦ at 48 hpi were 
collected to assess the capacity of infected MD-MΦ to release cell-free virus. Monolayers 
of uninfected HFF were seeded onto coverslips prior to inoculation with undiluted, filtered 
culture supernatants from mock and VZV infected M-MΦ and GM-MΦ at 24 hpi (Section 
2.14). After five days, HFF were assessed by IFA for the presence and localisation of VZV 
gE. In three independent experiments, supernatants from VZV infected M-MΦ did not 
generate viral plaques in inoculated HFF monolayers, as evidenced by the absence of VZV 
gE detection (Figure 3.14A). When mock infected supernatants from M-MΦ were inoculated 
onto HFF monolayers, no detectable VZV antigen staining was observed, and VZV antigen 
was not detected following staining with isotype antibodies. Supernatants from VZV 
infected GM-MΦ were inoculated onto HFF monolayers and no VZV gE staining was 
observable after five days (Figure 3.14B).  
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Figure 3.13: IFA of VZV infected M-MΦ and GM-MΦ. Human monocytes were differentiated 
in the presence of M-CSF or GM-CSF for six days to generate M-MΦ and GM-MΦ, respectively. 
Day 6 macrophages were co-cultured with mock or VZV infected, CFSE-labelled HFF. At 48 hpi, 
macrophages were collected and stained for IFA with antibodies against VZV pORF29, and 
counterstained for nuclear DAPI. (A-B) Representative merged images of VZV infected M-MΦ 
(A) and GM-MΦ (B) with detectable VZV pORF29 (purple), and nuclear DAPI (blue) with 
CFSE-labelled HFF inoculum (green). Merged images adjacent to individual coloured channels, 
and isotype staining of VZV infected M-MΦ and GM-MΦ (Isotype). Mock infected M-MΦ and 
GM-MΦ similarly depicted. Images are taken at 63X magnification and are representative of n=3 
independent blood donors. 
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Figure 3.14: Assessment of VZV infected M-MΦ and GM-MΦ supernatant for release of 
infectious virus by plaque assay. Human M-MΦ and GM-MΦ  were mock or VZV infected. At 
24 hpi, culture supernatant was collected, clarified, and filtered, prior to inoculation of HFF monolayers. 
(A-B) Monolayers were cultured in the presence of supernatant from mock or VZV infected (A) 
M-MΦ or (B) GM-MΦ for 5 days. Coverslips were fixed, permeabilised and immunostained for VZV 
late protein gE (red) or with corresponding isotype antibodies and counterstained with DAPI (blue). 
Composite images taken at 10X magnification and layouts display merged images adjacent to 
individual channels and isotype staining. Images are representative of n=3 independent 
experiments. 
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VZV gE staining was not detected following inoculation of supernatants from mock infected 
GM-MΦ, or when isotype antibodies were used. These results demonstrate that, similar to 
VZV infection of monocytes, M-MΦ and GM-MΦ do not release infectious cell-free VZV to 
the supernatant of cultures following in vitro infection. 
The detection of cell-surface VZV gE:gI by flow cytometry in the absence of uptake of the 
CFSE-labelled HFF inoculum, in conjunction with the presence of de novo VZV pORF29 
synthesis, demonstrate for the first time that M-MΦ and GM-MΦ generated in vitro are 
permissive to productive VZV infection. Together with evidence of productive VZV infection 
of human monocytes, the monocyte-macrophage axis represents a previously unexplored 
area of research into the immunomodulatory effects of VZV infection.  
 
 
  
  98 
3.3. Discussion 
Few studies have focused exclusively on the susceptibility of monocytes to VZV infection 
(39, 243, 322-324). This chapter identifies CD14+ monocytes as being fully permissive to 
productive VZV infection and these cells are capable of transmitting infectious virus to 
susceptible cells. Furthermore, it was demonstrated that both M-MΦ and GM-MΦ are 
similarly susceptible to productive VZV infection. Multiple studies have reported the 
susceptibility of the mononuclear cell (MNC) compartment to VZV infection in vivo and in 
vitro (42, 317, 319, 452, 453). The majority of these reports however did not identify the 
specific immune cells in which VZV was detected. Two publications that identified 
monocytes in MNC both observed the presence of intracellular VZV DNA (38, 318). A third 
study that isolated monocytes from children with varicella reported that 5% of adherent 
cells transmitted VZV, using a modified infectious centre assay (ICA) (454). Further attempts 
to investigate this relationship by exposing isolated monocytes to preparations of cell-free 
VZV (CF-VZV) have resulted in conflicting reports (39, 322-324). The results presented in 
this thesis address the limitations of these studies on multiple fronts.  
Two initial studies that exposed monocytes to CF-VZV in vitro determined VZV infection 
was abortive in monocytes (322, 323). These studies also suggested that differentiation of 
monocytes to macrophages was essential for productive VZV infection. Interestingly, these 
two studies isolated monocytes through adherence of monocytes to glass. Contrastingly, 
studies that isolated monocytes through adherence-independent MACS-bead selection 
reported detectable VZV gE in monocytes by IFA (39, 324). These results imply that 
adherence-mediated monocyte isolation may result in monocytes refractory to VZV 
infection until MD-MΦ differentiation occurs. Indeed, Bruun and colleagues observe 
adherence-mediated resistance of monocytes to HSV-1 infection suggesting that 
adherence alters monocyte differentiation states and restricts viral infection in vitro (455). 
Furthermore, adherence-isolated monocytes used to generate MDDCs in vitro were 
observed to have altered phagocytic function (456). Monocyte adherence is a crucial 
biological stimulus for differentiation and in certain conditions may be the only factor 
required for this maturation process (447, 457). As such, strict isolation and culture 
conditions must be maintained to reduce monocyte perturbation. Monocyte isolation 
through positive selection (such as methods performed in this thesis) carries little risk of 
activation or signal transduction as CD14 lacks a cytoplasmic tail, and therefore preserves 
the native biological state of circulating monocytes in vivo (458). Isolation through positive 
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selection also results in greater yields of target populations and higher purities in 
comparison to negative selection (459). This routinely performed technique represents the 
most robust method for investigating VZV infection in human monocytes and monocyte-
derived cells. 
Another factor separating the current study from previous literature is the use of a cell-
associated inoculum, as previous investigations, with the exception of one, utilised CF-VZV 
preparations (39, 322-324). The generation of CF-VZV produces prohibitively low titres that 
require concentration and is contaminated with cellular debris (460, 461). CA-VZV however, 
is routinely used to transfer VZV to permissive populations in vitro (34, 35, 40, 142) and 
promotes infection directly by cell-to-cell fusion and indirectly through infection from 
extracellularly-adherent virions (115). In contrast, low-titre CF-VZV can be insufficient in 
eliciting productive infection, as evidenced from the requirement of high-tire CF-VZV in 
infection of hESC-derived neurons (460). Surprisingly, the only identified study utilising a 
CA-VZV inoculum to infect adherence-isolated human monocytes, did not assay infected 
monocytes by flow cytometry or provide evidence of productive VZV infection in these cells 
(243). In contrast, productive infection of the monocytic-like THP-1 cell line by CA-VZV was 
confirmed via IFA and EM techniques (249). The techniques used to isolate monocytes and 
methods of VZV inoculation are important considerations that have previously not been 
addressed in the context of VZV infection of monocytes or macrophages. As such, 
exposure of immune cell subsets to VZV should be accompanied with in-depth validation 
of VZV infection to determine their susceptibility to infection. Our characterisation of VZV 
infection of primary monocytes represents the most comprehensive investigation to data 
of VZV interactions with this cell type.  
VZV infection of monocytes was characterised by, on average, 24-29% of monocytes 
expressing VZV antigen at the timepoints assessed, with a broad range between 7-62% of 
cells susceptible to VZV infection (Figure 3.2). The capacity of these VZV infected 
monocytes to transfer VZV directly would therefore be a significant means for viral 
dissemination in vivo. Indeed, transmission of VZV from monocytes to HFF was readily 
observed (Figure 3.8A-B), and although treatment with low-pH citrate resulted in fewer 
plaques from ICAs (Figure 3.8C), plaque formation was still observed. Inactivation of 
adherent infectious particles on the surface of citrate buffer treated VZV infected 
monocytes is presumably responsible for the discrepancy in plaque number in comparison 
to untreated VZV infected monocytes. The presence of extracellularly-adherent virions as 
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a model of viral transport has previously been proposed and is thought to contribute to the 
enhanced spread of VZV in adherent cultures (115). The detection of VZV virions on the 
surface of VZV infected monocytes by EM (Figure 3.6) also serves to highlight the potential 
of VZV infected monocytes to transmit infectious virus to neighbouring susceptible cells. In 
the future, the capacity of VZV infected monocytes to disseminate VZV to other immune 
cell types, such as DCs, NK cells, and T cells, should be examined.  
In the context of other alphaherpesviruses closely related to VZV, infection of monocytes 
by HSV-1 is suggested to be abortive (325). Monocytes exposed to HSV-1 typically 
generate <5% of cells with demonstrable productive infection suggesting that the vast 
majority of monocytes are subjected to abortive HSV-1 infection, or these cell do not 
support the entry and/or viral replication of HSV-1 (326, 332). Interestingly, differentiation 
of monocytes to macrophages appeared to enhance their susceptibility to HSV-1 infection 
(455, 462). These studies utilised cell-free HSV-1 infection of monocytes, and perhaps cell-
associated infection would result in non-abortive infection of these cells by HSV-1, although 
this would require in-depth characterisation to ensure the infection was productive. 
Similarly, EBV infection of monocytes is believed to be abortive (363) perhaps attributable 
to the minority of monocytes that express CD21, a monocyte-specific EBV entry receptor 
(360, 361). Interestingly, further investigation of monocyte susceptibility to EBV infection 
revealed lytic and latent EBV gene expression can be detected in primary monocytes, and 
in THP-1 cells (362, 363, 366, 463). These studies serve to demonstrate that initial 
investigations into the susceptibility of monocytes to herpesvirus infection may not 
accurately reflect the true nature of this infection. In contrast, monocytes are the primary 
target for the betaherpesvirus, human cytomegalovirus (HCMV), in vivo, and HCMV is 
known to utilise the monocyte-macrophage axis to facilitate widespread dissemination in 
the host (464, 465). KSHV similarly productively infects monocytes and establishes 
infection of CD34+ progenitors during infection in an effort to disseminate in the host (367-
369, 372). These studies highlight the advantageous nature of herpesviruses to target the 
myeloid lineage for dissemination and pathogenesis. In pursuit of this, VZV is known to 
infect multiple distinct immune cells, including T cells, DCs, NK cells, NKT cells, B cells, 
and now monocytes and MD-MΦ (23, 34, 40, 324), and displays the broadest tropism of 
all human herpesviruses (2, 11, 175).  
In order to appropriately address the susceptibility of MD-MΦ to VZV infection, we first 
sought to phenotype M-MΦ and GM-MΦ to demonstrate the complete differentiation of 
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monocytes (Figure 3.10 and 3.11). As expected, we observed the previously reported 
heterogeneity of M-MΦ, represented by expression of M1- and M2-like macrophage 
markers (445, 449), whereas GM-MΦ constituted a homogenous population of M1-like MΦ. 
MD-MΦ however, do not necessarily reflect the highly specialised and reprogrammable 
nature of in vivo trMΦ (415, 418). The inter-donor variability observed between successive 
MD-MΦ generations, combined with the lack of M1/M2 polarising cytokines (such as LPS, 
IFN-γ, or IL-4) (466) complicates the use of MD-MΦ generated in vitro as a complete 
representation of in vivo macrophages. Phenotyping of MD-MΦ prior to VZV infection does 
however allow for the examination of virus-specific impacts of infection in further 
experiments, and suggests that any virus-mediated influence on these cells may be 
reflected in vivo. We therefore represent macrophages in vivo in a similar manner to studies 
which have utilised MDDCs as representative of DCs in vivo (34, 37, 228).  
Although the susceptibility of monocytes to VZV infection after long periods of culture was 
previously suggested (322, 323), the permissive nature of M-MΦ and GM-MΦ to productive 
VZV infection has not been previously demonstrated. In comparison to each subset of MD-
MΦ generated, there was no difference in the proportions of VZV infected M-MΦ or VZV 
infected GM-MΦ (Figure 3.12). Furthermore, it has been reported that M2-like MΦ are more 
susceptible to influenza infection in contrast to M1-like MΦ (467). There was however, no 
relationship between CD14 expression (and thus M2-like MΦ) and susceptibility to VZV 
infection. However, VZV infected MD-MΦ in our study were not polarised using M1/M2 
specific cytokines (e.g. LPS or IL-4) prior to infection. The further differentiation of MD-MΦ 
into polarised subsets and investigation of their susceptibility to VZV infection is currently 
outside the scope of this study. As such, it is currently unclear if any specifically-polarised 
macrophage subsets are more or less susceptible to VZV infection. Interestingly, it was 
observed that greater proportions of VZV infected M-MΦ and GM-MΦ (Figure 3.12) in 
comparison to proportions of VZV infected monocytes (Figure 3.2). Furthermore, 
comparable numbers of VZV gE:gI+ monocytes were observed at each timepoint assessed, 
whereas numbers of VZV gE:gI+ M-MΦ and GM-MΦ significantly increased over time. The 
absence of CF-VZV secretion by infected monocytes may have limited the spread of VZV 
between monocytes, however neither VZV infected M-MΦ nor VZV infected GM-MΦ 
secreted infectious virus. MD-MΦ infections also utilised a lower ratio of infecting HFF 
inoculum (1 HFF to 5 MΦ) to infection of monocytes (1 HFF to 2 monocytes). This may 
suggest that MD-MΦ are more susceptible to VZV infection than human monocytes. A 
  102 
direct examination of human monocyte and MD-MΦ susceptibility to VZV infection with the 
same VZV infected HFF inoculum could be undertaken to confirm this finding.  
An alternate cause of the observable difference in the number of VZV infected MD-MΦ in 
comparison to monocytes may be the method of VZV spread in vitro. Propagation of VZV 
in HFF in vitro is asynchronous, strictly cell-associated, and relies on cell-to-cell spread 
through adherent monolayers, result in increasing proportions of infected cells over time 
(115, 122, 195). Infection of monocytes however, necessitated their infection in suspension, 
inducing contact by centrifugation, and this may render cell-to-cell spread much less likely 
to occur over the time course of infection. The detection of surface-bound virions on 
infected monocytes and presence of newly synthesised nucleocapsids in the nucleus of 
infected monocytes by BSEM (Figures 3.3.3-4) does however, demonstrate that monocytes 
support de novo synthesis of VZV virions. In contrast, MD-MΦ are adherent and are 
cultured with a cell density similar to that of highly permissive HFF cultures. The increased 
capacity for VZV infection to spread from cell-to-cell in MD-MΦ cultures may therefore 
contribute to the increasing number of infected cells over time. Alternatively, the probability 
of MD-MΦ phagocytising the infecting CFSE-labelled HFF inoculum may increase the 
proportion of infected MD-MΦ. However, CFSE-labelled inoculum HFF were easily 
discriminated from MD-MΦ during flow cytometry (Figure 3.12). As such, it is unlikely that 
phagocytosis of inoculum HFF would contribute more to this result than the increase cell-
to-cell spread within adherent MD-MΦ cultures. Relatedly, it is unsurprising that VZV 
infected monocytes and MD-MΦ did not release cell-free infectious virus as it is known that 
in vitro propagation of VZV remains highly cell-associated (135). As such, release of 
infectious VZV as a means of viral spread in vitro is not likely to influence the results that 
were observed. 
3.4. Conclusion 
Infection of other immune cells by VZV, such as DCs and T cells in particular, is limited in 
number in comparison to the broad range of VZV infected monocytes (34, 40). However, 
the proportion of monocytes susceptible to other human herpesviruses is surprisingly 
limited. Both HSV-1 and EBV are suggested to be abortively infected by VZV, whereas 
HCMV and KSHV actively utilise the monocyte-macrophage system for dissemination 
(Section 1.4.4). In contrast, an average of 25% CD14+ monocytes and an average of 42% 
of MD-MΦ exposed to VZV in vitro were permissive to VZV infection. Newly synthesised 
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viral nucleocapsids were readily detectable in VZV infected monocytes, and both 
monocytes and MD-MΦ exhibited newly synthesised VZV gene products. Moreover, VZV 
infected monocytes are capable of transmitting infectious virus, suggesting a role for 
monocytes in VZV dissemination in vivo. This study is the most comprehensive 
investigation to date into VZV infection of human monocytes and MD-MΦ, and clearly 
demonstrates production of monocytes and the first evidence that MD-MΦ are permissive 
to VZV infection. In combination with previous investigations detailing the permissiveness 
of DCs, T cells, and NK cells to VZV infection, it is unsurprising that monocytes and MD-
MΦ, an abundant and highly responsive arm of the innate immune system, are also 
susceptible to VZV infection. Furthermore, this model system of infecting key immune cell 
types will provide the foundation for investigating the impact on cell functioning in the next 
chapters. 
Chapter Four
Immunophenotyping of  
VZV Infected Human  
Monocytes and Macrophages
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4. Immunophenotyping of VZV Infected Human Monocytes and 
Macrophages  
4.1. Introduction 
Monocytes represent a continuous and stable source of myeloid cells that are capable of 
multiple independent functions. These include extravasation into multiple peripheral sites, 
differentiation into effector MDDC and MD-MΦ, and antigen presentation (242, 468, 469). 
Macrophages are also represented on a spectrum of phenotypic diversity and functional 
capabilities, as demonstrated by the heterogeneity of M-MΦ and their phenotypic 
distinction from GM-MΦ. As monocytes and macrophages mediate a broad range of 
functions via cell-surface signalling molecules and immune markers, it is important to 
understand the impact viral infection may have upon them. VZV infection of LPS-matured 
MDDCs resulted in the downregulation of MHC class I and multiple MDDC maturation 
markers (37). This phenotype was associated with an impairment of VZV infected MDDCs 
to signal allogenic T cells (37). Therefore, the capacity for surface phenotype changes to 
reflect functional modulation should not be understated. 
The techniques utilised to characterise immune cell phenotypes are advancing, as are the 
analyses performed to investigate modulation of these phenotypes by exogenous 
influences. Multi-parametric flow cytometry is now able to represent phenotype through 
high-dimensional analysis of multiple markers in combination. These analyses provide 
insight into immune cell subsets with high diversity and variability in surface marker 
expression, and have been previously used to represent the global influence of VZV 
infection in human cell types. Specifically, VZV infected T cells assessed through  
multi-parametric flow cytometry analysis have revealed the remodelling of infected T cells 
to reflect a more skin-homing subset (7). This study reported that there is no single marker 
representative of a skin homing phenotype, but multiple markers regulated in tandem by 
VZV infection generated this phenotype. More recently, work from the Abendroth laboratory 
has resulted in the novel identification of NK cell susceptibility to VZV infection, with a global 
impact on the maturation phenotype of NK cells in vitro (40). These studies reflect the 
developments in this field and highlight the complexity and significance of adopting 
advanced phenotyping techniques. 
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To this end, we sought to identify the changes in cell-surface phenotype that VZV infection 
may result in following infection of human monocytes and MD-MΦ. The in vitro VZV 
infection models established in Chapter Three were utilised to assess the changes in key 
cell-surface immune molecules. This is the first study to directly assess the impact VZV 
infection has on the immune phenotype of human monocytes and macrophages. 
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4.2. Results 
4.2.1. Immunophenotyping VZV infected monocytes  
As previous characterisation of VZV infection in human immune cells revealed VZV encoded 
mechanisms to selectively downregulate immune molecules (34, 37, 40, 470), similar cell-
surface immunophenotyping was performed on VZV infected monocytes for six functionally 
important immune markers. The chosen cell-surface markers included the highly conserved 
monocyte markers CD14 and CD11b which play key roles in establishing the functional 
phenotype of monocytes (384), and were used to identify monocytes in previous flow 
cytometry assays (Figures 3.1 and 3.2). HLA-ABC and HLA-DR, are known targets for VZV 
encoded selective downregulation, were also assessed (34, 156, 157, 263). Finally, the 
macrophage colony-stimulating factor receptor (M-CSFR), and the granulocyte-
macrophage colony-stimulating factor receptor (GM-CSFR) were both assessed as they 
play essential roles in initiating monocyte-to-macrophage differentiation (384, 444, 471). 
VZV proportionally lessens monocytes expressing CD14, M-CSFR, and, GM-CSFR. 
Monocytes were infected with a CFSE-labelled HFF inoculum as before, and mock and 
VZV infected monocytes were collected at 24 and 48 hpi for flow cytometry analysis. Mock 
and VZV infected monocytes were immunostained with antibodies specific to the above 
functionally important immune markers, or with respective isotype antibodies, in 
conjunction with VZV gE:gI and live/dead dye (Section 2.9). Analysis of monocytes for flow 
cytometry followed the previously outlined gating strategy (Figure 3.2A) with discrimination 
of VZV infected cells into VZV infected (VZV gE:gI+) and VZV exposed (VZV gE:gI–) 
monocytes. Mock infected monocytes, VZV infected and VZV exposed monocytes were 
examined for the proportion of cells expressing each immune marker from multiple 
independent blood donors. The proportions of VZV infected and VZV exposed monocytes 
expressing CD11b was not modulated in comparison to CD11b expressing mock infected 
monocytes (Figure 4.1A). Similarly, the proportions of VZV infected and VZV exposed 
monocytes expressing HLA-ABC or HLA-DR were not modulated in comparison to mock 
infected monocytes (Figure 4.1B-C). These phenotypes were consistent at 24 hpi and 48 
hpi and across multiple independent experiments. At 24 hpi and 48 hpi, VZV infected 
monocytes exhibited significantly fewer CD14 expressing monocytes in comparison to 
mock infected and VZV exposed monocytes (Figure 4.1D). VZV exposed monocytes also 
exhibited diminished proportions of CD14+ monocytes in comparison to mock infected 
monocytes at 48 hpi also (Figure 4.1D).  
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Figure 4.1: Cell-surface immunophenotyping of mock and VZV infected monocytes. 
Mock and VZV infected monocytes were collected at 24 and 48 hpi and immunostained for cell 
surface flow cytometry with antibodies against CD11b, HLA-ABC, HLA-DR, CD14, M-CSFR, 
GM-CSFR, and VZV gE:gI (or corresponding isotype antibodies). Analysis was performed following 
gating on size and excluded inoculating HFF. Proportions of mock (blue), VZV gE:gI+ (purple) 
and VZV gE:gI– (grey) monocytes which expressed indicated markers were examined. (A-F) 
Representative contour plots (left) are shown for 24 and 48 hpi and show isotype staining (dotted 
line). Graphs signify proportions of monocytes expressing indicated markers (±SEM) at each 
timepoint. Replicate experiments performed at 24 hpi and 48 hpi for CD11b (n=9) (A), HLA-ABC 
(n=7) (B), HLA-DR (n=7) (C), CD14 (n=20) (D), M-CSFR (n=8) (E), and GM-CSFR (n=3) (F). 
Statistics performed: RM one-way ANOVA with Geisser-Greenhouse correction and Tukey’s MC; 
* p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.00005, ns: not significant.
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When M-CSFR expressing cells were assessed, VZV infected monocytes exhibited 
significantly reduced proportions of M-CSFR+ monocytes in comparison to mock infected 
and VZV exposed (VZV gE:gI–) monocytes at 24 hpi and 48 hpi (Figure 4.1.E). VZV exposed 
monocytes did not demonstrate any modulation in proportion of M-CSFR expressing cells. 
Following analysis of GM-CSFR expressing VZV infected monocytes at 24 hpi, a 
downregulation in this cell proportion was observed, however this did not reach statistical 
significance (Figure 4.1F). At 48 hpi, significantly reduced proportions of VZV infected GM-
CSFR+ monocytes were observed in comparison to mock infected and VZV exposed 
monocytes. A small proportion of VZV exposed monocytes exhibited a significant reduction 
in the proportion of GM-CSFR+ monocytes at this timepoint also (Figure 4.1.F).  
These results demonstrate that VZV specifically targets CD14, M-CSFR, and GM-CSFR for 
selective downregulation within 48 hours of infection in monocytes, whilst CD11b,  
HLA-ABC, and HLA-DR remain unchanged at the proportional level. VZV exposed 
monocytes showed a modest reduction in the proportion of cells expressing CD14 and 
GM-CSFR at 48 hpi alone. 
VZV downregulates surface expression of CD14, HLA-DR, M-CSFR, and GM-CSFR. 
VZV infection selectively induced significant proportions of monocytes to lose expression 
of CD14, M-CSFR, and GM-CSFR. However, VZV infection did not completely ablate 
expression of these markers. To further explore the regulation of these markers by VZV 
infection, the levels of surface expression of these immune markers on monocytes was 
assessed. The median fluorescence intensity (MFI) of each examined immune marker on 
the surface of VZV infected and VZV exposed monocytes was normalised to respective 
mock infected monocyte MFI in matched experiments at indicated timepoints. This analysis 
showed that surface expression of CD11b was significantly downregulated on VZV infected 
monocytes at 48 hpi, but not 24 hpi (Figure 4.2A). Expression of HLA-ABC was not 
significantly modulated by VZV infection at either timepoint assessed (Figure 4.2B).  
Cell-surface expression of HLA-DR was significantly downregulated on the surface of VZV 
infected monocytes in comparison to mock infected and VZV exposed monocytes at 48 
hpi (Figure 4.2C). In addition to reduced proportions of CD14+ monocytes observed,  
cell-surface MFI of CD14 was significantly downregulated at 24 hpi and 48 hpi on VZV 
infected cells compares to mock and exposed cells (Figure 4.2D).  
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Figure 4.2: MFI of cell-surface immune markers on mock and VZV infected monocytes. 
Mock and VZV infected monocytes were collected at 24 and 48 hpi and immunostained 
for cell surface flow cytometry with antibodies against human CD11b, CD14, HLA-ABC, 
HLA-DR, M-CSFR, GM-CSFR, and VZV gE:gI (or corresponding isotype antibodies). 
Analysis was performed following gating on size and excluded inoculating HFF. VZV gE:gI+ 
(purple)and VZV gE:gI– (grey) monocytes were assessed for MFI of each marker normalised to 
mock infected monocytes (blue). (A-F) Representative histograms (left) are shown for 24 and 
48 hpi and depict isotype antibody staining (dotted line).  Graphs signify MFI±SEM normalised 
to mock at each timepoint. Replicate experiments performed at 24 hpi and 48 hpi for CD11b 
(n=9) (A), HLA-ABC (n=7) (B), HLA-DR (n=7) (C), CD14 (n=20) (D), M-CSFR (n=8) (E), and 
GM-CSFR (n=3) (F). Statistics performed: RM one-way ANOVA with Geisser-Greenhouse correction 
and Tukey’s MC; * p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.00005, ns: not significant.
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Cell-surface M-CSFR MFI was also significantly downregulated on VZV infected 
monocytes at 24 and 48 hpi in comparison to mock infected and VZV exposed monocytes, 
representing a 2.0-fold and 5.9-fold decrease in M-CSFR expression, respectively (Figure 
4.2E). In contrast, expression of M-CSFR was significantly upregulated on VZV exposed 
monocytes at the same timepoints (Figure 4.2E). Only VZV infected monocytes exhibited 
downregulation of GM-CSFR, with a significant reduction observed in comparison to mock 
infected monocytes at 24 hpi and to both mock infected and VZV exposed monocytes at 
48 hpi (Figure 4.2F). In comparison to mock infected monocytes, VZV infection 
downregulated GM-CSFR expression by a large 2.4-fold at 24 hpi, and 7.1-fold at 48 hpi 
decrease. 
In summation, these results indicate that VZV can manipulate the cell-surface phenotype 
of infected monocytes through selective downregulation of the proportions of monocytes 
expressing CD14, M-CSFR and GM-CSFR (Figure 4.1). Although no change in proportion 
of cells expressing HLA-DR was observed, VZV infection of monocytes targets HLA-DR for 
downregulation at the surface protein level. Furthermore, exposure of monocytes to VZV 
upregulates expression of M-CSFR. This phenotype may impact the functional responses 
of monocytes during VZV infection, and this will be further examined in Chapter Five.  
4.2.2. Immunophenotyping VZV infected M-MΦ  
Previous results have demonstrated the productive VZV infection of human MD-MΦ, which 
has not previously been reported (Figure 3.12 and 3.13). As such, no characterisation of 
the immune phenotype of MD-MΦ during VZV infection has been undertaken. We sought 
to investigate the potential of VZV to modulate the immune phenotype of productively 
infected M-MΦ and GM-MΦ. Immune marker phenotyping of VZV infection of monocytes 
selectively downregulates the proportion of cells expressing and the surface protein 
expression of CD14, HLA-DR, M-CSFR and GM-CSFR. To determine if VZV infection of 
MD-MΦ resulted in similar modulation, phenotyping of M-MΦ and GM-MΦ was performed. 
CD11b was examined as VZV infection modulated expression of CD11b on monocytes 
(Figures 4.1 and 4.2), and HLA-ABC and HLA-DR were also examined as these markers 
were shown to be influenced by VZV infection of MDDCs (37). Macrophage specific 
markers CD71 and MR (450), as well as M2-like macrophage specific markers CD14 and 
CD163 (445, 448), were also assessed to interrogate the influence of VZV infection on the 
heterogenous population of M-MΦ. 
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Dimensionality-reducing analysis of VZV infected M-MΦ.  
Conventional analysis of flow cytometric data, such as that performed on VZV infected 
monocytes, represents each marker assessed in isolation. Although this analysis does have 
the capacity to represent the phenotype of the population, it is more applicable for 
interrogating the relationship between individual markers and an external influence such as 
viral infection. A global shift in the phenotype of a population is often represented in 
conventional analysis by individual changes in multiple markers, and could conceivably be 
hidden during these analyses. However, recent advances in flow cytometric data analysis, 
have provided tools to visual multi-parameter datasets whilst preserving the overall high-
dimensional phenotype of the data. These dimensionality-reducing techniques support 
mapping cells with similar properties on a two-dimensional plot. This technique has 
recently been utilised in the Abendroth lab to demonstrate the influence of VZV infection 
upon non-homogenous populations of mature and immature NK cells (40). The immune 
phenotype of a population can therefore be represented through conventional and 
dimensionality-reducing techniques with each analysis providing unique interpretations of 
the same dataset. Phenotyping of VZV infected monocytes was undertaken by individual 
analysis of each immune marker across several independent experiments. Reagent 
availability prohibited the use of tSNE analysis to assess the phenotype of VZV infected 
monocytes and limited the number of immune markers that could be assessed on the 
surface of MD-MΦ. As such, M-MΦ and GM-MΦ were generated and VZV infected for 
tSNE analysis.  
M-MΦ were generated from a single donor and infected at 1:5 (HFF:M-MΦ) with mock or 
VZV infected CFSE-labelled HFF (Section 2.8.3-4). Macrophages were collected at 24 hpi 
and stained for flow cytometry with antibodies against phenotyping markers CD11b, CD71, 
MR, CD163, CD14, in conjunction with antibodies against VZV gE:gI and live/dead dye 
(Section 2.9). Analysis was performed on MΦ gated by size, viability, and expression of 
VZV gE:gI. Datasets containing an equal number of mock infected, VZV infected (VZV 
gE:gI+), and VZV exposed (VZV gE:gI–) MΦ were combined for t-distributed stochastic 
nearest neighbour embedding (tSNE) analysis. tSNE analysis was configured to distribute 
data according to expression of CD14, CD11b, CD71, MR, and CD163, in combination with 
forward and side scatter (Section 2.9.4). This technique generates a two-dimensional 
scatter plot grouping cells based on mutual expression of each marker included in the 
configuration. Following tSNE distribution, mock infected, VZV infected, and VZV exposed 
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MΦ were separated and heatmaps of each indicated marker were generated with 
expression values of each marker globally scaled (Section 2.9.4).  
VZV infection may modulate expression of CD14 and CD163 on M-MΦ.  
tSNE distributed data of mock infected, VZV infected (VZV gE:gI+), and VZV exposed (VZV 
gE:gI–) M-MΦ revealed that VZV gE:gI expression did not cluster to any discrete location in 
this population (Figure 4.3). Rather, VZV gE:gI expression was distributed consistently 
across the entire population of VZV infected M-MΦ. This result indicates that VZV infection 
of M-MΦ did not result in phenotypic modulation to the extent that VZV infected M-MΦ 
could be considered phenotypically distinct from mock infected or VZV exposed M-MΦ. 
This does not however exclude the possibility that VZV infection may modulate expression 
of induced M-MΦ markers. 
Interestingly, tSNE distribution of M-MΦ revealed the clustering of mock infected M-MΦ 
into three distinct foci commensurate with high expression of CD14 and CD163 (Figure 4.3, 
dotted regions: 1-3). VZV infected M-MΦ did not localise specifically to these foci rather a 
proportion of VZV infected M-MΦ, and to an extent a proportion of VZV exposed M-MΦ, 
clustered to an independent localisation within the same area creating a forth foci (Figure 
4.3, dotted region: 4). The changing localisation of VZV infected M-MΦ expressing CD14 
and CD163 may suggest VZV infection modulates expression of these markers. Further 
inferences into this relationship can be drawn from conventional flow cytometry analysis. 
The distribution and expression profile of CD11b and CD71 remained relatively consistent 
across all groups assessed although an inverse correlation was observed between 
CD14+CD163+ M-MΦ and expression of CD11b (Figure 4.3). MR expression in all groups 
appeared to correlate with expression of CD163 and CD14, and independently of CD71 
expression. However, comparable distribution and expression levels of CD71 and MR 
expressing M-MΦ were observed across all groups assessed (Figure 4.3). tSNE distribution 
of M-MΦ phenotype data therefore revealed a consistent distribution of VZV gE:gI 
expression following VZV infection, rather than identifying a targeted infection in a particular 
subset of M-MΦ. Moreover, this data suggests that expression of CD14 and CD163 may 
be modulated by VZV infection of M-MΦ.  
 
 
Mock
VZV gE:gI CD14
VZV 
Infected
VZV 
Exposed
Figure 4.3: Assessment of cell-surface immunophenotype of VZV infected M-MΦ by tSNE. Differentiated M-MΦ  from a single donor were mock 
an VZV infected. At 24 hpi, macrophages were collected for flow cytometry. Cells were gated on by size and viability prior to downsampling on an 
equal number of cells. Dimensionality reduction by t-distributed stochastic neighbour embedding (tSNE) was configured to distribute data according 
to expression of CD14, CD11b, CD71, MR, and CD163, and forward and side scatter. VZV gE:gI was manually gated following tSNE distribution, and 
mock, VZV infected (VZV gE:gI+ ) and VZV exposed (VZV gE:gI–) M-MΦ were assessed individually. Colourised tSNE heatmaps were generated and 
expression values were globally scaled. Heatmaps depict mock infected, VZV infected, and VZV exposed M-MΦ at 24 hpi representing expression 
levels of indicated immune markers. Dotted regions represent independent numbered foci of interest in distributed data of mock infected, VZV 
infected, and VZV exposed M-MΦ. 
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VZV infection of M-MΦ induces minor proportional changes in phenotype.  
To further explore the results observed through tSNE distribution of VZV infected M-MΦ, 
we sought to establish the phenotype of these cells through conventional analysis of flow 
cytometry data. The same dataset used to generate tSNE distributed data was integrated 
with multiple further independent experiments, and analysed for the proportion of cells 
expressing each immune marker as well as the MFI for each cell-surface immune marker.  
M-MΦ were generated and infected at 1:5 (HFF:M-MΦ) with CFSE-labelled HFF inoculum. 
Macrophages were collected and stained for flow cytometry with antibodies against above 
immune markers CD11b, CD71, HLA-ABC, HLA-DR, MR, CD163, and CD14, or respective 
isotype antibodies, in conjunction with VZV gE:gI and live/dead dye (Section 2.9). Flow 
cytometry analysis was undertaken with the same gating strategy employed for 
determination of VZV infected MD-MΦ (Figure 3.12). At 24 and 48 hpi, the proportion of 
mock infected, VZV infected (VZV gE:gI+), and VZV exposed (VZV gE:gI–) M-MΦ expressing 
each immune marker was assessed and compared. There was no observable change in 
the proportions of VZV infected M-MΦ expressing CD11b, CD71, HLA-ABC, HLA-DR, or 
CD163 in comparison to mock infected and VZV exposed M-MΦ (Figure 4.4A-D and 4.4F). 
In comparison, VZV exposed M-MΦ demonstrated a modest downregulation of HLA-ABC+ 
cells in comparison to VZV infected M-MΦ at 48 hpi (Figure 4.4C), and there was a modest 
downregulation of HLA-DR+ VZV exposed M-MΦ was observed in comparison to VZV 
infected M-MΦ at 24 hpi (Figure 4.4D). A significant, although modest, reduction in the 
proportion of MR+ VZV infected M-MΦ was observed in comparison to mock infected  
M-MΦ, however this phenotype was observable at 48 hpi only (Figure 4.4E). At 48 hpi,  
a modest reduction in the proportion of CD14+ VZV infected M-MΦ was observed in 
comparison to mock infected and VZV exposed M-MΦ, although this result did not reach 
statistical significance (Figure 4.4G). These results were consistent across multiple 
independent experiments and corroborated previous tSNE visualisations that VZV infection 
did not significantly alter the proportional phenotype infected M-MΦ. These experiments 
also demonstrated that VZV infection of M-MΦ resulted in a minor, yet significant, reduction 
in the proportion of MR+ M-MΦ alone.  
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Figure 4.4: Cell-surface immunophenotyping of mock and VZV infected M-MΦ. Differentiated 
M-MΦ were mock or VZV infected. At 24 and 48 hpi, macrophages were collected for flow cytometry. 
Cells were gated by size and viability to the exclusion of HFF inoculum. Mock infected, VZV infected 
(VZV gE:gI+) and VZV exposed (VZV gE:gI–) M-MΦ were analysed for proportion of cells 
expressing indicated immune markers. (A-G) Graphs signify proportions of M-MΦ expressing 
each marker (±SEM) across several independent donors: (A) CD11b (n=7), (B) CD71 (n=9), 
(C) HLA-ABC (n=8), (D) HLA-DR (n=8), (E) MR (n=7), (F) CD163 (n=5), and (G) CD14 (n=7). 
Statistics performed: RM one-way ANOVA with Geisser-Greenhouse correction and 
Tukey’s MC; * p < 0.05, ns: not significant. 
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VZV infection of M-MΦ significantly modulates expression of CD11b, HLA-ABC and 
CD163. 
Following tSNE distribution which suggested VZV infection modulated expression of CD14 
and CD163, and proportional analyses revealed the minor modulation of MR, cell-surface 
expression levels (MFI) of M-MΦ retaining expression of these markers was assessed.  
The MFI of each immune marker on VZV infected and VZV exposed M-MΦ was determined 
and normalised to MFI of matched mock infected M-MΦ across multiple independent 
experiments. There was a significant reduction in the expression of CD11b on VZV infected 
M-MΦ in comparison to both mock infected and VZV exposed M-MΦ at 24 hpi and 48 hpi 
(Figure 4.5A). An increase in CD71 expression was also observed at 24 hpi and 48 hpi on 
VZV exposed M-MΦ in comparison, although this did not reach statistical significance 
(Figure 4.5B). Interestingly, a significant increase in HLA-ABC expression was observed on 
VZV infected M-MΦ at 24 and 48 hpi, when compared to mock infected cells (Figure 4.5C). 
Furthermore, at 48 hpi VZV exposed M-MΦ expression of HLA-ABC was significantly 
greater than that of VZV infected M-MΦ and mock infected M-MΦ. In contrast, no 
modulation of HLA-DR expression was observed at either 24 or 48 hpi (Figure 4.5D). A 
significant reduction in the expression of MR on VZV exposed M-MΦ in comparison to 
mock infected and VZV infected M-MΦ was observed at 24 hpi (Figure 4.5E). At 48 hpi 
however, MR expression was significantly reduced on both VZV infected and VZV exposed 
M-MΦ in comparison to mock infected monocytes, and VZV exposed cells had significantly 
less MR than VZV infected cells (Figure 4.5E). CD163 expression remained unchanged at 
24 hpi, however by 48 hpi a significant reduction in CD163 expression was observed on 
VZV infected M-MΦ in comparison to mock infected and VZV exposed M-MΦ (Figure 4.5F). 
This change represented a 2.3-fold decrease in the expression of CD163 at 48 hpi. Surface 
expression of CD14 remained unchanged at 24 hpi, however by 48 hpi a significant 
upregulation in CD14 was evident on VZV exposed M-MΦ in comparison to VZV infected 
M-MΦ alone (Figure 4.5G).  
The immunophenotype of VZV infected M-MΦ was assessed through dimensionality-
reducing tSNE visualisation and through conventical analyses. Overall these results 
revealed no global shifts in phenotype of VZV infected M-MΦ, however, virus-specific 
downregulation of CD11b, CD163, and MR was observed.  
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Figure 4.5: MFI of cell-surface immune markers on mock and VZV infected M-MΦ. 
Differentiated M-MΦ were mock or VZV infected. At 24 and 48 hpi, macrophages were collected 
for flow cytometry. Cells were gated by size and viability to the exclusion of HFF inoculum. Mock 
infected, VZV infected (VZV gE:gI+) and VZV exposed (VZV gE:gI–) M-MΦ were analysed and MFI 
of indicated immune markers was assessed. (A-G) Graphs depict MFI of M-MΦ expressing each 
marker normalised to respective mock infected cells at each timepoint (±SEM) across multiple 
independent donors: (A) CD11b (n=7), (B) CD71 (n=9), (C) HLA-ABC (n=8), (D) HLA-DR (n=8), (E) 
MR (n=7), (F) CD163 (n=5), and (G) CD14 (n=7). Statistics performed: RM one-way ANOVA with 
Geisser-Greenhouse correction and Tukey’s MC; * p < 0.05, ns: not significant.
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Moreover, a correlation of increased HLA-ABC and CD14 expression and decreased MR 
expression following exposure to VZV infected cells was evident. These experiments detail 
the specific, and unique, modulatory relationship of VZV infection in M-MΦ.  
4.2.3. Immunophenotyping VZV infected GM-MΦ.  
As VZV infection and exposure resulted in the selective modulation of several immune 
markers on the surface of M-MΦ, we sought to examine whether VZV infection or exposure 
would impact the expression of functionally important immune markers on the surface of 
GM-MΦ. To this end, GM-MΦ were generated from a single donor and infected at 1:5 
(HFF:GM-MΦ) with mock or VZV infected CFSE-labelled HFF (Section 2.8.3-4). 
Macrophages were collected at 24 hpi and stained for flow cytometry with antibodies 
against immune markers including: CD14, CD11b, CD71, MR, and CD163, in conjunction 
with antibodies against VZV gE:gI and live/dead dye (Section 2.9). Mock infected, VZV 
infected (VZV gE:gI+), and VZV exposed (VZV gE:gI–) GM-MΦ were subject to gating and 
tSNE configuration in parallel to analyses of M-MΦ, to examine the global phenotype of 
VZV infected GM-MΦ.  
VZV infection does not modulate the global phenotype of GM-MΦ.  
tSNE distribution of VZV infected GM-MΦ revealed no discrete localisation of VZV gE:gI 
expressing cells (Figure 4.6). This result suggested that VZV infection of GM-MΦ does not 
result in modulation of the examined immune markers to the extent that VZV infected  
GM-MΦ constituted a different global phenotype to mock infected or VZV exposed  
GM-MΦ. CD14+ cells constitute a minority of GM-MΦ and were therefore represented in 
tSNE distributed data. In VZV infected GM-MΦ populations, a dense proportion of cells 
localised to areas expressing high levels of CD14, CD11b and MR, and independent of 
CD71 expression was evident (Figure 4.6, dotted regions). A similarly-dense proportion of 
cells was not evident in tSNE distributed data of mock infected or VZV exposed GM-MΦ, 
and suggests VZV infection may modulate the enrichment of CD14+ CD71– GM-MΦ or 
modulate expression of CD71. There was no observable modulation of CD11b and MR 
expression levels following VZV infection, and CD163, which was previously shown to not 
be expressed on GM-MΦ, remained absent on these cells (Figure 4.6).  
In summation, tSNE distributed data of GM-MΦ phenotyping data demonstrated that VZV 
infection did not modulate the global distribution of GM-MΦ although this dataset did 
provide evidence for the potential modulation of CD71 and/or CD14 expression.  
Expression Level
Figure 4.6: Assessment of cell-surface immunophenotype of VZV infected GM-MΦ by tSNE. Differentiated GM-MΦ from a single donor were 
mock and VZV infected. At 24 hpi, macrophages were collected for flow cytometry. Cells were gated on by size and viability prior to downsampling 
on an equal number of cells. Dimensionality reduction by t-distributed stochastic neighbour embedding (tSNE) was configured to distribute data 
according to expression of CD14, CD11b, CD71, MR, and CD163, and forward and side scatter. VZV gE:gI was manually gated following tSNE 
distribution, and mock, VZV infected (VZV gE:gI+ ) and VZV exposed (VZV gE:gI–) GM-MΦ were assessed individually. Colourised tSNE heatmaps 
were generated and expression values were globally scaled. Heatmaps depict mock infected, VZV infected, and VZV exposed GM-MΦ at 24 hpi 
representing expression levels of indicated immune markers. Dotted regions represent areas of interest in distributed data of VZV infected and VZV 
infected GM-MΦ. 
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VZV infection does not significantly alter the proportional phenotype of GM-MΦ.  
To further examine the potential for VZV infection to modulate the phenotype of GM-MΦ,  
conventional analysis for proportions of cells expressing several immune markers, in 
combination with the expression levels of each marker expressed, was undertaken.  
GM-MΦ were generated and infected at 1:5 (HFF:GM-MΦ) with mock or VZV infected 
CFSE-labelled HFF (Section 2.8.3-4). Macrophages were collected at 24 hpi and 48 hpi and 
immunostained for flowy cytometry with antibodies against CD11b, CD71, HLA-ABC,  
HLA-DR, MR, CD163, and CD14, or respective isotype antibodies, in conjunction with 
antibodies against VZV gE:gI, and live/dead dye (Section 2.9). GM-MΦ were gated by size 
and viability as in previous analyses, and mock infected, VZV infected (VZV gE:gI+) and VZV 
exposed (VZV gE:gI–) GM-MΦ were assessed for the proportion of cells expressing the 
above immune markers.  
At 24 hpi and 48 hpi, there was no significant change in the proportion of mock infected, 
VZV infected, or VZV exposed GM-MΦ expressing CD11b, CD71, HLA-ABC, HLA-DR, or 
MR (Figure 4.7A-E). GM-MΦ were not previously observed to express CD163 or CD14 to 
a significant degree in comparison to M-MΦ, however a minor proportion (<10%) of  
GM-MΦ retain expression of either marker (Figure 3.11). There was no significant 
modulation in the proportion of CD163+ GM-MΦ at 24 hpi, however a modest but 
statistically significant reduction in CD163+ GM-MΦ was observed in VZV exposed  
GM-MΦ in comparison to mock infected GM-MΦ at 48 hpi (Figure 4.7F). However, the 
overall expression of CD163 on mock infected, VZV infected, and VZV exposed GM-MΦ 
remained relatively low in comparison to proportions of cells expression other immune 
markers. The proportion of CD14+ GM-MΦ was not altered at any timepoint in any 
population of cells observed (Figure 4.7G). These results were consistent over multiple 
independent blood donors. Taken together, these results indicate that VZV infection  
GM-MΦ does not modulate the proportion of cells expressing the majority of immune 
markers tested, with a very minor change in the proportion of CD163+ VZV exposed GM-
MΦ being observed.  
VZV selectively downregulates expression of CD71 on GM-MΦ. 
Mock infected, VZV infected, and VZV exposed M-MΦ and GM-MΦ were also assessed 
by flow cytometry for the protein expression of retained cell-surface immune markers 
following infection.  
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Figure 4.7: Cell-surface immunophenotyping of mock and VZV infected GM-MΦ. 
Differentiated GM-MΦ were mock or VZV infected. At 24 and 48 hpi, macrophages were 
collected for flow cytometry. Cells were gated by size and viability to the exclusion of HFF 
inoculum. Mock infected, VZV infected (VZV gE:gI+) and VZV exposed (VZV gE:gI–) GM-MΦ were 
analysed for proportion of cells expressing indicated immune markers. (A-G) Graphs signify 
proportions of M-MΦ expressing each marker (±SEM) across several independent donors: (A) 
CD11b (n=3), (B) CD71 (n=5), (C) HLA-ABC (n=4), (D) HLA-DR (n=4), (E) MR (n=7), (F) CD163 
(n=3), and (G) CD14 (n=3). Statistics performed: RM one-way ANOVA with Geisser-Greenhouse 
correction and Tukey’s MC; * p < 0.05, ns: not significant. 
Figure 4.8: MFI of cell-surface immune markers on mock and VZV infected GM-MΦ. 
Differentiated GM-MΦ were mock or VZV infected. At 24 and 48 hpi, macrophages were collected 
for flow cytometry. Cells were gated by size and viability to the exclusion of HFF inoculum. Mock 
infected, VZV infected (VZV gE:gI+) and VZV exposed (VZV gE:gI–) GM-MΦ were analysed and MFI 
of indicated immune markers was assessed. (A-G) Graphs depict MFI of GM-MΦ expressing each 
marker normalised to respective mock infected cells at each timepoint (±SEM) across multiple 
independent donors: (A) CD11b (n=3), (B) CD71 (n=5), (C) HLA-ABC (n=4), (D) HLA-DR (n=4), and 
(E) MR (n=5). Statistics performed: RM one-way ANOVA with Geisser-Greenhouse correction and 
Tukey’s MC; * p < 0.05, ns: not significant.
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The MFI of each marker on VZV infected and VZV exposed macrophages was normalised 
to the respective MFI of mock infected GM-MΦ at each timepoint. At 24 and 48 hpi, there 
was no significant change in the expression of CD11b on the surface of VZV infected  
GM-MΦ (Figure 4.8A).  
In contrast, at 24 hpi, CD71 expression was significantly downregulated on the surface of 
VZV infected GM-MΦ in comparison to mock infected and VZV exposed GM-MΦ, although 
this downregulation appeared to be lost by 48 hpi (Figure 4.8B). There was no significant 
change in HLA-ABC expression observed on both VZV infection and VZV exposed GM-MΦ 
at 24 hpi and 48 hpi (Figure 4.8C). HLA-DR expression on GM-MΦ was not modulated by 
VZV infection at any timepoint measured (Figure 4.8D), nor was expression of MR on  
GM-MΦ regulated by VZV infection at any timepoint tested (Figure 4.8E). As <10% of VZV 
infected GM-MΦ expressed detectable CD14 or CD163, levels of expression were below 
the limit of detection these analyses (data not shown). These results therefore demonstrate 
that VZV infection of GM-MΦ results in the transient modulation of CD71 at 24 hpi.  
In conclusion, immunophenotyping of VZV infected and VZV exposed GM-MΦ revealed no 
global shift in phenotype, nor changes in the proportions of cells expressing the tested 
immune markers, in comparison to mock infected GM-MΦ. However, virus-specific 
modulation of immune markers was observed. In particular, VZV infection mediated the 
downregulation of CD71 expression during early stages of infection, whereas VZV exposed 
GM-MΦ did not undergo similar changes. In comparison, VZV infection of M-MΦ mediated 
downregulation of CD163 and MR, whereas VZV exposure of M-MΦ was characterised by 
downregulation of MR and upregulation of HLA-ABC. These results therefore demonstrate 
the profound variability of VZV-specific immune marker modulation that takes places 
following VZV infection of monocytes, M-MΦ, and GM-MΦ. 
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4.3. Discussion 
Infection of human immune cells by VZV has generally been characterised by extensive 
modulation of cellular phenotype, demonstrated in part by the loss of maturity markers on 
VZV infected mature-MDDC, and the comprehensive remodelling of VZV infected T cells 
(7, 34, 37, 40). In comparison, the analyses undertaken in the current study to interrogate 
the surface phenotype of monocytes and MD-MΦ in response to VZV infection did not 
demonstrate such extensive modulation by VZV infection (Table 4.1-2). Selective 
downregulation of CD14, M-CSFR, and GM-CSFR on VZV infected monocytes and of MR 
on VZV infected M-MΦ was observable from 24 hpi (Table 4.1). However, modulation of 
CD11b on VZV infected monocytes only occurred after 48 hpi, and expression of CD71 
was changed on VZV infected GM-MΦ but not on VZV infected M-MΦ. The expression of 
a majority of assessed immune markers however were not changed following VZV infection 
or exposure to VZV infected cells. These results demonstrate a more stable immune 
phenotype in monocytes and macrophages following VZV infection and reflects the 
diversity through which VZV subverts the immune system.  
Perhaps the most striking result observed following VZV infection of monocytes was the 
near ablation of surface M-CSFR and GM-CSFR at the proportionate and protein 
expression levels (Figures 4.1 and 4.2). These receptors govern the intrinsic capacities of 
monocytes to generate MD-MΦ from stimulation with M-CSF and GM-CSF respectively 
(466). The functional consequences of VZV infection on monocyte differentiation may have 
far-reaching implications in the context of replenishing in vivo trMΦ niches. Interestingly, 
EBV BARF1 encodes a decoy M-CSF receptor, restricting M-CSF mediated macrophage 
development (472, 473). Although limited homology is observed between EBV encoded 
BARF1 and VZV gene products (474), the capacity for HCMV and KSHV to modulate 
monocyte to macrophage differentiation is well established (353, 376). As MD-MΦ have 
been shown to be susceptible to VZV infection, further investigation into the capacity of 
VZV infected monocytes to generate viable macrophages has been undertaken in Chapter 
5. Furthermore, both M-CSF and GM-CSF are drivers of cell survival and proliferation (475). 
Investigation into the viability of VZV infected monocytes, as a response to the lytic nature 
of VZV infection and to the loss of M-CSFR and GM-CSRF, is also of interest and will be 
examined further in Chapter Five.  
 
Table 4.1 – Cell-surface immune marker changes observed following VZV infection and VZV exposure of monocytes, M-MΦ, and GM-MΦ
Table 4.2 – MFI changes of cell-surface immune markers observed following VZV infection and VZV exposure of monocytes, M-MΦ, and GM-MΦ
Marker 24 hpi 48 hpi 24 hpi 48 hpi 24 hpi 48 hpi 24 hpi 48 hpi 24 hpi 48 hpi 24 hpi 48 hpi
CD11b – – – – – – – – – – – –
HLA-ABC – – – – – – – – – – – –
HLA-DR – – – – – – – – – – – –
CD14 ↓ ↓↓ – ↓ – – – – – – – –
M-CSFR ↓↓ ↓↓↓ – – n/a n/a n/a n/a n/a n/a n/a n/a
GM-CSFR – ↓↓↓ – ↓ n/a n/a n/a n/a n/a n/a n/a n/a
CD163 n/a n/a n/a n/a – – – – – – – ↓
CD71 n/a n/a n/a n/a – – – – – – – –
MR n/a n/a n/a n/a – ↓ – – – – – –
Marker 24 hpi 48 hpi 24 hpi 48 hpi 24 hpi 48 hpi 24 hpi 48 hpi 24 hpi 48 hpi 24 hpi 48 hpi
CD11b – ↓ – – ↓ ↓ – – – – – –
HLA-ABC – – – – ↑ ↑ – ↑↑↑ – – – –
HLA-DR – ↓↓ – – – – – – – – – –
CD14 ↓↓ ↓↓ – – – – – ↑ – – – –
M-CSFR ↓↓ ↓↓ ↑↑ ↑↑↑ n/a n/a n/a n/a n/a n/a n/a n/a
GM-CSFR ↓↓ ↓↓↓ – – n/a n/a n/a n/a n/a n/a n/a n/a
CD163 n/a n/a n/a n/a – ↓↓ – – – – – –
CD71 n/a n/a n/a n/a – – – – ↓↓ – ↓ –
MR n/a n/a n/a n/a – ↓↓ ↓↓ ↓↓ – – – –
Infected GM-MΦ Exposed GM-MΦ
Infected Monocytes Exposed Monocytes Infected  M-MΦ Exposed M-MΦ Infected GM-MΦ Exposed GM- Φ
Infected Monocytes Exposed Monocytes Infected M-MΦ Exposed M-MΦ
Marker 24 hpi 48 hpi 24 hpi 48 hpi 24 hpi 48 hpi 24 hpi 48 hpi 24 hpi 48 hpi 24 hpi 48 hpi
CD11b – – – – – – – – – – – –
HLA-ABC – – – – – – – – – – – –
HLA-DR – – – – – – – – – – – –
CD14 ↓ ↓↓ – ↓ – – – – – – – –
M-CSFR ↓↓ ↓↓↓ – – n/a n/a n/a n/a n/a n/a n/a n/a
GM-CSFR – ↓↓↓ – ↓ n/a n/a n/a n/a n/a n/a n/a n/a
CD163 n/a n/a n/a n/a – – – – – – – ↓
CD71 n/a n/a n/a n/a – – – – – – – –
MR n/a n/a n/a n/a – ↓ – – – – – –
Marker 24 hpi 48 hpi 24 hpi 48 hpi 24 hpi 48 hpi 24 hpi 48 hpi 24 hpi 48 hpi 24 hpi 48 hpi
CD11b – ↓ – – ↓ ↓ – – – – – –
HLA-ABC – – – – ↑ ↑ – ↑↑↑ – – – –
HLA-DR – ↓↓ – – – – – – – – – –
CD14 ↓↓ ↓↓ – – – – – ↑ – – – –
M-CSFR ↓↓ ↓↓ ↑↑ ↑↑↑ n/a n/a n/a n/a n/a n/a n/a n/a
GM-CSFR ↓↓ ↓↓↓ – – n/a n/a n/a n/a n/a n/a n/a n/a
CD163 n/a n/a n/a n/a – ↓↓ – – – – – –
CD71 n/a n/a n/a n/a – – – – ↓↓ – ↓ –
MR n/a n/a n/a n/a – ↓↓ ↓↓ ↓↓ – – – –
Infected GM-MΦ Exposed GM-MΦ
Infected Monocytes Exposed Monocytes Infected  M-MΦ Exposed M-MΦ Infected GM-MΦ Exposed GM-MΦ
Infected Monocytes Exposed Monocytes Infected M-MΦ Exposed M-MΦ
↓↓↓
↓↓
↓
n/a
– no modulation relative to mock infection
not assessed
<30% modulation relative to mock infection
30-60% modulation relative to mock infection
>60% modulation relative to mock infection↑↑↑
↑↑
↑
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In relation to the previous reports of VZV infection remodelling susceptible immune cells, a 
number of reports have demonstrated the consistent reduction of cell-surface MHC class 
I expression, particularly on VZV infected MDDC, HFF, and T cells (34, 37, 156, 294). In the 
current study, VZV infected monocytes and GM-MΦ showed unaltered levels of  
cell-surface MHC class I, whereas upregulation of HLA-ABC was observed following 
infection of M-MΦ (Figures 4.2, 4.5, and 4.8). It was previously hypothesised that 
downregulation of MHC class I expression by VZV infection aided evasion of CD8+ T cell 
recognition (157), however upregulation of this marker may rather confer protection from 
NK cell mediated clearance instead (476). Further investigation into this protection may be 
confounded by the susceptibility of NK cells to VZV infection (40), and the potential for VZV 
infection to influence NK cell function (T. Campbell, personal communication). Our results 
may therefore indicate that human monocytes and GM-MΦ potentially maintain higher 
endogenous expression of MHC class I, or that recycling of MHC to the surface of VZV 
infected cells occurs too rapidly to be detectable at our assessed timepoints. A possibility 
does remain however, that replication of VZV in GM-MΦ and monocytes is not supportive 
of the viral mechanisms that induce MHC class I upregulation, and that modulation of MHC 
class I by VZV is cell-type specific.  
VZV infection of monocytes significantly downregulated expression of HLA-DR at 48 hpi 
(Figure 4.2). Previously, endogenous MHC class II expression remained unaltered following 
VZV infection of MDDC and HFF (37, 263). Modulation of MHC class II expression by VZV 
has only been observed in human keratinocytes and HFF following IFN-γ-induced 
upregulation (157, 263). In these studies, VZV infection downmodulated MHC class II to 
endogenous levels. Thus, our observations in monocytes represent the first instance of a 
reduction of endogenous MHC class II following VZV infection. A reduction of cell-surface 
MHC class II may suggest altered recognition and susceptibly of VZV infected monocytes 
to CD4+ T cells. However, APC assays involving CD4+ T cells would be complicated by the 
susceptibility of T cells themselves to VZV infection (23, 34) with any observed change in 
CD4+ T cell activity towards VZV infected monocytes potentially influenced if VZV infection 
of these effector cells alters their function. Although examining the presentation of antigen 
on monocytes to T cells is problematic, these myeloid subsets have been demonstrated to 
uptake environmental antigen (468) in their capacity as antigen presentation cells (APCs) 
(242). Whether the observed modulation in MHC class II is coupled with an impairment in 
the earlier processes of antigen presentation would be critical in resolving the full impact 
  133 
of VZV infection has on this integral pathway, and have been further examined in Chapter 
Five. Additionally, the cross-linking of HLA-DR on the surface of monocytes is known to 
induce apoptosis (477, 478). M-CSFR and GM-CSFR are also known mediators of cellular 
viability (475, 479), and it was observed that modulation of these markers as well as 
alteration in HLA-DR expression following VZV infection. Collectively, these results bring 
into question the viability of monocytes following VZV infection, and as such, experiments 
evaluating the viability of human monocytes following VZV infection were undertaken in 
Chapter Five.  
tSNE analyses of VZV infected MD-MΦ were configured to distribute data according to 
expression of selected immune markers and did not include viral antigen expression so as 
to not bias the clustering of infected cells. VZV infected MD-MΦ did not preferentially 
cluster in any discrete localisation, however VZV infection was observed to modulate 
multiple immune markers. tSNE visualisation has been previously used by the Abendroth 
laboratory to investigate the immune profile of human NK cells to VZV infection (40). This 
study of NK cell infections implemented tSNE analyses configured to exclude viral antigen 
expression, and demonstrated the independent clustering of VZV infected NK cells in 
comparison to mock infected NK cells. This profile was suggested to represent either a 
preferential infection of NK cells falling within this localisation, or to indicate that VZV 
infection modulates multiple receptors to the degree that VZV infected NK cells constitute 
an independent phenotype to mock infected NK cells. Our analyses of VZV infected  
MD-MΦ did not reflect such localisation, suggesting that although VZV infection was 
demonstrated to modulate certain immune markers, a global shift in MD-MΦ phenotype 
was not observed. Furthermore, interrogation of CD14 expression demonstrated no 
preferential infection of CD14+ or CD14- M-MΦ by VZV.  
Monocytes and MD-MΦ can contribute to anti-inflammatory signalling and pathogen 
clearance during viral infection (480-482). Macrophages in particular, when responding to 
HIV-1 infection, are skewed towards pro-inflammatory phenotypes, which even promotes 
the susceptibility of macrophages to HIV-1 infection (483, 484). Moreover, exposure of 
monocytes and macrophages to a cell-associated VZV inoculum was demonstrated to 
induce secretion of TLR2-mediated IL-6 (243). Inflammatory signalling on monocytes and 
MD-MΦ is facilitated by a multitude of independent receptors, mediated in part, by CD71, 
CD11b, and CD14 (485-488). Freshly isolated monocytes do not express CD71 unless 
exogenously induced, such as during macrophage differentiation (Figure 3.11). CD71 
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expression was not significantly modulated on VZV infected M-MΦ (Figures 4.4 and 4.5) 
whereas VZV infected GM-MΦ exhibited significant downregulation of CD71 at the early 
timepoint of infection (Figure 4.8). CD71 is a transferrin receptor responsible for the 
transport of iron and can facilitate inflammatory signalling and increased phagocytic 
responses (485). CD71 expression on macrophages has also been associated with highly 
inflammatory alveolar macrophage subsets contributing to disease-states (489, 490). 
Previously, VZV infection of IFN-γ treated HFF did not result in modulation of CD71 (34, 
157), nor did other studies that examined endogenous CD71 expression on VZV infected 
cells (263, 491, 492), whereas HSV-1 infection of THP-1 cells does not result in altered 
CD71 expression (493). In comparison to the heterogeneously inflammatory M-MΦ 
populations (Table 3.1), perhaps the highly inflammatory profile of GM-MΦ is preferentially 
targeted during VZV infection. Although the expression of CD71 on the surface of CD14– 
M-MΦ was not directly assessed, tSNE analysis did not demonstrate modulation of these 
cells following VZV infection.  
CD11b was significantly downregulated on VZV infected monocytes (Figure 4.2) and  
M-MΦ (Figure 4.5). CD11b forms half of the complement receptor 3 (CR3) complex in 
association with CD18 (494), and is involved in a range of functions including recognition 
of pathogen-associated molecular patterns (PAMPs) (486), adhesion, migration, 
chemotaxis, and phagocytosis (495, 496). Detection for CR3 was not undertaken in this 
current study, however, the loss of CD11b on the surface of infected monocytes and 
macrophages would likely impact the CR3 complex, and suggests VZV infection would 
influence the functions CR3 mediates.  
In particular, CD11b has been demonstrated to recognise extracellular dsRNA to elicit 
macrophage immune responses and that this response is essential for TLR3-regulated 
immune protection from viral infections (497). In a similar manner, CD14 plays a role in 
TLR4-mediated LPS signalling, acting as a co-receptor and binding LPS directly (498, 499) 
although there is little consensus on which concentrations of LPS require CD14 binding 
(498, 500, 501). Moreover, CD14 can mediate the activation and signalling of several 
independent surface-bound and endosomal TLRs (502, 503). The selective downregulation 
of CD11b and CD14 by VZV infection on human monocytes may therefore be reflected by 
an impaired capacity to mediate inflammatory signalling. TLRs mediate a wide response to 
large set of stimuli to facilitate processes essential to host responses to infection, including 
pro-inflammatory signalling (480, 504). Ancillary proteins facilitating inflammatory 
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signalling, such as CD14 and CD11b, may present a target for VZV to modulate 
inflammatory signalling. VZV infection has previously been observed to activate  
TLR2-mediated inflammatory cytokine expression in human monocytes and macrophages 
(243). Furthermore, TLR signalling is inherently involved in activation of inflammasome 
complexes, and VZV infection of THP-1 cells was demonstrated to induce formation of IL-
1b secreting complexes (249). These studies provide evidence that VZV infection plays an 
integral role in inflammatory signalling in these cells, and this role will be expanded upon in 
Chapter Five.  
The loss of CD14 expression by VZV infection may also be explained by the conversion of 
classical monocytes (CD14+ CD16-) into non-classical subsets (CD14loCD16+) mimicking  
in vivo differentiation (348). However, CD16 was below the threshold for detection on 
monocytes during the 24-72-hour timecourse of infection (data not shown). Interestingly, 
CD14 expression was not modulated following VZV infection M-MΦ. The regulation of 
CD14 on M2-like M-MΦ was clearly variable between donor populations, although this did 
not influence the proportion of VZV infected M-MΦ at any timepoint following infection. It 
is unclear why VZV preferentially targeted CD14 expression on monocytes in comparison 
to M-MΦ as CD14 is a known mediator of MΦ-specific inflammatory actions during disease 
(487, 488). Further investigation into the influence of VZV infection on CD14 signalling, and 
the pro- and anti-inflammatory capabilities of VZV infected monocytes and MD-MΦ is 
therefore of interest, and is discussed further in Chapter Five. 
Expression of MR and CD163 was also significantly downregulated on VZV infected M-MΦ 
(Figures 4.4 and 4.5), whereas MR was not modulated on GM-MΦ (Figures 4.7 and 4.8). 
MR and CD163 are responsible for the internalisation of environmental antigens through 
their functioning as receptors for mannose- and dextran-based antigens (505), and as a 
scavenger receptor (506), respectively. As was the case with modulation of CD11b and 
CD71 expression, it is unclear why expression of MR was not modulated on both MD-MΦ 
subsets, other than our observation that GM-MΦ differentiation generated consistently 
higher proportions of MR+ cells (Figure 3.11). Functional analyses into the capacity for VZV 
infected MD-MΦ to interact with environmental antigens in the context of antigen 
presentation will be further examined in Chapter Five. 
A number of modulated cell-surface immune molecules were observed on VZV exposed 
monocytes and MD-MΦ, proposed to be a result of exposure to VZV infected cells. 
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However, these cells were identified on the basis of undetectable VZV gE:gI expression 
and there is uncertainty regarding whether these cells represent true uninfected cells. 
These “bystander” cells may constitute cells undergoing early stages of infection with 
undetectable VZV gE:gI expression, or potentially cells undergoing abortive infection. 
Drawing inferences from these populations would require more detailed investigation to 
proportional attribute any impacts observed to VZV exposure, and not early or abortive 
infection. In the future, this could be further explored, and could perhaps be expanded to 
a detailed study of all VZV exposed immune cells including NK cells, and T cells.  
4.4. Conclusion 
VZV infection is known to infect a wide variety of immune cells with some of these cell types 
critical for virus dissemination throughout the host (41). In certain immune cells, it has been 
reported that VZV can actively modulate and manipulate these cells as an immune evasive 
strategy. The results presented in this chapter serve to represent the extent to which novel 
susceptible immune cells can be interrogated for the specific immunomodulatory effects 
VZV infection confers. Furthermore, these results highlight the variability of this regulation 
in different susceptible immune cells, even those derived from common precursors. The 
observed alteration in monocyte and macrophage phenotype following infection may be 
reflective of the functional consequences of VZV infection in these cells. In particular, the 
capacity for VZV infected monocytes to generate viable macrophages is unclear, as is the 
viability of these cells following VZV infection. Furthermore, it is not certain that VZV 
infected monocytes and macrophages would retain their APC capabilities and whether the 
interactions between these cells and other immune regulatory cells, such as NK cells and 
T cells, would be maintained following VZV infection. Lastly, these results indicated that 
VZV infection modulates the broad range of ancillary proteins which facilitate inflammatory 
signalling throughout this myeloid lineage. The capacity for monocytes and macrophages 
to secrete both pro- and anti-inflammatory mediators in response to pathogens is critical 
to resolution of some infections (507). It remains to be seen the extent to which VZV 
infection modulates the inflammatory responses of these cells, and what, if any, impact this 
may have on resolution of viral infection. 
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5. Functional Modulation of VZV Infected Human Monocytes 
and Macrophages  
5.1. Introduction 
The functions of monocytes and macrophages are essential for the control and clearance 
of microbial infection and serve to bridge the innate and adaptive immune systems. In 
particular, monocytes are abundant in circulation and are capable of expansion and 
infiltration of tissues to replenish site-specific MD-MΦ and MDDCs (384, 388, 393, 507). 
Infiltrating monocytes may effectively control infection although they can also be implicated 
in the pathogenesis of disease (508). The signalling pathway of monocyte to macrophage 
differentiation in vivo is tightly regulated and drivers of differentiation are also known to 
intersect with cell death pathways (509, 510). Impairment of monocytes during viral 
infection may influence the infection-specific support they provide, and may lead to 
incomplete and/or delayed resolution of infection (507). As such, it is crucial to assess the 
capacity of monocytes to generate viable macrophages in the context of viral infection.  
Monocytes also contribute to the recognition of viral infection through their activity as 
professional APCs (478). Classical monocytes are capable of circulating environmental 
antigen through draining lymph nodes to induce TH1 cell activation, without specialisation 
and while maintaining the classical monocyte phenotype (511, 512). Additionally, 
macrophages can also be essential in the delivery of cognate antigen to B cells in lymph 
nodes in vivo (513, 514). Together, these studies provide evidence for the role of early 
myeloid lineage cells in antigen presentation (reviewed in 469).  
Monocytes and macrophages are also potent sources for pro-inflammatory and anti-
inflammatory cytokine production that contribute to controlling infection, however 
dysregulation of these functions may facilitate disease (reviewed in 401). Production of 
these mediators, including TNF, IFN-γ, IL-1, IL-6, IL-8, and IL-10, has been widely 
demonstrated across a number of different infectious and sterile-injury settings (515-517). 
Moreover, the capacity of monocytes and macrophages to release these cytokines is 
context-dependent as cytokine production from these cells is shown to be dependent upon 
exogenous stimulation (466).  
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It is understood that the functions of monocytes and macrophages are altered following 
infection with other herpesviruses, such as HCMV and EBV (375, 376, 440, 518). Therefore, 
the functions of monocytes and macrophages present a potential target for 
alphaherpesviruses, such as VZV. To this end, monocyte and macrophage functioning was 
investigated following VZV infection. This chapter serves to further explore the influence of 
VZV infection on function as suggested by the phenotypic modulation of VZV infected 
monocytes and macrophages (Chapter 4).  
5.2. Results 
5.2.1. Differentiation of VZV infected monocytes to macrophages. 
The development of site-specific MDDC and MD-MΦ from circulating monocytes is 
essential in maintaining steady-state homeostasis and is fundamental in instigating and 
resolving pathogen-mediated inflammation (507). As such, differentiation of monocytes has 
been demonstrated to be an important target during viral infection (353). VZV infection of 
monocytes was shown to lead to a decrease in cell-surface expression of M-CSFR and 
GM-CSFR (Table 4.1). As these receptors are responsible for signalling of M-CSF and  
GM-CSF during in vitro and in vivo generation of M-MΦ and GM-MΦ (466), we sought to 
assess the functional impact of M-CSFR and GM-CSFR downregulation, and thus the 
influence of VZV infection on macrophage differentiation.  
VZV infected monocytes are unable to progress through M-MΦ differentiation. 
Monocytes were mock or VZV infected, and cells were investigated at various times to 
assess macrophage differentiation. Mock and VZV infected monocytes at 24 hpi were 
collected and adhered in serum-free media onto fresh culture plates. After two hours, non-
adherent cells were removed and adherent cells were cultured for M-MΦ differentiation 
(Section 2.7.3). Initial experiments were performed with M-CSF for M-MΦ generation. 
Monocytes at day zero (D0) prior to seeding, and adherent monocytes during differentiation 
on D1-D3 were collected for immunostaining for VZV gE:gI, CD11b, and MR, in conjunction 
with live/dead dye for subsequent flow cytometric analysis (Figure 5.1A) (Section 2.9).  
Adherent monocytes from mock or VZV infected cultures were assessed for viability, as 
indicated by live/dead dye staining, prior to differentiation and at each timepoint during 
differentiation. Gating was performed on single cells prior to gating on VZV gE:gI+ (VZV 
infected monocytes.  
AFigure 5.1: Viability and VZV antigen expression of monocytes during M-MΦ differentiation. 
(A) Human monocytes were mock or VZV infected. At 24 hpi, non-adherent monocytes were 
adhered into fresh culture wells for 2 hours and differentiated in the presence of 25 ng/mL M-CSF. 
Adherent monocytes were collected for flow cytometry at 1, 2, and 3 days post-differentiation. 
Proportions of adherent VZV gE:gI+ monocytes were assessed in four independent experiments. 
(B) Bar graph depict proportion of viable mock infected and VZV infected (VZV gE:gI+) monocytes 
(±SEM) at each timepoint. Statistics performed: paired two-tailed t-test; * p<0.05, ns: not 
significant. (C) Bar graph depicts mean of viable mock and VZV infected (VZV gE:gI+) 
monocytes at each timepoint and symbols represent individual donors. (D) Line graph depict 
proportion of VZV infected monocytes represented as individual donors connected with lines. 
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The majority of adherent monocytes were viable from D1 to D2, regardless of exposure to 
mock or VZV infection (Figure 5.1B). At D3, significantly fewer VZV infected adherent 
monocytes were viable (Figure 5.1B). A commensurate proportion of VZV infected 
monocytes were detected at 24 hpi prior to seeding (D0) (Figure 5.1C) in comparison to 
previously observed numbers of VZV infected monocytes (Figure 3.2). Unexpectedly, the 
average number of VZV infected monocytes declined from D1 to D3 (Figure 5.1C). When 
analysed as individual experiments from four biologically independent blood donors, each 
experiment demonstrated sequential decreased proportions of VZV infected cells over this 
timecourse (Figure 5.1D). By D3, viable monocytes no longer remained in cultures from two 
donors, and for the other two donors the remaining viable cells contained <5% VZV 
infected monocytes. In comparison, mock infected monocytes under the same culture 
conditions retained viable populations of adherent cells (Fig 5.1B). This result demonstrates 
that VZV significantly impairs the longevity of infected monocytes during culture for M-MΦ 
differentiation, with the loss of VZV infected monocytes possibly due to cell death.  
VZV infection and exposure impairs early macrophage marker upregulation.  
As VZV infected monocytes remained detectable at D1-D2 of the M-MΦ differentiation 
timecourse, the early cell-surface phenotype of these cells was assessed by flow 
cytometry. Expression of macrophage-specific MR was examined, as upregulation of MR 
occurs following M-CSF differentiation (Figure 3.11). CD11b was also examined as this 
highly expressed marked is further upregulated during M-CSF and GM-CSF differentiation 
(519). Flow cytometry was performed on adherent mock infected, VZV infected (VZV 
gE:gI+), and VZV exposed (VZV gE:gI–) monocytes for proportions and protein expression 
of MR+ adherent monocytes. Flow cytometry was performed on D1 and D2 as viability of 
VZV infected and exposed monocytes was equivalent to that of mock infected monocytes 
at these times (Figure 5.1B). Gating was performed on viable single cells prior to gating on 
VZV gE:gI+ monocytes.  
Mock infected monocytes at D1 and D2 exhibited readily detectable MR, whereas, 
significantly fewer MR+ VZV infected monocytes were observed at both timepoints (Figure 
5.2A). VZV exposed monocytes similarly demonstrated a reduction in MR+ cells, although 
at D1 alone (Figure 5.2A). The surface protein expression level of MR on MR+ VZV infected 
and VZV exposed monocytes was normalised to the MFI of mock infected cells at each 
timepoint.  
BFigure 5.2: Differentiation of VZV infected monocytes to M-CSF derived macrophages. 
Human monocytes were mock or VZV infected. At 24 hpi, non-adherent monocytes were adhered 
into fresh culture wells for 2 hours and differentiated in the presence of 25 ng/mL M-CSF. Flow 
cytometry was performed on mock, VZV infected (gE:gI+), and VZV exposed (gE:gI–) monocytes at 
day 1 (D1) and D2 of differentiation for expression of MR and CD11b. (A) Proportion of adherent 
mock, VZV infected, and VZV exposed monocytes expressing MR (left), and MFI of MR expression 
normalised to mock infected monocytes at each timepoint (right). (B) Proportion of adherent 
mock, VZV infected, and VZV exposed monocytes expressing CD11b (left), and MFI of CD11b 
expression normalised to mock infected monocytes at each timepoint (right). Statistics performed 
in comparison to mock infected monocytes: RM two-way ANOVA with Tukey’s  MC; * p<0.05, 
** p<0.005, *** p<0.0005, ns: not significant. 
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Expression of MR was significantly decreased on VZV infected and VZV exposed 
monocytes in comparison to mock infected monocytes at D1 and D2 (Figure 5.2A). When 
expression of CD11b was examined, no significant difference was observed in the 
proportions of CD11b+ cells between mock and VZV infected or VZV exposed monocytes 
at either timepoint (Figure 5.2B). However, cell-surface protein expression of CD11b was 
significantly decreased on VZV infected monocytes by D2, whereas an increase and 
subsequent decrease in CD11b MFI was observed on VZV exposed monocytes at D1 and 
D2 respectively (Figure 5.2B). These results suggest that, in addition to the impaired 
longevity of VZV infected monocytes, macrophage surface markers MR and CD11b are 
downmodulated, dependent upon VZV infection and/or exposure.  
M-MΦ differentiation progresses in the presence of VZV-induced soluble mediators.  
As the early phenotype to M-CSF differentiation was influenced following exposure to VZV 
infected cells, it was important to evaluate the release of soluble mediators from VZV 
infected monocytes and from inoculating VZV infected HFF inoculum cells that may 
contribute to this process. Monocytes were mock and VZV infected as previously described 
(Section 2.8) and supernatants were collected at 24 hpi, using cells from four independent 
blood donors. Supernatants were clarified and filtered prior to use to remove any infectious 
cellular debris (Section 2.8.5). Monocytes from an additional independent donor were 
isolated and adhered for M-MΦ differentiation for 2 hours. Non-adherent monocytes were 
removed and adherent monocytes were cultured for M-MΦ differentiation in the presence 
of supernatants from mock or VZV infected monocytes in combination with M-CSF (Section 
2.7.3). After six days, resultant M-MΦ were imaged by light microscopy and immunostained 
with antibodies against VZV gE:gI, CD11b, CD71, and CD14, in conjunction with live/dead 
dye, for assessment by flow cytometry (Section 2.9).  
M-MΦ generated in the presence of supernatants from mock infected monocytes (mock 
supernatant) exhibited expected morphology, including both elongated (M2-like) and 
rounded (M1-like) macrophages previously observed (Figure 5.3A). M-MΦ generated in the 
presence of supernatants from VZV infected monocytes (VZV supernatant) similarly 
exhibited a heterogenous macrophage morphology (Figure 5.3B). There was no detectable 
expression of VZV gE:gI on M-MΦ in the presence of mock supernatant or VZV supernatant 
(data not shown). There was also no change in the proportion of viable cells when  
 
Figure 5.3: Differentiation of monocytes in the presence of supernatants from mock and VZV 
infected monocytes. Human monocytes were mock or VZV infected. At 24 hpi, supernatants were 
collected, clarified, and filtered. Monocytes from an independent donor were isolated and cultured 
for M-MΦ differentiation in the presence of supernatants from mock or VZV infected monocytes 
with 25 ng/mL M-CSF. Light microscopy and flow cytometry for CD11b, CD71 and CD14 was 
performed after six days differentiation. (A-B) Representative light microscopy of M-MΦ after 
differentiation in the presence of supernatants from mock infected (A) or VZV infected (B) 
monocytes. Images taken at 10X (left) and 64X (right) magnification. (C) Graph depicts proportions 
of monocytes expressing CD11b, CD71, and CD14 after differentiation in the presence of 
supernatants from mock or VZV infected monocytes. Symbols indicate independent donors. 
(D) Graphs depict MFI of CD11b, CD71, and CD14 expressing M-MΦ (±SEM), normalised to 
M-MΦ differentiated in the presence of supernatants from mock infected monocytes. Statistics 
performed: Paired two-tailed student’s t-test; ns: not significant. 
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comparing M-MΦ differentiated in mock supernatant to M-MΦ differentiated in virus free 
supernatant from VZV infected cells (data not shown). No significant difference in the 
proportions of CD11b+, CD71+, or CD14+ M-MΦ were observed when M-MΦ were 
generated in the presence of mock supernatant or VZV supernatant (Figure 5.3C). Similarly, 
when cell-surface expression levels of each macrophage marker were assessed at the 
protein level, no significant difference was detected between M-MΦ generated in mock 
supernatant or VZV supernatant (Figure 5.3D). These results suggest that VZV infection of 
monocytes or HFF does not result in the release of soluble mediators that impact 
significantly upon M-MΦ differentiation. Furthermore, as no VZV gE:gI staining was 
observed on monocytes cultured in VZV infected cell supernatants, these results 
corroborate previously observed results demonstrating VZV infection of monocytes does 
not release infectious cell-free virus (Figure 3.9) and demonstration that VZV infected HFF 
do not release infectious cell-free virus (520).  
In conclusion, VZV infection of monocytes results in impaired longevity, which is presumed 
to confound the capacity of monocytes to differentiate into M-CSF-derived macrophages. 
Furthermore, this impact did not appear to be facilitated by the release of VZV-inducible 
soluble mediators.  
5.2.2. Assessment of monocyte cell viability following VZV infection. 
The previous results indicate VZV infected monocytes do not retain viability after three days 
culture for M-CSF mediated differentiation (Figure 5.1). Previously, our laboratory has 
assessed the impact of VZV infection on apoptosis (6, 142, 143). Programmed cell death 
(PCD) by apoptosis was readily detected in VZV infected HFF, whereas VZV infection of 
human sensory neurons and keratinocytes induces protection, with VZV protein ORF63 
shown to provide an anti-apoptotic effect (6, 142, 143). Susceptibility to VZV-induced 
apoptosis has been documented to be cell-type specific, as both T and B lymphocytes 
succumb to apoptosis during in vitro exposure to VZV infection (39). This study also 
assessed monocytes following exposure to VZV and reported only 12% of monocytes with 
detectable VZV gE staining by IFA. Furthermore, 18-21% of VZV exposed monocytes 
exhibited signs of cell death, including annexin V binding, retention of propidium iodine (PI), 
and terminal deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL) expression, 
although combination staining of VZV gE with these markers was not undertaken. 
Therefore, to examine the specific processes of PCD that VZV infection induces in these 
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cells, we sought to examine the viability of human monocytes in culture and following 
infection with VZV.  
Mock and VZV infected monocytes exhibit sustained viability up to 48 hours. 
In an effort to examine the early and late stages of apoptosis following VZV infection,  
a multi-discriminate flow cytometry staining technique was employed. Intracellular staining 
for the terminal effector of apoptosis, cleaved caspase-3 (CC3), is indicative of early stages 
of apoptosis (521). In combination with a live/dead (L/D) which preferentially stains 
membrane permeable cells, late stages of apoptosis are equally discernible. Together, 
these markers discriminate between viable cells and cells undergoing early and late stages 
of apoptosis, as well as cells undergoing non-apoptotic cell death and have been 
previously used to evaluate the impact of VZV infection on apoptosis (142). Non-viable cells 
that are not undergoing apoptotic cell death, may be undertaking more inflammatory 
pathways of cell death, including but not limited to, pyroptosis (522). The combinatory use 
of these markers in assessing cellular viability thus provides more valuable information than 
the use of viability dyes alone.  
Freshly isolated monocytes were collected and cultured without HFF for up to 48 hours (h). 
Monocytes were aspirated and stained for flow cytometry with a live/dead dye and 
antibodies against intracellular CC3 after 24 h and 48 h of culture (Section 2.9 and 2.13). 
Monocytes were then separated into the four defined categories of; viable cells (CC3– and 
LD–), early apoptotic cells (CC3+ and LD–), late apoptotic cells (CC3+ and LD+), and, “other” 
non-viable non-apoptotic cells (CC3– and LD+) (Figure 5.4A). After 24 h culture, on average 
56% of monocytes remained viable (range 32-82%), whereas 25% of cells were 
undergoing early apoptosis (range 6-45%), 18% undergoing late apoptosis (range 9-25%), 
and 2% of cells undergoing non-apoptotic forms of cell death (range 0.3-2%) (Figure 5.4B). 
These results were largely consistent after 48 h culture and across n=8 independent blood 
donors. These results corroborate in vivo studies demonstrating the spontaneous 
apoptosis of monocytes within 1-2 days (348) and serve as a biological standard for 
monocyte viability, following VZV infection.  
VZV infection induces apoptotic and non-apoptotic cell death. 
To examine the effects of VZV infection on monocyte viability, monocytes were isolated 
and infected as before with CTV-labelled mock and VZV-infected HFF (Section 2.8.3-4).  
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Figure 5.4: Viability of mock and VZV infected monocytes. Freshly isolated monocytes 
were cultured for 24 and 48 hours prior to immunostaining with live/dead dye and for 
intracellularly cleaved caspase-3 (CC3). (A) Representative plot indicate detection of live/dead 
and CC3 in monocytes and stratifies the population into indicated groups. (B) Proportions 
of viable (CC3–L/D–), early apoptotic (CC3+L/D–), late apoptotic (CC3+L/D+), and “other” non-viable 
non-apoptotic (CC3–L/D+) monocytes were enumerated after 24 and 48 hours culture without HFF. 
(C-D) Freshly isolated monocytes were mock or VZV infected and at 24 and 48 hpi cells were 
collected for immunostaining with live/dead dye, and for surface VZV gE:gI and intracellular CC3. 
Mock, VZV infected gE:gI+, and VZV exposed gE:gI– monocytes were assessed for proportions 
of viable, early, late, and non-viable non-apoptotic cells at 24 hpi and 48 hpi. Results from n=7-8 
independent donors. Statistics performed: RM two-way ANOVA with Tukey’s  MC; * p<0.05, 
** p<0.005, *** p<0.0005, **** p<0.00005, ns: not significant.
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At 24 and 48 hpi, mock and VZV infected monocytes were aspirated and stained for flow 
cytometry with live/dead dye and antibodies against surface VZV gE:gI and intracellular 
cleaved caspase-3 (Sections 2.9 and 2.13). Monocytes were analysed by gating on single 
cells and to exclude the CTV-labelled infecting HFF inoculum. Monocytes were then 
discriminated on the basis of VZV gE:gI expression prior to assessing the viability of mock 
infected, VZV infected (VZV gE:gI+) and VZV exposed (VZV gE:gI–) monocytes.  
In comparison to monocytes cultured without HFF (Figure 5.4B), mock infected, VZV 
infected, and VZV exposed monocytes exhibited increased proportions of viable cells at 24 
and 48 hpi (Figure 5.4C-D). When compared to mock infected monocytes however, VZV 
infected monocytes exhibited significantly fewer viable monocytes commensurate with a 
significant increase in cells undergoing early apoptosis, late apoptosis, and other forms of 
cells death at 24 hpi (Figure 5.4C). VZV exposed monocyte viability was comparable to the 
viability of mock infected monocytes at this timepoint. At 48 hpi, VZV infected monocytes 
demonstrated a significant reduction in viable cells which was accompanied by an increase 
in early and late apoptotic cells in comparison to mock infected monocytes (Figure 5.4D). 
VZV exposed monocytes displayed a significant reduction in viable cells in comparison to 
mock infected monocytes at this timepoint, but retained greater proportions of viable cells 
than VZV infected monocytes (Figure 5.4D). Only proportions of late apoptotic cells were 
significantly elevated in VZV exposed monocytes in comparison to mock infected 
monocytes at this timepoint. These results indicate that co-culture of human monocytes 
with an HFF inoculum results in cells with greater viability than monocytes cultured alone. 
Furthermore, VZV infection resulted in impaired viability and an increase in cells undergoing 
apoptosis as well as other forms of cell death.  
VZV confers modest resistance to staurosporine-induced apoptosis. 
As VZV has been shown to both induce and protect from apoptosis in a cell-specific 
manner, we sought to determine whether VZV infection of monocytes resulted in a 
protective influence in the presence of the apoptosis-inducing agent staurosporine (STS). 
Stimulation with STS induces the intrinsic apoptotic pathway by inhibiting Akt 
phosphorylation by protein kinase C (PKC) (523) and has previously been used to assess 
the capacity of VZV to modulate apoptosis in keratinocytes (142). To this end, monocytes 
were treated with STS for four hours to induce apoptosis prior to collection and 
immunostaining (Section 2.13).  
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After 24 h culture, the majority of monocytes treated with STS were undergoing early 
apoptosis, with a smaller proportion of monocytes exhibiting markers of late apoptosis 
(Figure 5.5A). Fewer monocytes were observed undergoing early apoptosis after 48 h 
culture whereas an increase in late apoptotic monocytes was similarly observed. These 
results indicate that STS treatment of human monocytes induces apoptosis that is 
detectable by L/D and CC3 staining.  
The capacity of STS to induce apoptosis in monocytes following mock and VZV infection 
was then examined. Monocytes were mock and VZV infected as before and treated with 
STS for four hours prior to collection at 24 and 48 hpi. Monocytes were then immunostained 
to assess cellular viability as described previously (Section 2.13). In comparison to 
monocytes at 24 hpi that did not undergo treatment with STS (Figure 5.4C-D), STS 
treatment of mock infected, VZV infected, and VZV exposed monocytes reduced the 
number of viable monocytes at 24 hpi and 48 hpi (Figure 5.5B-C). At 24 hpi, significantly 
fewer STS-treated VZV infected monocytes were undergoing early apoptosis when 
compared to mock infected and VZV exposed monocytes (Figure 5.5B). This result was 
accompanied with an increase in the proportion in viable cells, late apoptotic cells, and 
cells undergoing other forms of cell death. This increase was also consistent with previously 
observed proportions of viable and non-viable cells in untreated VZV infected monocytes 
at the same timepoint (Figure 5.4C). VZV exposed monocytes exhibited viability 
comparable with that of mock infected monocytes at 24 hpi (Figure 5.5B). At 48 hpi, VZV 
infected monocytes exhibited fewer cells undergoing early apoptosis when compared to 
mock infected monocytes, although no corresponding rise in viable cells was observed 
(Figure 5.5C). There was no statistical difference between VZV infected monocytes and 
mock infected monocytes that were undergoing late apoptosis or other forms of cell death 
(Figure 5.5C). Interestingly, the viability of VZV exposed monocytes was significantly 
impaired, however there was no changes in the proportions of cells undergoing any form 
of cell death examined when compared to mock (Figure 5.5C). 
These results suggest that VZV infection in monocytes results in a small, yet significant, 
increase in cells undergoing apoptosis, and other forms of cell death. Furthermore, VZV 
infection conferred a modest resistance to STS-induced apoptosis as evidenced by a 
decrease in early apoptotic STS-treated VZV infected monocytes. This contrasts with 
evidence that VZV infection of monocytes induces apoptosis and non-apoptotic forms of 
cell death without induction of PCD with exogenous stimulation (39).  
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Figure 5.5: Viability of VZV infected and STS treated monocytes. Freshly isolated monocytes 
were cultured for 24 and 48 hours before immunostaining with live/dead dye and for intracellularly 
cleaved caspase-3 (CC3). Monocytes were treated with staurosporine 4 hr prior to collection. (A) 
Proportions of viable (CC3–L/D–), early apoptotic (CC3+L/D–), late apoptotic (CC3+L/D+), and 
“other” non-viable non-apoptotic (C3–L/D+) monocytes were enumerated after 24 and 48 hours 
culture without HFF. (B-C) Freshly isolated monocytes were mock or VZV infected and at 24 and 
48 hpi cells were collected for immunostaining with live/dead dye, and for surface VZV gE:gI and 
intracellular CC3. Monocytes were treated with STS 4 hr prior to collection. Mock, VZV infected 
gE:gI+, and VZV exposed gE:gI– monocytes were assessed for proportions of viable, early, late, 
and non-viable non-apoptotic cells at 24 hpi and 48 hpi. Results from n=4 independent donors. 
Statistics performed: RM two-way ANOVA with Tukey’s  MC; * p<0.05, ** p<0.005, *** p<0.0005, 
**** p<0.00005, ns: not significant.
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These results also provide evidence that monocytes co-cultured with mock or VZV infected 
HFF exhibit preserved viability in comparison to freshly isolated monocytes cultured 
without HFF for the same period of time.  
When assessed in combination with VZV infected monocytes undergoing macrophage 
differentiation (Figure 5.1), it was evident that VZV infection of monocytes results in 
impaired viability of these cells. Moreover, the capacity for VZV infected monocytes to 
remain adherent during the differentiation process would likely impact the observed 
reduction in monocyte viability during M-CSF differentiation. However, those experiments 
represent different culturing conditions, whereas at 24 hpi and 48 hpi, the vast majority of 
VZV infected monocytes not undergoing M-CSF differentiation remained viable (Figure 
5.5C). As such, the capacity of human monocytes to undertake effector functioning during 
this period is presumably feasible, as would the capacity for VZV infection to result in the 
subversion of these functions. In light of this, further experimentation into the functional 
consequences of VZV infection in human monocytes was undertaken. 
5.2.3. Assessing endocytic capacity in VZV infected monocytes and macrophages.  
There is increasing evidence that monocytes possess the capacity to uptake environmental 
antigen, migrate to lymph nodes, and acts a professional APCs (reviewed in 242). 
Macrophages are also known to be essential in presentation of antigen by B cells (513, 
514). These actions are predominantly mediated through a MHC class II-restricted 
mechanism (478). Previous studies have identified the selective downregulation of MHC 
class I and IFN-γ mediated MHC class II expression by VZV infection in primary human 
cells, immune cells, and cell lines (37, 156, 263, 294). The results presented in this current 
study report the selective downregulation of HLA-DR expression following VZV infection of 
monocytes (Figure 4.2) although attempts to associate this modulation with an impairment 
in MHC-class II-restricted antigen presentation are complicated by the susceptibility of 
CD4+ T cells to VZV infection (23). The C-type lectin MR is known to facilitate 
micropinocytosis in MDDC, mediating the uptake of environmental antigen for 
concentration in MHC class II-expressing compartments for antigen presentation (524). 
Although freshly isolated monocytes do not readily express MR (Figure 3.11), previous 
reports have demonstrated the upregulation of MR and endocytic functioning following  
12-24 hours in culture in vitro (227, 525). Furthermore, the downregulation of surface MR 
expression was observed on VZV infected M-MΦ, but not GM-MΦ (Figures 4.5 and 4.8). 
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Thus, the capacity for VZV infected monocytes and macrophages to uptake antigen, an 
integral process in the pathway of antigen presentation, was assessed. 
VZV infected monocytes exhibit impaired endocytosis. 
Human monocytes were isolated and mock and VZV infected as before. At 24 hpi, 
monocytes were incubated with 1 mg/mL dextran-FITC (Dx) for one hour at 37˚C or 4˚C to 
differentiate between internalised and surface-bound dextran respectively (518) (Section 
2.15). Monocytes were then immunostained for flow cytometry with antibodies against 
CD11b and VZV gE:gI in conjunction with live/dead dye (Section 2.9). Monocytes were 
gated by size, viability, and the infecting CTV-labelled HFF inoculum excluded, prior to 
discrimination of VZV infected (VZV gE:gI+) and VZV exposed (VZV gE:gI–) monocytes.  
Dextran was readily detectable in mock infected, VZV infected, and VZV exposed 
monocytes following Dx incubation at 37˚C (internalised) in comparison to incubation at 4˚C 
(surface-bound) (Figure 5.6A). The MFI of Dx at 4˚C was subtracted from the MFI of Dx at 
37˚C to generate an ‘internalised MFI’, which was normalised to the internalised MFI of 
mock infected monocytes across three independent replicates. VZV infected monocytes 
exhibited significantly less internalised Dx in comparison to mock infected monocytes 
(Figure 5.6B). VZV exposed monocytes also exhibited significantly reduced internalised Dx 
in comparison to mock infected monocytes. Although VZV exposed monocytes appeared 
to internalise more Dx in comparison to VZV infected monocytes, this trend did not reach 
statistical significance. This result demonstrates that VZV infected monocytes are impaired 
in their ability to uptake environmental antigens, and suggests a similar impairment may 
result following exposure to VZV infected cells.  
M-MΦ constitute a dual proportion of high and low endocytic macrophages.  
M-MΦ were generated and mock and VZV infected as described previously. At 24 hpi, M-
MΦ were incubated with 1 mg/mL Dx for one hour at 37˚C or 4˚C (Section 2.15). 
Macrophages were collected and immunostained for flow cytometry with antibodies 
against CD11b, CD14, and VZV gE:gI in conjunction with live/dead dye. M-MΦ were gated 
as in previous infections (Figure 3.12). Internalisation of Dx was assessed on mock infected, 
VZV infected, and VZV exposed M-MΦ (Figure 5.7A). M-MΦ demonstrated greater 
internalisation of Dx at 37˚C in comparison to 4˚C. Unexpectedly, Dx internalisation on  
M-MΦ was characterised by two distinct ‘peaks’, most evident following VZV infection of 
M-MΦ (Figure 5.7A, arrows).  
Figure 5.1: QIAGEN qPCR array 
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Figure 5.6: VZV infected monocytes exhibit decreased endocytic capacity. Human 
monocytes were mock or VZV infected for 24 hours. Non-adherent monocytes were collected, 
and incubated with 1 mg/mL dextran-FITC for 1 hour at 4˚C or 37˚C. Monocytes 
were immunostaining for flow cytometry to detect viability and expression of CD11b and VZV 
gE:gI (or with equivalent isotype antibodies). (A) Representative histograms of dextran-FITC was 
assessed in mock infected (blue), VZV infected (gE:gI+) (purple), and VZV exposed (gE:gI– ) (grey) 
monocytes following incubation at 37˚C (solid) in comparison to incubation at 4˚C (dotted) or 
without dextran-FITC (black). (B) Internalised MFI (±SEM) was enumerated by subtracting 4˚C 
MFI from 37˚C MFI and normalising to respective mock MFI in n=4 independent experiments. 
Statistics performed: RM one-way ANOVA with Geisser-Greenhouse correction and Tukey’s MC; 
** p < 0.005, *** p < 0.0005, **** p < 0.00005, ns: not significant.
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As M-MΦ have been demonstrated to be a heterogenous population with variable 
proportions of CD14+ and CD163+ cells (Figure 3.11), expression of these markers may 
facilitate MR-mediated endocytosis. M-MΦ were therefore discriminated on the basis of 
CD14 expression, prior to establishing proportions of VZV infected and VZV exposed M-
MΦ, and each group was assessed for Dx internalisation (Figure 5.7A-B). Strikingly, when 
Dx internalisation of mock infected CD14+ was compared to mock infected CD14– M-MΦ, 
the previously identified dual peaks of Dx internalisation were resolved, yielding two 
populations: high-endocytic CD14+ M-MΦ and low-endocytic CD14– M-MΦ (Figure 5.7B). 
This phenotype was also observed in VZV infected and VZV exposed CD14+ and CD14–  
M-MΦ. As such, prior to establishing the capacity of M-MΦ to endocytose Dx following 
VZV infection, these populations were first gated on single viable cells, followed by gating 
on CD14+ and CD14– M-MΦ, and then gated on VZV gE:gI.  
VZV infected CD14+ and CD14– M-MΦ exhibit impaired endocytosis. 
Mock infected, VZV infected, and VZV exposed CD14+ and CD14– M-MΦ were examined 
for the internalisation of Dx, as described above. When the MFI of internalised Dx was 
assessed, VZV infected CD14+ M-MΦ demonstrated significantly reduced internalisation of 
Dx in comparison to mock infected CD14+ M-MΦ and VZV exposed CD14+ M-MΦ (Figure 
5.7C). VZV exposed CD14+ M-MΦ exhibited a significant reduction in Dx internalisation in 
comparison to mock infected CD14+ M-MΦ. The internalisation of Dx on low-endocytic 
CD14– M-MΦ was significantly impaired following VZV infection in comparison to mock 
infection, although no significant difference was observed in comparison to VZV exposed 
CD14– M-MΦ (Figure 5.7D).  
These results demonstrate that M-MΦ comprise a heterogenous population of cells with 
high and low endocytic activity, correlating with CD14 expression, although CD14 may not 
be essential for this activity (discussed below). Furthermore, CD14+ and CD14– M-MΦ 
exhibited a significant impairment in their capacity to endocytose Dx following VZV 
infection.  
VZV infected GM-MΦ do not exhibit impaired endocytosis. 
GM-MΦ were generated and mock and VZV infected as before. At 24 hpi, GM-MΦ were 
incubated with 1 mg/mL Dx for one hour at 37˚C or 4˚C (Section 2.15). Macrophages were 
collected and immunostained for flow cytometry with antibodies against CD11b and VZV 
gE:gI in conjunction with live/dead dye. GM-MΦ were gated as in previous infections 
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(Figure 3.12). As GM-MΦ do not express detectable CD14, these cells were assessed as 
one homogenous population (Figure 3.11). The profile of Dx internalisation in GM-MΦ did 
not appear to reach the same level as monocytes (Figure 5.6A) or CD14+ M-MΦ (Figure 
5.7B), suggesting that similar to CD14– M-MΦ, GM-MΦ are low-endocytic (Figure 5.8A). Dx 
internalisation of VZV infected GM-MΦ appeared to be reduced in comparison to mock 
and VZV exposed GM-MΦ, although this result did not reach statistical significance (Figure 
5.8B). VZV exposed GM-MΦ however retained significantly higher internalisation of Dx in 
comparison to VZV infected GM-MΦ (Figure 5.8B). These results suggest that 
internalisation of Dx in GM-MΦ may be equivalent to internalisation of Dx in CD14– M-MΦ, 
however, VZV infection may not modulate Dx internalisation of GM-MΦ.  
Taken together, these results demonstrate a suppression in the capacity of VZV infected 
monocytes and M-MΦ to endocytose Dx-based antigens. Furthermore, the identification 
of two endocytic profiles discriminated in these experiments through expression of CD14, 
provides a potential avenue to address the modulation by VZV infection, as CD14 is co-
expressed with CD163 and MR (Figures 4.3 and 4.6). These markers have been previously 
demonstrated to be involved with uptake of environmental antigens (505, 524).  
5.2.4. Assessment of VZV-mediated production of inflammatory cytokines. 
The production of pro-inflammatory cytokines from monocytes and macrophages 
contributes to differing, and at times contrasting, roles. These actions can range from host 
defence mechanisms against microbial invasion, to adverse effects, such as mediating 
systemic toxic shock (526). In the context of viral infection however, monocyte release of 
pro-inflammatory cytokines can contribute to resolution of infection (527, 528). More 
specifically, exposure of human monocytes to VZV induced the secretion of  
highly-inflammatory IL-6 in a TLR2-dependent manner (243). In combination, with TNF and 
IL-1β, these cytokines are widely associated with mediating highly inflammatory responses 
(380, 529). As such, the secretion of inflammatory cytokines, such as TNF, IL-1β, and  
IL-18, were examined following VZV infection of monocytes and macrophages.  
VZV infection does not induce TNF secretion of human monocytes or MD-MΦ. 
To determine if VZV infection of human monocytes or MD-MΦ potentiated the production 
and release of TNF, supernatants from mock and VZV infected cells were assessed by 
commercial ELISA (Section 2.16 and 2.17).  
Mock Infected Exposed
0.00
0.25
0.50
0.75
1.00
1.25
1.50
In
te
rn
al
ise
d 
M
FI
 (n
or
m
al
ise
d 
to
 m
oc
k)
A
Dextran 37˚C
Dextran   4˚C 
No Dextran
Figure 5.8: VZV infected GM-MΦ exhibit unmodulated endocytic capacity. GM-MΦ 
were generated as previous and mock or VZV infected for 24 hours. Macrophages were 
collected, and incubated with 1 mg/ML dextran-FITC for 1 hour at 4˚C or 37˚C. Macrophages 
were immunostaining for flow cytometry to detect viability and expression of VZV 
gE:gI (or with equivalent isotype antibodies). (A) Representative histograms of dextran-FITC 
MFI at 37˚C (solid), 4˚C (dotted) or without dextran-FITC incubation (black) on mock 
infected (blue), VZV infected (purple) and VZV exposed (grey) GM-MΦ. (B) Internalised 
MFI (±SEM) was enumerated by subtracting 4˚C MFI from 37˚C MFI and normalising to 
respective mock MFI in n=3 independent experiments. Statistics performed: RM one-way 
ANOVA with Geisser-Greenhouse correction and Tukey’s MC; ** p < 0.005, ns: not significant.
B
Mock infected VZV infected VZV exposed
Dextran-FITC
N
or
m
al
ise
d 
to
 m
od
e
p = 0.3 *
ns
  158 
The limit of detection for TNF in these experiments was <5 pg/mL and TNF protein 
standards were included the validate successful detection of TNF (Section 2.16). 
Monocytes, M-MΦ, and GM-MΦ were generated from three independent blood donors and 
mock and VZV infected as before. At 24 hpi, supernatants from these cultures were 
collected, clarified to remove cellular debris, and assessed for TNF secretion by ELISA. 
There was no detectable concentration of TNF in the supernatant from mock and VZV 
infected monocytes at 24 hpi (Figure 5.9A). Supernatants from mock and VZV infected  
M-MΦ at 24 hpi similarly did not contain detectable concentrations of TNF (Figure 5.9B), 
nor did supernatants from mock and VZV infected GM-MΦ (Figure 5.9C). These results 
demonstrate that mock and VZV infection of monocytes, M-MΦ, and GM-MΦ does not 
induce the secretion of TNF.  
VZV infection does not alter LPS-induced release of TNF by human monocytes.  
VZV infection did not induce endogenous secretion of TNF from monocytes, although these 
experiments investigated constitutive or VZV-mediated release of TNF, and did not directly 
examine the production of TNF secreted following stimulation. Exogenous stimulation with 
TLR ligands, such as TLR4 ligand LPS, are widely used to reproduce the in vivo stimulation 
of monocytes to induce production and secretion of inflammatory cytokines, including TNF 
and IL-1β (526, 530). As such, we sought to investigate whether VZV infection of monocytes 
influenced the exogenous stimulation of TNF production.  
Monocytes were mock and VZV infected as previously described (Section 2.8). At 24 hpi, 
mock infected monocytes and VZV infected and exposed monocytes were resuspended in 
fresh media and treated with 100 ng/mL LPS for 3 hours (Section 2.17). VZV infected 
monocyte cultures contained both VZV gE:gI+ and VZV gE:gI– monocytes, and both mock 
and VZV infected monocyte cultures contained inoculum HFF. In parallel, mock and VZV 
infected HFF were cultured and treated with LPS at 24 hpi (Section 2.17). As a control, 
supernatants from mock and VZV infected monocytes and HFF were collected and the 
concentration of LPS-induced TNF was measured in by ELISA (Section 2.16). LPS 
stimulation induced TNF secretion at an average concentration of approximately 1967 
pg/mL from mock infected monocytes (range 220-6870 pg/mL), and 2883 pg/mL from VZV 
infected monocytes (range 290-6290 pg/mL) (Figure 5.9D). In contrast, TNF secretion from 
untreated and LPS treated mock and VZV infected HFF was below the threshold for 
detection (data not shown). 
Figure 5.9: Assessment of TNF release following VZV infection and LPS treatment. 
Human monocytes were isolated and mock and VZV infected. M-MΦ and GM-MΦ were generated 
as before, and mock and VZV infected in parallel. At 24 hpi, supernatants from cultures of infected 
monocytes and macrophages were collected and assessed for secretion of TNF. (A) Mock and 
VZV infected monocyte secretion of TNF at 24 hpi (n=3). (B) Mock and VZV infected M-MΦ 
secretion of TNF at 24 hpi (n=3). (C) Mock and VZV infected GM-MΦ secretion of TNF at 24 
hpi (n=3). Symbols represent individual donors. In certain experiments, mock and VZV infected 
monocytes were treated 100 ng/mL LPS for 3 hours prior to assessment of cytokine secretion. 
(D) Mock and VZV infected monocyte secretion of TNF following stimulation with LPS. Symbols 
depict matched independent donors across n=5 experiments. (E) Concentration of TNF following 
LPS treatment of VZV infected monocytes was normalised to mock infected monocytes in n=5 
donor matched experiments. Bars represent mean concentration (±SEM). Statistics performed: 
Paired two-tailed student’s t-test; ns: not significant.
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In comparison to the level of secreted TNF from mock infected monocytes, there was no 
consistent increase or decrease in secreted TNF associated with VZV infection, across five 
independent experiments (Figure 5.9D). Furthermore, the measured concentration of TNF 
appeared to vary between donors, and between stimulations (Figure 5.9D). As such, the 
concentration of TNF released from VZV infected monocytes was normalised to the 
concentration of TNF released from donor-matched mock infected monocytes (Figure 
5.9E). Although an increase in released TNF appeared evident following VZV infection, this 
result did not reach statistical significance. These results demonstrate that LPS stimulation 
does induce the secretion of TNF, although VZV infection of human monocytes does not 
significantly modulate this response. 
VZV infection does not induce IL-1β or IL-18 release from monocytes. 
To further investigate the influence of VZV infection on pro-inflammatory cytokine secretion, 
we sought to examine a highly inflammatory process known as inflammasome formation. 
Inflammasomes are multi-protein complexes that form following recognition of pathogens, 
binding of danger signals, or perturbations in homeostasis (531, 532). These complexes 
facilitate the activation of pro-inflammatory caspases which mediate the cleavage and 
release of IL-1β and IL-18. The most well-studied of these is the NLRP3 inflammasome and 
formation is activated by TLR ligand binding and exposure to bacterial and viral ligands 
(533). Previously, VZV infection of the monocytic-cell line THP-1 was associated with 
NLRP3 inflammasome formation and release of IL-1β (249). However, whether VZV 
infection induces such events in primary human monocytes has not been previously 
reported. NLRP3 inflammasome activation in vitro requires a two-step activation, involving 
‘priming’ of monocytes through stimulation with TLR4 ligand LPS to induce transcription of 
inflammasome associated genes (Figure 5.10A, i), and subsequent activation of the 
inflammasome complex with either ATP or the pore-forming toxin nigericin (Ngn) (Figure 
5.10A, ii) (534). Thus, we sought to directly assess whether VZV productive infection of 
primary human monocytes impacts inflammasome-associated IL-1β.  
VZV infection modulates inflammasome-associated IL-1β release from monocytes. 
Monocytes were mock and VZV infected as before, and supernatants at 24 hpi were 
collected to detect the concentration of IL-1β at this timepoint (Section 2.17). The limit of 
detection for IL-1β in these experiments was <1 pg/mL and IL-1β protein standards were 
included the validate successful detection of IL-1β (Section 2.16).  
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Figure 5.10: Assessment of inflammasome-related cytokine secretion from VZV infected 
monocytes. Human monocytes were mock and VZV infected as before. (A) At 24 hpi, monocytes 
were collected and treated with 100 ng/mL LPS for 3 hours (i) prior to treatment with 10 µM 
nigericin (Ngn) for a further 30 minutes (ii) to stimulate the secretion of IL-1β and IL-18. (B) Bars depict 
mean concentration of secreted IL-1β (±SEM) from mock and VZV infected monocytes (n=5). (C) 
Concentration of IL-1β from VZV infected monocytes was normalised to mock infected monocytes 
in n=5 matched experiments. Bars represent mean concentration (±SEM). (D) Bars depict mean 
concentration of secreted IL-18 (±SEM) from mock and VZV infected monocytes (n=3). 
(E) Concentration of IL-18 from VZV infected monocytes was normalised to mock infected 
monocytes in n=3 matched experiments. Bars represent mean concentration (±SEM). Statistics 
performed: Paired two-tailed student’s t-test; * p < 0.05, *** p < 0.0005, ns: not significant. 
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In parallel, supernatants from mock and VZV infected HFF at 24 hpi were assessed for 
secretion of IL-1β. There was no detectable concentration of IL-1β released from mock or 
VZV infected monocytes or HFF at 24 hpi (data not shown). Mock and VZV infected 
monocytes and mock and VZV infected HFF at 24 hpi had cell media replaced with fresh 
media and were subsequently treated with 100 ng/mL LPS for 3 hours (Section 2.17). In 
some experiments, following LPS stimulation, mock and VZV infected monocytes and HFF 
underwent further treatment with 10 µM Ngn for 1 hour (Section 2.17). (Figure 5.10A). 
Following stimulation, supernatants were collected and the concentration of IL-1β was 
measured in an ELISA (Section 2.16). Supernatants from mock and VZV infected 
monocytes which did not receive LPS or Ngn treatment, and from monocytes which had 
received LPS treatment alone, contained relatively low concentrations of IL-1β (Figure 
5.10B). These concentrations ranged from 20 pg/mL to levels below the assay-specific 
threshold for detection (Section 2.16). Supernatants from mock and VZV infected 
monocytes stimulated with Ngn alone also did not contain detectable IL-1β (data not 
shown). Supernatants from mock and VZV infected monocytes treated sequentially with 
LPS and Ngn contained IL-1β at an average concentration of approximately 2391 pg/mL 
(range 1898-3045 pg/mL) from mock infected monocytes and 418 pg/mL (range 35-1030 
pg/mL) from VZV infected monocytes (Figure 5.10B). Supernatants from mock and VZV 
infected HFF did not contain detectable concentrations of IL-1β following treatment with 
LPS, Ngn, or combination treatment with LPS and Ngn (data not shown).  
As measured concentrations of IL-1β exhibited variability between independent blood 
donors, the concentration of IL-1β from VZV infected monocytes was normalised to IL-1β 
concentration from matched mock infected monocytes. This analysis showed that VZV 
infected monocytes were significantly impaired for the secretion of IL-1β following 
treatment with LPS and Ngn (Figure 5.10C). This was characterised by a 5.6-fold decrease 
in the amount of normalised IL-1β secreted from these cells. There was, however, no 
change in the concentration of IL-1β secreted from untreated monocytes, or those treated 
with LPS alone, when mock and VZV infected monocytes were compared. Therefore, these 
results demonstrate that VZV infection of monocytes significantly impairs the release of 
NLRP3-inflammasome-mediated IL-1β.  
 
 
  163 
VZV infection modulates inflammasome-associated IL-18 release from monocytes. 
Variability in the concentration of IL-1β released following LPS and Ngn stimulation of mock 
infected monocytes may be attributable to the fluctuating efficiency of LPS priming 
between independent experiments. However, inflammasome formation results in the 
production of both IL-1β and IL-18, and IL-18 is constitutively transcribed, independent of 
LPS-mediated transcription (535, 536). Furthermore, assessment of LPS-independent 
cytokine secretion may yield useful information regarding the observed impairment of VZV 
infected monocytes to release inflammasome-associated IL-1β. As such, the capacity for 
mock and VZV infected monocytes to secrete L-18 following stimulation with LPS and Ngn 
was examined.  
Monocytes were mock and VZV infected as before, and supernatants at 24 hpi were 
collected to detect the concentration of IL-18 at this timepoint (Section 2.17). The limit of 
detection for IL-18 in these experiments was 6.25 pg/mL and IL-18 protein standards were 
included the validate successful detection of IL-18 (Section 2.16) Supernatants from mock 
and VZV infected HFF at 24 hpi were assessed for secretion of IL-18 in parallel. There was 
no detectable IL-18 released from mock or VZV infected monocytes or HFF at 24 hpi (data 
not shown). This result was to be expected as IL-18 is constitutively transcribed but not 
constitutively released from the cell (536). Mock and VZV infected monocytes at 24 hpi 
were resuspended in fresh culture media and treated with 100 ng/mL LPS for 3 hours, and 
where required, treated with 10 µM Ngn for a further hour (Section 2.17). Mock and VZV 
infected HFF at 24 hpi were treated in parallel. Following treatment, supernatants from 
mock and VZV infected monocytes and HFF were collected, clarified to remove cellular 
debris, and the concentration of IL-18 determined by ELISA (Section 2.16). Supernatants 
from mock and VZV infected monocytes that did not undergo treatment, or received LPS 
treatment alone, did not secrete IL-18 at a detectable level (Figure 5.10D). Unexpectedly, 
supernatants from mock and VZV infected monocytes stimulated with Ngn alone also did 
not contain detectable IL-18 (data not shown) suggesting that IL-18 secretion may be 
dependent upon LPS treatment (discussed in Section 5.3). In contrast, a robust 
concentration of IL-18 was detectable following LPS and Ngn treatment of mock infected 
monocytes, with supernatants from these cells containing on average 3048 pg/mL (range 
1525-4997 pg/mL) (Figure 5.10D). Supernatants of VZV infected monocytes at 24 hpi 
following LPS and Ngn treatment contained on average 868 pg /mL (range 606-1356 
pg/mL) (Figure 5.10D). Supernatants from mock and VZV infected, LPS treated-HFF, Ngn 
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treated-HFF, or combination LPS- and Ngn treated-HFF, did not contain detectable IL-18 
(data not shown).  
The measured concentration of IL-18, similarly to those of IL-1β, varied between 
independent blood donors. As such, the concentration of IL-18 from VZV infected 
monocytes following LPS and Ngn treatment were normalised to the equivalent 
concentration released from mock infected monocytes in matched experiments. There was 
a significant decrease in the normalised concentration of IL-18 secreted from VZV infected 
monocytes in comparison to mock infected monocytes (Figure 5.10E). This was 
characterised by an average of a 2.9-fold decrease in LPS and Ngn stimulated IL-18 
secretion.  
Taken together, these results indicate that VZV infection of monocytes does not induce the 
endogenous secretion of TNF, IL-1β, or IL-18. However, following stimulation of NLRP3 
inflammasome formation with LPS and Ngn, VZV infection significantly impaired the release 
of both IL-1β and IL-18, without affecting the concentration of LPS-induced TNF release. 
These results highlight the capacity for VZV infected monocytes to influence the secretion 
of pro-inflammatory cytokines, and provide insight into how VZV may subvert the viral-
recognition pathways associated with inflammasome formation.  
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5.3. Discussion 
The main objective of this study was to identify the functional capabilities of monocytes 
and macrophages following productive VZV infection. These results demonstrated that VZV 
infected human monocytes are unable to generate viable macrophages, and that VZV 
infection dysregulates cell viability. Furthermore, the induction of apoptosis following VZV 
infection of monocytes was observed, whereas VZV infected monocytes were resistant to 
STS-induced apoptosis. These results also demonstrated for the first time that VZV 
infection of monocytes and M-MΦ results in an impairment in endocytosis, whereas, VZV 
infection of GM-MΦ did not result in a similar impairment. Finally, the release of  
LPS-induced TNF from VZV infected monocytes was unchanged, however, VZV infection 
of monocytes impaired the release of inflammasome-associated IL-1β and IL-18 release. 
Collectively, these results represent the most comprehensive analysis of monocyte and 
macrophage function following VZV infection, and identify previously unrecognised 
immunomodulatory activities that VZV is capable of undertaking.  
The susceptibility of VZV infected monocytes to programmed cell death (PCD) has been 
investigated previously (39). This study reported approximately 18-25% of monocytes with 
detectable annexin V binding, retention of propidium iodine (PI), and TUNEL staining 
following exposure to VZV. The loss of cell membrane integrity permits the binding of 
phosphatidylserine (PS) residues to annexin V and is as a hallmark of both apoptosis and 
necrosis (537). These forms of cell death are indistinguishable, and even with the use of a 
discriminating marker, such as PI or TUNEL staining, these markers are unable to 
conclusively demonstrate the induction of apoptosis in these cells. Furthermore, this study 
did not examine these markers in combination, opting to assay them independently, and 
did not specifically identify VZV antigen in cells undergoing PCD (39). As such, it is difficult 
to associate VZV infection of monocytes with an increase in apoptosis-specific PCD. The 
combinatory detection of annexin V and TUNEL or PI staining can however represent early 
and late stages of programmed cell death, although more specific techniques are able to 
detect apoptosis-specific PCD via the detection of cleaved caspase-3 (CC3) (142, 538). 
The method utilised in this current study identifies the early and late stages of  
apoptosis-specific cell death, while also identifying the proportion of non-viable cells that 
are undergoing non-apoptotic forms of cell death, such as necrosis and pyroptosis  
(539-541). In conjunction with VZV gE:gI staining, the detection of cleaved caspase-3 in 
combination with cell viability permits the direct assessment of cellular viability following 
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VZV infection of monocytes. Through this analysis, it was determined that monocytes  
co-cultured with HFF remained viable longer than those cultured in the absence of HFF  
(Figure 5.4).  
It has been shown that classical circulatory monocytes undergo spontaneous apoptosis 
and have a lifespan in circulation of approximately 1.6 days (348). Therefore, interactions 
between HFF and monocytes are likely to provide a source for cell survival in vitro. Indeed, 
monocyte viability may be sustained through CD11b-mediated interactions with  
extra-cellular matrix (ECM) components such as fibrinogen (519) or through transforming 
growth factor α (TGF-α) engagement of the epidermal growth factor receptor (EGFR) (542). 
Gene expression profiles of HFF used as feeder cells for hESC differentiation report  
highly-expressed transcripts of fibrinogen, and other ECM components sulfatase-1 and 
collagen α-1, as well as high expression of growth factors include TGF-α (543, 544). 
Therefore, contact between HFF-derived fibrinogen or TGF-α and monocyte CD11b or 
EGFR respectively may influence how monocyte viability was supported in our infection 
system. As discussed previously, VZV infected monocytes exhibited reduced CD11b 
expression at 48 hpi (Figure 4.2), although expression of the CD11b:CD18 complex, CR3, 
was not directly examined. Assessment of CR3 would therefore provide greater insight into 
the potential impact of VZV infection on the activity of this complex (494). Furthermore, it 
is difficult to attribute the perceived increased in VZV infected apoptotic monocytes at 24 
and 48 hpi directly to the loss of CD11b (Figure 5.4), although, the lytic nature of VZV 
infection is well-established and may account for this (41, 202). Alternatively, the supportive 
effects of HFF co-culture could conceivably be lessened by VZV-mediated apoptosis of 
the infecting HFF inoculum in these co-cultures (6). Additionally, mock and VZV infected 
monocytes from HFF co-cultures underwent STS-induced caspase-3-mediated apoptosis 
(Figure 5.5), suggesting that interactions between monocytes and HFF merely stabilise, but 
do not irrevocably halt, PCD in monocytes.  
Unexpectedly, a significant reduction in VZV infected monocyte viability during  
M-CSF-mediated differentiation was observed (Figure 5.1). VZV infection of human 
monocytes was also demonstrated to significantly downregulate the expression of M-
CSFR and GM-CSFR (Figures 4.1 and 4.2), the receptors responsible for M-CSF- and GM-
CSF-mediated macrophage differentiation, respectively (466). As viability was impaired 
within three days of differentiation, it is difficult to directly attribute the inability of VZV 
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infected monocytes to generate viable macrophages to the impairment of M-CSFR 
expression alone. 
Due to the impaired viability of VZV infected monocytes, it also wasn’t possible to 
investigate the influence VZV infection has on GM-MΦ or MDDC differentiation. However, 
M-CSF is also a driver of cell survival and proliferation (475). The inability of VZV infected 
monocytes to maintain viability during M-CSF differentiation may be a result of impaired 
M-CSF signalling through the M-CSFR. In contrast, mock infected monocytes, and VZV 
exposed monocytes that exhibited an significant upregulation in M-CSFR (Figure 4.2), 
remained viable during differentiation with M-CSF. As M-MΦ were demonstrated to 
support productive VZV infection (Figures 3.12 and 3.13), the inability of VZV infected 
monocytes to generate viable macrophages is attributable to effects of VZV infection alone, 
and not the non-permissive nature of M-MΦ to VZV infection. Interestingly, M-CSFR 
expression is reduced in the presence of LPS, IL-2, and IL-4 (545), attributed to the actions 
of TNF-alpha-converting enzyme (TACE) resulting in M-CSFR shedding and release to cell 
supernatants (546). Further investigation could focus on the capacity for VZV to modulate 
TACE activity which may account for the loss of M-CSFR, although release of TNF was not 
observed during VZV infection of monocytes and no changes were observed during  
LPS-induced TNF release from these cells. Furthermore, the shedding of M-CSFR is 
detectable by ELISA (547) and examination of this in the supernatant from mock and VZV 
infected monocytes and macrophages would provide further insight into how VZV 
modulates M-CSFR expression, and any subsequent functional impact resulting from the 
loss of expression of this receptor. 
The widespread dissemination of HCMV is predicated on infection of myeloid cells, 
primarily transported throughout the host by monocytes and macrophages (352, 353). 
Latent infection of monocytes with HCMV results in temporal control of viability to induce 
macrophage differentiation (353), and unique phosphorylation of Akt by HCMV suppresses 
capase-3-mediated death (350, 351), mimicking that of M-CSF and GM-CSF mediated 
survival (479, 548). In contrast, VZV infection results in cell death of infected monocytes 
within 72 hours of infection (Figure 5.2) and would likely compromise their capacity to serve 
as precursors to MD-MΦ or MDDC VZV infection in the skin is characterised with an 
infiltration of pDCs and CD14+ monocytes, as observed in varicella lesions (227). Our results 
suggest that should monocytes migrate from the periphery to sites of active infection, 
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subsequent exposure to VZV would mediate VZV infection of these cells and subsequent 
impairment of differentiation may result.  
Although VZV infection was observed to impair the viability of monocytes in two 
independent experimental settings, VZV infected monocytes displayed a reduction in cells 
succumbing to STS-induced apoptosis explicated by a commensurate increase in viable 
VZV infected monocytes (Figure 5.5). Treatment with STS induces activation of the intrinsic 
apoptotic pathway through inhibition of PKC (523). However, although STS is routinely 
used to investigate apoptotic pathways previously (142, 549), ligand interactions with other 
receptors, such as the interactions of Fas and FasL, are also capable of initiating intrinsic 
apoptosis and cleavage of caspase-3 (550, 551). As such, it is not definitive that VZV 
infection is capable of protecting human monocytes for all initiators of apoptosis, yet the 
results in this current study demonstrate that VZV infection confers protection from intrinsic 
apoptosis when driven through STS-induced pathways. 
VZV-specific resistance to apoptosis is also observed in primary human sensory neurons 
in vitro following nerve growth factor withdrawal, and in human neuronal and keratinocyte 
cell lines following STS-treatment, which has been attributed to the actions of VZV ORF63 
(6, 142, 143). Investigation of ORF63 in the context of monocyte infection, akin to the 
lentiviral-mediated ORF63 expression studies in keratinocytes, may provide further 
elucidation of this protective mechanism in human monocytes (142). Furthermore, the 
induction of non-apoptotic cell death by VZV infection observed in the absence of  
STS-induced apoptosis may encompass other forms of programmed cell death, such as 
pyroptosis. Relatedly, VZV infected THP-1 cells were previously observed to develop an 
NLRP3-associated IL-1β-processing inflammasome in vitro, a process that intersects with 
pyroptotic cell death (249, 522). In contrast, our results in primary human monocytes did 
not corroborate this release of IL-1β, or IL-18, during VZV infection alone (Figure 5.10, Table 
5.1). Additionally, following stimulation with NLRP3 inflammasome-inducing agents LPS 
and Ngn, VZV infection of monocytes resulted in impaired release of IL-1β and IL-18 (Figure 
5.10, Table 5.1). IL-18 is constitutively produced in monocytes and upregulation of IL-18 is 
therefore LPS-independent (535, 536). Assessment of IL-18 secretion allows for the 
evaluation of fluctuating efficiencies in LPS stimulation and subsequent variation in IL-1β 
concentrations. However, release of IL-18 following Ngn stimulation alone was not 
observed, suggesting that although transcription of IL-18 is LPS-independent, secretion is 
still mediated by proteins reliant on an LPS priming event.  
Cytokine Marker
24 hpi <5 pg/mL <5 pg/mL <5 pg/mL <5 pg/mL <5 pg/mL <5 pg/mL <5 pg/mL <5 pg/mL
NT <5 pg/mL <5 pg/mL <5 pg/mL <5 pg/mL
LPS 1967 pg/mL 2883 pg/mL <5 pg/mL <5 pg/mL
24 hpi <1 pg/mL <1 pg/mL <1 pg/mL <1 pg/mL
NT 3.8 pg/mL 5.5 pg/mL <1 pg/mL <1 pg/mL
LPS 10.1 pg/mL 4.7 pg/mL <1 pg/mL <1 pg/mL
LPS + Ngn 2391 pg/mL 418 pg/mL <1 pg/mL <1 pg/mL
24 hpi <6.25 pg/mL <6.25 pg/mL <6.25 pg/mL <6.25 pg/mL
NT <6.25 pg/mL <6.25 pg/mL <6.25 pg/mL <6.25 pg/mL
LPS <6.25 pg/mL <6.25 pg/mL <6.25 pg/mL <6.25 pg/mL
LPS + Ngn 3048 pg/mL 868 pg/mL <6.25 pg/mL <6.25 pg/mL
VZVMockVZVMock VZV Mock VZV Mock
Monocytes HFF M-MΦ GM-MΦ
TNF-α
– – – –
– – – –
– – – –
IL-1β – – – –
– – – –
– – – –
IL-18 – – – –
–
– – – –
– – –
– – – –
Table 5.1 – Cytokine release from treated and untreated, mock and VZV infected monocytes, M-MΦ, and GM-MΦ 
Detectable concentration specified
Concentration below analytical sensitivity
Not assessed–
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This is further established by studies demonstrating the release of IL-18 facilitated, in part, 
by the LPS-dependent transcription of pro-caspase-1 (552). Similarly, the release of IL-1β 
or IL-18 following stimulation with LPS or Ngn independently was not observed. Individual 
stimulation with LPS or Ngn has previously been sufficient to induce IL-1β and IL-18 
secretion from monocytes, although treatment was undertaken at higher concentrations 
and for longer time periods than those undertaken in our study (534, 553, 554).  
The release of IL-1β and IL-18 was impaired in VZV infected monocytes and as such in the 
future we will address which stage/s of inflammasome formation VZV is able to modulate. 
MD-MΦ were not further examined in these experiments, as stimulation with LPS induces 
further differentiation of these cells into polarised MΦ subsets, assessment of which is 
outside the scope of this study (discussed in Chapter 3). This area of research is 
complicated by the multifaceted mechanisms regulating inflammasome formation, as basal 
expression of inflammasome proteins pro-IL-1β and pro-caspase-1 fluctuate between cell 
types (534, 555) and the mechanism for inflammatory cytokine secretion is incompletely 
understood (556, 557). As both IL-1β and IL-18 are leaderless proteins, the secretion is 
likely to intersect with cell death pathways given the inflammatory nature of the signalling 
mediators involved (558-560).  
Recently it was determined that cytokine secretion from NLRP3 inflammasomes can be 
mediated by activation of gasdermin-D, resulting in pyroptotic cell death and release of  
IL-1β and IL-18 (561). Should this be the case, this process would release both processed 
and full-length pro-forms of IL-1β and IL-18 to cell supernatants following pyroptotic cell 
death. Furthermore, uncertainty surrounds the specificity of commercially available ELISA 
kits to accurately discriminate between full-length pro-IL-1β and cleaved IL-1β (562, 563). 
As such, analysis for the release of IL-1β and IL-18 may not be sufficient in demonstrating 
a deficiency in caspase-1 mediated processing of either cytokine, but rather, provide 
insight into whether total proteins levels (i.e. pro-forms and cleaved forms) are ultimately 
affected (564). Further investigations into this could focus on identification of cleaved IL-1β 
in supernatants or secretory cleaved caspase-1 by western blotting. 
Our results have highlighted that VZV infection can lead to the selective downregulation of 
CD14, an LPS co-receptor, which was predicted to affect CD14-mediated signalling 
(Figures 4.1 and 4.2, discussed in Chapter 4.3). An association between CD14 and LPS 
binding has been previously established, although the concentration of LPS necessitating 
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CD14 co-receptor binding is unclear (498, 500, 501). Despite the observed impairment of 
LPS-dependent IL-1β and IL-18 secretion, there was no alteration in the concentration of 
LPS-dependent TNF secretion from VZV infected monocytes (Figure 5.9, Table 5.1). 
Therefore it is unlikely that CD14 modulation is directly responsible for the impairment of 
IL-1β and IL-18 release observed during VZV infection. Interestingly, KSHV ORF63 encodes 
a homolog of NLRP1 as a functional inhibitor, impairing caspase-1-mediated processing 
of IL-1β and IL-18, but not affecting TNF secretion (565). KSHV ORF63 does not share 
homology with VZV ORF63, and the only known functional homolog of this protein has 
been identified in rhesus macaque rhadinovirus (RRV) (565). Conserved functional 
homology is however observed between HSV-1 ICP0 and VZV IE61 (566).  
HSV-1 ICP0 has been associated with DNA sensing by NLRP3 and IFI16, resulting in 
formation and subsequent inhibition of an NLRP3 inflammasome within the first hours of 
infection (567-570). A similar role for VZV IE61 in recognition and evasion of DNA sensors 
has yet to be established, rather IE61-mediated inhibition of the NF-κB pathway is likely 
more influential. Sequestration of p50 and p65 and retention of IκBα has been 
demonstrated following VZV infection of epidermal cells (308), which was also observed by 
our own laboratory in VZV infected MDDCs (309). These actions would likely limit the 
capacity for NF-κB activatory ligands to license caspase-1 transcription during 
inflammasome signalling (571). Further investigation into the capacity for VZV infection to 
modulate the caspase-1-dependent processing of IL-1β and IL-18 could therefore focus 
on the regulation of pro-caspase-1 processing and subsequent cleavage of inflammatory 
cytokines by active caspase-1. Lastly, there remains the potential for VZV infection of 
monocytes to confer protection against inflammasome-associated pyroptotic cell death, 
analogous to the modest protection observed during STS-induced apoptosis of these cells. 
This would likely limit the release of both IL-1β and IL-18 following stimulation as these 
cytokines would be retained in viable VZV infected monocytes.  
It was observed that VZV infected and VZV exposed monocytes during M-CSF 
differentiation did not reflect the early macrophage phenotype exhibited by mock infected 
monocytes (Figure 5.2). Surface expression of CD11b and MR are upregulated during  
M-CSF differentiation (466, 519) and as such, VZV infection and exposure may impair the 
cumulative increase of M-CSF-induced CD11b and MR. However, VZV exposed 
monocytes demonstrated significant upregulation of M-CSFR (Figure 4.2). In addition,  
M-CSF differentiation in the presence of supernatants from mock VZV infected monocytes 
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progressed as expected (Figure 5.3) suggesting these effects were mediated by direct 
contact between monocytes and VZV infected cells. As a result, it is difficult to attribute the 
modulation of MR and CD11b to inefficient M-CSF signalling alone. Moreover, CD11b was 
significantly downregulated on VZV infected monocytes (Figure 4.2), and MR expression 
was significantly downregulated on VZV infected and VZV exposed M-MΦ (Figure 4.5). As 
these experiments did not rely on M-CSF for expression of MR and CD11b, this suggest 
that VZV infection modulates surface expression of these markers independent of M-CSFR 
ligand binding.  
Dextran endocytosis was significantly impaired following VZV infection and VZV exposure 
of monocytes and M-MΦ, suggesting that exposure to VZV infected cells is sufficient to 
mediate this impairment (Figures 5.6 and 5.7). Furthermore, both high-endocytic CD14+ 
and low-endocytic CD14– M-MΦ exhibited VZV-specific impairment (Figure 5.7) and CD14 
expression did not alter the proportion of VZV infected M-MΦ (Figure 3.12). Importantly, 
the low-endocytic capacity of GM-MΦ was not altered with VZV infection (Figure 5.8). To 
elucidate the mechanistic basis of high- and low-endocytic M-MΦ, it is important to 
consider the receptors facilitating Dx endocytosis, such as MR and CD163 (524, 572). 
Expression of MR is associated with pathogen recognition and is essential for phagocytosis 
(505). There exists a broad ligand specificity for MR, and engagement with the receptor 
elicits individual responses unique to the binding ligand (573). Specificity of MR for dextran 
was first demonstrated by inhibition of antigen capture following the addition of mannan 
(524). Further understanding of this pathway demonstrated uptake of antigen by MR leads 
to incorporation of antigen into MHC class I-expressing early endosomes (574, 575), 
whereas, uptake of antigen via scavenger receptors, such as CD163, results in presentation 
of antigen in the context of MHC class II (576, 577). Interestingly, in this current study 
endocytosis by M-MΦ was heterogeneous and delineated by expression of CD14 (Figure 
5.7). CD14 involvement has yet to be reported in dextran endocytosis and in this current 
study, CD14 is likely a surrogate representation of the heterogenous in vitro M-MΦ 
populations. Expression of MR and CD163 was significantly altered on the surface of VZV 
infected M-MΦ, although these analyses did not specifically separate this population on 
the basis of CD14 expression. 
Other markers expressed on this highly-endocytic subset and not on GM-MΦ, such as  
DC-SIGN or CD163, may facilitate internalisation of Dx (572). Freshly isolated monocytes 
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do not readily express MR (Figure 3.11) although previous reports have demonstrated the 
upregulation of MR and endocytic functioning within 12-24 hours culture in vitro (227, 525). 
Furthermore, dextran-endocytosis has previously been used to evaluate the antigen uptake 
capabilities of HCMV-exposed monocytes in vitro (518). MR and CD163 expression were 
not directly examined on cultured monocytes, however, GM-MΦ retained expression of MR 
and CD163 and the capacity to efficiently endocytose dextran (Figure 5.8). These results 
suggest that VZV impairs the surface binding of dextran to either MR or CD163. As this 
result was exhibited by both VZV infected and VZV exposed monocytes and M-MΦ, direct 
exposure to virally infected cells may potentiate the loss of these receptors, or in fact 
mediate competitive binding. Indeed, VZV glycoproteins gE, gH, gB, and gI possess 
complex N-linked oligosaccharides containing mannose-6-phosphate residues (127). 
These residues have been hypothesised to mediate VZV entry into cells through  
mannose-6-phopsphate receptors (127, 129, 578). Interestingly, this area of research also 
suggests that VZV infection modulates endosomal transport involved in both viral entry and 
egress (193, 442, 579). This presents another avenue through which VZV may modulate 
endocytosis, via manipulation of internal shuttling of antigen through endosomes. However, 
as mentioned previously, further investigation into antigen presentation to CD4+ and CD8+ 
T cells is complicated by their susceptibility to VZV infection (23, 34, 40). 
5.4. Conclusion 
The functioning of monocytes and macrophages is essential for immune recognition and 
resolution of infection. As an integral arm of the innate immune system, these cells are able 
to infiltrate sites of infection, mediate recruitment of adaptive immune cells, and provide 
inflammatory and haemostatic balance to these sites. In the context of viral infection, both 
monocytes and macrophages are prime targets of herpesvirus infection, and are utilised 
by these viruses to disseminate throughout the body, whilst also subverting their functions 
to evade the immune response (Section 1.4.4). The results presented in this chapter 
interrogate a number of monocyte functions, many of which are targeted by VZV infection 
and exposure. Most strikingly, the inability of VZV infected monocytes to generate viable 
macrophages highlights the potential impact of VZV infection on monocyte-derived cells, 
including MD-MΦ and MDDC. Furthermore, monocyte and macrophage antigen uptake 
and presentation, inflammatory cytokine production, and responses to pathogenic stimuli, 
were demonstrably impaired. The susceptibility of monocytes and macrophages to VZV 
infection was previously underdeveloped in comparison to our understanding of VZV 
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tropism for T cells. It is therefore unsurprising that these novel methods for immunoevasion 
have previously gone unrecognised. 
  
Chapter Six
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6. General Discussion 
6.1. Introductory Statement. 
Primary infection with VZV involves widespread dissemination of the virus throughout the 
host and results in lifelong infection through the establishment of latency in sensory 
neurons of the DRG (4, 51). The extensive distribution of VZV within the host is predicated 
upon the susceptibility of immune cells in circulation (3, 7, 41). Following exposure to VZV 
but prior to the onset of VZV disease, an asymptomatic incubation period of 2-3 weeks is 
presumed to be largely due to the extensive subversion of host defences by VZV (41). It is 
well established that VZV is able to evade immune recognition and disarm the host 
response to infection (Section 1.4.3). There are limitations to exploring these immune 
modulatory effects of VZV, as infection is restricted to cells of human origin, and VZV 
remains highly cell-associated in vitro (2, 135). Furthermore, there are currently no small 
animal models or in vitro models that recapitulate all stages of VZV infection (19, 580). 
Humanised murine models of infection, such as the SCIDhu model, have been developed 
and have provided valuable insight into the pathogenesis of VZV (21-27). SVV infection of 
non-human primates, which causes a varicella-like disease, has similarly been used to 
model VZV infection in vivo (581, 582). However, these models fail to encompass all aspects 
of the immune response to VZV, as it is not currently possible to reconstitute the entire 
human immune system in these models. In the current study, we examined the 
susceptibility of human monocytes and macrophages to VZV infection in vitro to better 
understand the impact VZV has on these immune cells during infection in vivo. As such, 
the following discussion will explore the implications of our findings in the context of current 
literature, with specific reference to clinically relevant areas of VZV disease, including 
circulation, the skin, and the DRG. 
In the first results chapter we explored the susceptibility of primary human monocytes and 
monocyte-derived macrophages to VZV infection (Chapter Three). This work demonstrated 
the productive infection of these cells with VZV and provided the most comprehensive 
characterisation of VZV infection of myeloid cells to date. Additionally, we provided the first 
evidence that VZV infected monocytes are capable of transmitting infectious virus to 
permissive HFF, suggesting a role for monocytes in dissemination of VZV.  
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The second results chapter examined the phenotype of VZV infected and VZV exposed 
monocytes and macrophages (Chapter Four). These results highlighted the alteration of 
monocyte immune molecules during VZV infection, and the disparate regulation of immune 
molecules when comparing VZV infected M-MΦ to VZV infected GM-MΦ. This 
characterisation of monocytes and macrophages following VZV infection and VZV 
exposure also demonstrated previously unrecognised alteration of key immune molecules, 
including M-CSFR, GM-CSFR, CD14, MR, and HLA-DR. As the altered cell-surface 
immune profile of these cells may be associated with potentially related functional 
modulations, this work provided a framework for subsequent investigation into monocyte 
and macrophage functioning during VZV infection.  
The third results chapter sought to investigate the functional capacity of human monocytes 
and macrophages following VZV infection and demonstrated the broad disabling power of 
direct productive VZV infection as well as exposure to VZV (Chapter Five). This work 
provided evidence that VZV infection of human monocytes dysregulates cellular viability 
such that VZV infected monocytes are unable to generate viable macrophages. Moreover, 
we identify two previously unrecognised immunomodulatory influences of VZV infection, 
specifically, the impairment of human monocytes and macrophages to undertake 
endocytosis, and an impairment in release of inflammatory cytokines from VZV infected 
monocytes. These results encompass a subset of immune functions that VZV subverts and 
provides a basis for how VZV infection of this integral immune subset may influence both 
the innate and adaptive immune response to VZV infection and VZV pathogenesis. 
6.2. VZV Infection of Human Monocytes and Macrophages. 
This current investigation is the first comprehensive study to examine the susceptibility of 
human monocytes to VZV infection and is the first to date to demonstrate productive 
infection of primary human monocytes and M-CSF- and GM-CSF-derived macrophages. 
Earlier reports of monocytes exposed to VZV in vitro described abortive infection in these 
cells, however, the extended culture of monocytes to macrophages resulted in replicative 
VZV infection (322, 323). These reports were further substantiated by reports of VZV 
infection of monocyte cell lines such as U937 cells following differentiation with PMA into 
macrophage-like cells (331). Furthermore, this current study extends these observations by 
demonstrating that monocyte-derived macrophages support productive VZV infection, 
with this current study utilising M-MΦ and GM-MΦ which are more broadly reflective of in 
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vivo macrophages and have not been previously demonstrated to support VZV infection. 
VZV infection of other immune cells, including T cells, B cells, MDDCs, and NKT cells, is 
surprisingly limited, with generally less than 20% of cells becoming VZV antigen positive 
following infection in vitro (23, 34, 37, 40, 324). A notable exception however is VZV 
infection of peripheral blood NK cells, which currently are reported as the most permissive 
immune cell to VZV infection, with on average 45% of cells VZV antigen positive (range 17-
65%) (40). In comparison, the results from this current study demonstrate that monocytes 
and macrophages are more broadly susceptible to VZV infection than the majority other of 
permissive immune cells, with demonstrable VZV infection of an average of 25% of 
monocytes (range 7-57%), 49% of M-MΦ (range 16-71%), and 40% of GM-MΦ (range 13-
68%).  
VZV exposed monocytes and macrophages are poorly understood.  
By establishing the proportion of monocytes and macrophages that were permissive to 
productive VZV infection, a population of cells exposed to a VZV inoculum without 
detectable VZV gE:gI expression was identified by flow cytometry. VZV infection of 
monocytes in particular was associated with a consistent proportion of VZV gE:gI negative 
cells (Figure 3.2). As previously mentioned in Section 4.3, these “bystander” monocytes 
may represent cells that are abortively infected, undergoing early stages of infection, or 
truly uninfected. Abortive infection of monocytes is observed following exposure to HSV-1 
and is associated with an absence of viral replication and viral gene expression (325, 332). 
VZV exposed monocytes may therefore represent a proportion of cells unable to support 
complete VZV replication or gene expression. However, a more likely explanation is that at 
least a portion of these monocytes are undergoing early stages of VZV infection, as 
infection with cell-associated inoculums are often asynchronous (115). The impaired 
viability of VZV infected monocytes may account for the unchanging proportions of infected 
cells at each timepoint, in that, as late-stage infected monocytes succumb to programmed 
cell death (PCD), the dying population is replaced by monocytes progressing from earlier 
stages of infection to late stages of infection and thus replenishing the population. A third 
alternative does however remain, whereby a proportion of monocytes may be refractory to 
VZV infection. Although monocytes support EBV infection, those lacking CD21 as an entry 
receptor are not susceptible to infection (360, 361). There is currently no consensus 
regarding an entry receptor for VZV infection and previously described putative entry 
receptors are generally ubiquitously expressed, with the exception of neuron-associated 
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MAG (120, 127, 130). To broaden our understanding of these VZV antigen negative 
populations, synchronous infection with CF-VZV could be undertaken in combination with 
IFA analyses for IE, E, and L genes at each hour following inoculation. This may reveal the 
underlying mechanism(s) responsible for this potentially uninfected proportion of 
monocytes. A complicating factor in this approach is that low titres of CF-VZV may be 
insufficient in eliciting productive VZV infection, as previous CF-VZV infection of human 
monocytes was reported to be abortive (322, 323). Future investigation in this area would 
be better served by generating higher titre CF-VZV preparations to ensure adequate 
infection of exposed human monocytes.  
Modulation of cell-surface immune molecules by VZV. 
It was observed that VZV infection of monocytes and macrophages resulted in the 
modulation of several cell-surface immune molecules (Table 4.1). This modulation was 
primarily observed in the earliest timepoint tested (24 hpi), however, alteration of GM-
CSFR, CD11b, and HLA-DR on VZV infected monocytes, and alteration of CD163 and MR 
on M-MΦ, was only observed after 48 hpi. Although the implications of the selective 
downregulation of these markers by VZV has been previously discussed (Section 4.3), the 
mechanism regulating this process has not yet been examined. Human herpesviruses 
initiate viral protein synthesis through a tightly regulated and sequential cascade of viral 
gene expression (115, 583). Therefore, the potential for VZV to subvert the immune system 
through selective impairment of key cell-surface immune may occur at any stage during 
this temporal expression of viral genes. To this end, there are multiple approaches that may 
be implemented to better understand VZV encoded mechanisms regulating the expression 
of cell-surface molecules.  
Although this current study utilised a cell-associated method of VZV infection, UV-
inactivation of VZV infected cells efficiently inhibits active VZV replication in target cells and 
any alteration of target cells is thus attributable to viral binding, entry, or to the actions of 
VZV tegument proteins (584). This UV-inactivation method has previously been used to 
demonstrate that increased IL-6 release from VZV infected human fetal skin is a result of 
de novo VZV gene expression (585). In combination with the model of infection in this 
current study, UV-inactivated VZV could be utilised to establish whether the selective 
downregulation of immune molecules on monocytes and macrophages is due to de novo 
VZV gene expression.  
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Alternatively, previous work has demonstrated the temporal expression of individual VZV 
IE, E, and L gene products on an hour-to-hour basis following infection (115). To provide 
insight into which VZV gene product(s) may be targeting the immune molecules changed 
at 24 hpi, earlier timepoints prior to 24 hpi could be examined to associate this modulation 
with the VZV kinetic class of genes expressed at these times. Additionally, the importance 
of VZV IE, E, and L gene expression could be further investigated by treating VZV infected 
cells with inhibitors, such as phosphonoacetic acid (PAA). PAA inhibits viral DNA synthesis 
and subsequent L viral gene expression (586). PAA has been previously used to 
demonstrate the activation of the JNK signalling pathway during early stages of VZV 
infection (587) and that L gene products do not mediate downregulation of cell-surface 
MHC class I on VZV infected HFF (156). 
Finally, if a potential VZV gene candidate is determined, altered expression and 
experimental mutation of these viral protein candidates may implicate them in regulating 
these host cell immune molecules. For example, lentiviral transduction of VZV ORF63 into 
keratinocytes demonstrated the activity of this viral protein in regulating apoptosis (142), 
whereas, full and partial deletions of VZV ORF54 highlighted the requirement for ORF54 in 
viral DNA packaging (588). Furthermore, these techniques have been extensively used 
recently to identify candidate genes regulating the interactions between HSV-1 infected 
cells and NK cells (589). 
Elucidation of the mechanisms of these viral proteins in modulating impairment of cell-
surface immune molecule expression similarly involves multiple approaches. In identifying 
the mechanisms of MHC class I downregulation following VZV infection, IFA was 
undertaken to demonstrate retention of MHC class I proteins in the golgi compartment of 
VZV infected cells (156). Analysis of host cell proteins at the transcriptional and protein 
levels have revealed the impairment of IFN-γ mediated MHC class II upregulation as a result 
of altered IRF-1 transcription and impaired JAK/STAT protein expression (263). 
Furthermore, IFA analysis similarly revealed the stabilisation of IκBα and sequestration of 
p50 and p65 in the cytoplasm of infected cells impaired NF-κB signalling (308, 309). 
Therefore, a combination of IFA for localisation of immune molecules and associated 
regulatory proteins, in combination with qRT-PCR to determine transcriptional regulation 
of these proteins, could be used to further examine the mechanisms regulating host 
immune molecules during VZV infection of monocytes and macrophages.  
  181 
Modulation of host cytokines and chemokines by VZV. 
In combination with the modulation of cell-surface immune molecules, it was also observed 
that VZV infected monocytes exhibited impaired release of IL-1β and IL-18 (Table 5.1). 
There are multiple pathways through which herpesvirus modulate host cytokines and 
chemokines (590, 591). Human gammaherpesviruses encode a number of viral homologs 
of host cytokines, as well as decoy receptors designed to antagonise host cytokine 
receptor binding (592-594). Moreover, these viral proteins function to block the activity of 
host cytokines, demonstrated by HCMV UL111A which encodes viral homologs of human 
IL-10 that block the release of TNF, IL-1β, and IL-6 (595-597). To date, there are no known 
viral homologs of host cytokines encoded by VZV, however, HSV-1, HSV-2, and VZV 
encode a viral chemokine binding protein (vCKBP) through expression of highly-conserved 
gC, that is able to bind 27 independent chemokines (598). VZV gC is unique in its ability to 
actively enhance the chemotactic ability of its cognate chemokines. In future studies, it 
would be of interest to examine the capacity of VZV infected monocytes to migrate across 
chemokine gradients, however this may prove technically challenging due to the complexity 
of accurately representing the vascular endothelial barrier in vitro (599) and the 
susceptibility of vascular endothelial cells to herpesvirus infection (296, 600, 601). However, 
multiple ligands for key chemokine receptors regulating circulatory and inflammatory 
monocytes are bound by VZV gC with nanomolar affinities (598). These include CCL19 and 
CCL21 as ligands for the lymph node homing receptor CCR7 (602, 603) and CCL5 as a 
ligand for CCR5 which is involved in inflammatory monocyte infiltration (508, 604). The 
activity of VZV gC may therefore regulate the migratory capacity of human monocytes in 
vivo. The analyses of monocytes following VZV infection undertaken in this current study 
did not directly examine the expression of monocyte chemokine receptors by flow 
cytometry. However, recent methods such as single cell mass cytometry have made it 
possible to establish deep profiles of surface and intracellular immune markers and have 
been used to document the phenotypic and functional changes of VZV infected T cells 
(470, 605). This approach, combined with the model of VZV infection of monocytes and 
macrophages used in this current study would permit a deeper investigation of the capacity 
for VZV infection to remodel the phenotype of the myeloid lineage.  
Relatedly, VZV infection may impact upon the signalling cascades required for generation 
and release of inflammatory cytokines as evidenced by the impaired release of 
inflammasome-associated IL-1β and IL-18 (Table 5.1). There appear to be multiple 
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independent and overlapping pathways regulating LPS binding and TLR4 signalling, each 
involving the activation of NF-κB, JAK/STAT, and mitogen-activated protein kinase family 
(MAPK) signalling cascades, or a combination thereof (606-609). Indeed, transcription of 
caspase-1 and LPS-induced IL-1β involves NF-κB activation (610, 611), although IL-1β 
transcription is also mediated by JAK/STAT signalling, as is the release of TNF (606, 612). 
Subversion of the immune response by VZV has been demonstrated to involve the 
sequestration of NF-κB subunits to impair NF-κB signalling in epidermal cells (308) and this 
mechanism of immune modulation has been recapitulated in MDDCs (309). As such, VZV 
infection of human monocytes may similarly inhibit NF-κB functioning, contributing to the 
impaired release of NF-κB-dependent caspase-1 processing and/or IL-1β secretion. 
Analysis of caspase-1 and IL-1β transcription, as well as analysis into processing of the 
pro-forms of these proteins following VZV infection of monocytes would be worthwhile 
avenues to explore. In addition, examination of NF-κB subunits and signalling together with 
the above mentioned experiments would be required to elucidate the mechanisms of this 
modulation, and the potential influence of altered NF-κB signalling.  
Furthermore, VZV and SVV encode multiple viral proteins which function to block 
JAK/STAT signalling and the upregulation of interferon stimulated genes (ISGs) (613). The 
broad inhibitory effects of VZV infection on these signalling cascades highlights the 
complexity in establishing a direct mechanism of VZV-mediated inhibition of IL-1β and IL-
18. It was demonstrated that VZV infection of monocytes substantially downmodulates 
expression of cell-surface CD14 (Table 4.1), which is a known co-receptor of NF-κB-
activating LPS (498, 500, 501, 614). TNF release from VZV infected monocytes was 
however unchanged following LPS stimulation (Figure 5.9), suggesting that it is unlikely that 
CD14 modulation is directly responsible for this result. However, LPS might regulate the 
induction of these cytokines through alternate, independent pathways. The induction 
process may be dependent upon the source of LPS, as bacterial strains generate a diverse 
range of LPS with different physiochemical properties, as well as the concentration of LPS 
used and the kinetics of stimulation (615). Future studies may include a more extensive 
timecourse examining the effects of multiple concentrations of LPS to induce inflammatory 
cytokine release from VZV infected monocytes and macrophages. Additionally, release of 
LPS-induced IL-6 is inhibited by suppressor of cytokine signalling 1 (SOCS1) through 
dysregulation of the JAK/STAT pathway, whereas TNF release is not affected by SOCS1 
(616). Interestingly, SOCS1 is upregulated following VZV infection of MRC-5 cells but not 
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THP-1 cells (617). The capacity for SOCS1 expression to mediate the inhibition of IL-1β 
and IL-18 release could be directly examined further in primary human monocytes, as could 
the capacity for VZV to modulate other effector proteins involved with inflammasome 
pathways, such as caspase-1 (534). In summation, VZV infection induces cell-type specific 
responses to many signalling cascades at multiple independent levels, and it remains to be 
determined how VZV manipulates these pathways within infected monocytes and 
macrophages.  
6.3. Infection of Myeloid Cells May Influence VZV Pathogenesis. 
Monocytes and macrophages in the circulation and the skin.  
The immune response to VZV infection involves the activation and infiltration of a range of 
immune cells to sites of infection, namely the skin and the DRG (618) (Section 1.4) (Figure 
6.1A). Previous work from the Abendroth laboratory identified the presence of pDC and 
Langerhans cells (LC) in VZV infected skin, many of which were observed to be VZV 
infected (228). This site of infection was also characterised by the loss of LC and an influx 
of pDC. The loss of LC was attributed to either the loss of CD1a on LC retained in the skin, 
cell death of LC, or, migration of LC out of the skin (228). Interestingly, biopsies taken of 
VZV skin lesions have also identified the presence of CD14+ cells and CD68+ cells presumed 
to represent monocytes and macrophages, respectively (227, 296, 618). Results from this 
current study demonstrated that VZV infection of monocytes did not permit the generation 
of viable macrophages, which was attributed to virus-induced cell death and not to an 
inherent resistance to differentiation (Figures 5.1, 5.2 and 5.4). As such, it is possible that 
differentiation of VZV infected monocytes to MDDC could be similarly compromised. 
Therefore, in sites of VZV infection where infiltrating monocytes are observed, VZV infection 
and subsequent cell-death would contribute to the absence of site-specific MD-MΦ and 
DCs as infected monocytes would be precluded from replenishing these populations 
(Figure 6.1B). Previous studies from the Abendroth laboratory revealed multiple unidentified 
immune cells that were VZV antigen positive in biopsies from VZV skin lesions (J. Huch, 
personal communication). It would be of interest to further examine these skin biopsies for 
the presence of monocytes and macrophages, and whether or not VZV infection of 
monocytes and macrophages occurs in clinically important sites of infection in vivo.  
The capacity of VZV infection to induce migration of leukocytes is demonstrated, in part, 
by the skin-homing profile of T cells following VZV exposure (7, 470, 605).  
Skin
Blood
Figure 6.1: Monocytes and dendritic cells in the skin during VZV infection. (A) The immune 
cells present within the skin is largely comprised of site-specific DCs, termed Langerhans cells 
(LCs). Circulating monocytes are able to enter this site and generate monocyte-derived DCs to 
replenish this population. (B) Skin biopsies from patients with varicella have demonstrated the 
influx of plasmacytoid DCs (pDCs) and CD14+ monocytes to the skin, accompanied with the loss 
of local LC populations. Both pDCs and LCs are susceptible to VZV infection, as are circulating 
monocytes. Monocytes in circulation, including VZV infected monocytes, will migrate to the skin. 
This may aid in viral dissemination to the skin, and may account for the absence of site-specific 
DCs, as VZV infected monocytes are unable to generate viable differentiated cells.
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Furthermore, VZV gC is a unique vCKBP with homology to monocyte chemokine receptors 
CCR5 and CCR7, and is suggested to intercept and boost host chemokine activity to 
enhance immune cell migration (598). Interestingly, gC-deficient strains of VZV displayed 
reduced replication in the skin, supporting a role for VZV gC to enhance infectivity, although 
the mechanisms of this are not well understood (24). Relatedly, exposure of human 
monocytes to HCMV also results in enhanced survival and migration of monocytes to 
facilitate viral dissemination (334, 352, 440, 619). Given the relationship between immune 
cell infection and the induction of migration, there remains the potential for VZV infection 
of human monocytes and macrophages to encompass a similar strategy to enhance viral 
spread through the host. Thus it would be of interest in future studies to assess chemokine 
receptor expression on VZV infected human monocytes and establish using chemotaxis 
transwells assays whether these cells have the potential to migrate towards chemokines, 
such as CCL2, CCL5, and/or CCL7.  
Of note, VZV infected monocytes were demonstrated to support transfer of infectious virus 
to permissive HFF (Figure 3.8). Therefore, it remains a possibility that VZV infected 
monocytes may disseminate virus to other immune cells by direct contact in circulation. In 
support of this, future studies into the capacity for VZV infected monocytes to transfer 
infectious VZV to constituent populations of PBMC would provide evidence for this 
possibility. Furthermore, as monocytes are observed to infiltrate into the skin during primary 
varicella (227), there remains an opportunity for infiltrating monocytes to enter the skin prior 
to VZV infection, and subsequently become infected at this site. As such, the capacity for 
newly-entered monocytes in the skin to replenish monocyte-derived cells, such as MD-MΦ 
and MDDC, as well as provide supportive immune responses may be impaired during 
varicella and herpes zoster (Figure 6.1B). 
Monocytes and macrophages in the DRG. 
There is increasing evidence for the presence of macrophages in VZV infected DRG. 
Analysis of post-mortem ganglia from patients with active herpes zoster at time of death 
revealed an immune infiltrate comprising CD8+ T cells, CD4+ T cells, NK cells, and most 
predominantly, CD68+ macrophages (288) (M. Steain, personal communication). The 
enhanced expression of CXCL10 in these tissues was also suggested to contribute to the 
immune infiltrate during active VZV reactivation in vivo (286). Murine models of neuronal 
injury have also identified infiltrating macrophage populations in close contact with DRG 
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neurons, and supplementing the activity of the supporting satellite glial cells (SGCs) (620, 
621). These findings demonstrate the substantial migration of immune cells such as 
macrophages into the DRG during herpes zoster and as a response to neuronal 
inflammation. The permissive nature of infiltrating macrophages to VZV infection may 
therefore provide the means for viral dissemination during primary infection, or following 
reactivation to herpes zoster. Investigations into VZV dissemination have demonstrated a 
role for VZV infected T cells to transfer infectious virus to DRG in a SCIDhu model of 
infection (8). Similar experiments utilising monocytes and macrophages in place of T cells 
may provide insight into whether these cells are a source of viral dissemination to DRG in 
vivo. 
The association between macrophages and SGCs is important, as SGCs possess features 
of both macrophages and immature DCs (291). Neurons within the DRG are ensheathed in 
layers of SGCs that provide physical support, aid in degeneration and regeneration of 
axons, and mediate local immune responses (290-292) (Figure 6.2A). SGCs also possess 
features of conventional APCs, and high expression of monocyte and macrophage markers 
CD14, CD11b, CD68 and MHC class II (291). In the context of VZV, SGCs are demonstrated 
to potentially support productive infection. Electron microscopy of post-mortem ganglia 
from patients with herpes zoster at the time of death revealed VZV virion formation within 
SGCs (622). Furthermore, the Abendroth laboratory has previously shown VZV infection of 
intact human ganglia explants and the susceptibility of both neurons and SGCs to VZV 
infection in vitro (520). In addition, DRG xenografts in SCIDhu models demonstrated the 
susceptibility of SGCs to VZV infection in vivo (289, 623). In combination with the previously 
suggested role for VZV permissive macrophages to infiltrate the DRG to aid in viral 
dissemination, spread of VZV from macrophages to SGCs may contribute to the 
establishment of latent infection within the DRG (Figure 6.2B) 
Furthermore, SGCs are fundamental in maintaining the integrity of neuronal cell bodies by 
forming neuron-satellite complexes along the neuronal cell body (291), and VZV infection 
may therefore disrupt this activity. Indeed, analysis of post-mortem ganglia from herpes 
zoster patients demonstrated the breaching of this layer by T cells in response to 
reactivation (287) (Figure 6.2C). Therefore, the susceptibility of both macrophages and 
macrophage-like SGCs to VZV infection would likely influence their ability to control VZV 
infection in this clinically important site and may even pre-empt breaching of the SGC  
 
Figure 6.2: Macrophages and satellite glial cells in the DRG during VZV infection. 
(A) Sensory neurons within the DRG are connected by axonal processes to the periphery. These 
processes are comprised of bundles of axons containing connected neurons with each neuronal 
cell body ensheathed by satellite glial cells (SGCs). SGCs closely resemble cells of the myeloid 
lineage through expression of macrophage markers and the capacity to release inflammatory 
cytokines. (B) Both macrophages and SGCs are susceptible to VZV infection. During herpes 
zoster, CD68+ macrophages are also known to infiltrate into latently infected DRG. Primary VZV 
infection may therefore be characterised by transfer of VZV from permissive macrophages to 
SGCs and/or sensory neurons themselves. (C) Reactivation to herpes zoster is characterised 
by infiltration of T cells to latently infected DRG, which breach the surrounding SGCs to directly 
contact neurons. VZV infection of SGCs may weaken the protective layer of cells and promote 
T cells breaching the SGC barrier. (D) Both macrophages and SCGs are permissive to VZV 
infection and are capable of secreting inflammatory cytokines. VZV infection may influence the 
release of TNF, IL-6, or IL-1β, and may play a role in neuropathic pain associated with herpes 
zoster and post-herpetic neuralgia (PHN).
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barrier through direct infection, allowing for enhanced contact between neurons and 
infiltrating immune cells (Figure 6.2C). Additionally, the macrophage endocytic pathways 
are impaired by VZV infection (Figure 5.7), and as such, investigation into the functional 
abilities of SGCs, antigen presentation in particular, as well as cell-surface immune 
molecule expression following VZV infection, should be undertaken to evaluate the full 
influence of VZV infection on these cells.  
Interestingly, although SGCs support productive VZV infection, post-mortem ganglia from 
individuals with a previous history of varicella revealed latent VZV in neurons but not SGCs 
(624). This may suggest that SGCs do not support latent VZV infection and activation of 
SGCs during VZV reactivation may result in an enhanced susceptibility to infection. SGC 
activation is mediated by a range of factors that further connect SGCs with cells of the 
myeloid lineage. For example, SGC activation with CCL2 facilitates the release of 
inflammatory cytokines TNF, IL-6, and IL-1β (625-628). More specifically, HSV-1 infection 
of SGCs induces activation and release of IL-6, TNF, and upregulation of MHC class I and 
II (629-631). Relatedly, SVV infection of non-human primates induces SGC activation and 
increased expression of CD68 and MHC class II (631). Productive infection of SGC in vivo 
may therefore contribute to the subversion of host immune recognition as VZV is known to 
modulate both MHC class I and MHC class II on professional APCs (Section 1.4.3). 
Furthermore, it is likely that following reactivation of VZV, productively infected SGCs would 
undergo activation which may potentiate the release of inflammatory cytokines from these 
cells (Figure 6.2D). Interestingly, there was no release of TNF from VZV infected monocytes 
or macrophages, although release of IL-1β and IL-18 from VZV infected monocytes was 
impaired (Table 5.1). Further assessment of inflammatory cytokine release from 
macrophages and SGC during VZV infection would provide insight into how integral these 
populations are to controlling VZV reactivation in vivo, as well as potentially providing an 
underlying mechanism to the neuropathic pain associated with herpes zoster and PHN.  
Murine models of neuropathic pain have identified a similar influx of macrophages which 
have been associated with the development and maintenance of allodynia (632, 633). This 
work highlights the potential for macrophages to contribute to neuropathic pain associated 
with herpes zoster and PHN at the level of the DRG, in addition to the possible impact of 
macrophages on neuropathic pain in the periphery (discussed below). More recently, a self-
renewing population of cells within the DRG, termed DRG resident cycling cells (DRCCs), 
were identified and comprised predominantly of site-specific macrophages and SGCs 
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(634). Interestingly, local proliferation of these cells was inhibited following withdrawal of 
M-CSF. Previous results have demonstrated the selective downregulation of M-CSFR 
expression on VZV infected monocytes (Table 4.1), and failure to respond to M-CSF may 
have contributed to increased cell death during macrophage differentiation. Thus, there 
remains the potential for VZV infection of DRCCs to negatively impact this sustained self-
renewing population, and the immune responses necessary to control VZV infection.  
Association of monocytes and macrophages with neuropathic pain.  
VZV infection of the dermis is associated with exposure of peripheral sensory nerve 
terminals to VZV that is presumed to facilitate dissemination of VZV through direct infection 
of sensory neurons (197, 202, 301). Reactivation from latency to herpes zoster is associated 
with severe neuropathic pain, as is PHN in a significant number of patients, although the 
mechanisms of this neuralgia are poorly understood (635). The presence of monocytes and 
macrophages in the peripheral dermis may however influence neuropathic pain. 
Macrophage infiltration to sites of peripheral nerve injury is essential in maintaining nerve 
degeneration and repair (636, 637) and nerve damage rapidly induces the activity of trMΦ 
and mediates infiltration of monocytes to generate protective MD-MΦ (638, 639). The 
absence of effector macrophages and/or impaired recruitment of monocytes to sites of 
nerve injury would therefore be detrimental to regeneration of damaged nerves, and a 
potential mechanism for prolonged allodynia (637). The demonstration that monocytes and 
macrophages are susceptible to productive VZV infection, and that monocytes are 
precluded from generating viable macrophages, may limit the capabilities of infected 
myeloid cells to respond to injured nerves. Although this has not been directly examined, 
neuro-protective macrophages have previously been associated with an increase in 
expression of immune markers, including MHC class II, CD80, and CD86 (640). Although 
the modulation of HLA-DR was not observed on VZV infected MD-MΦ, VZV infection of 
LPS-matured MDDC was associated with significant downregulation of CD80 and CD86 
expression (37). Examination of immune molecules associated with neuronal protection 
following VZV infection of macrophages is a further avenue for exploration into the 
mechanisms underlying VZV-induced neuropathic pain. Additionally, this area of 
investigation would benefit from exploring the chemotactic response of VZV infected 
monocytes, as well as the capacity of monocytes and macrophages to migrate to clinically 
relevant sites of infection, such as the skin and DRG, in humanised SCIDhu models of VZV 
infection. 
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Alternatively, monocytes and macrophages in vivo may actually contribute to neuropathic 
pain. Previously, treatments of neuropathic pain have involved antagonism of monocyte 
chemokine signalling (641, 642). Targeting of CCL2, CCL7 and CCL8 with the small-
molecule bindarit has yielded favourable results in the alleviation of neuropathic pain in 
patients with infectious and non-infectious neuropathies (642-644). Direct inhibition of 
monocyte chemotaxis with CCR2 and CCR5 blocking agents has similarly reduced 
inflammatory pain in models of rodent neuropathy (641). Monocytes and macrophages are 
capable of releasing pro-nociceptive signals, such as IL-1β, TNF, IL-6, CCL2, and NGF, 
facilitating the recruitment of immune cells, including T cells and neutrophils (645-647). 
There was no detectable release of inflammatory cytokines following VZV infection of 
monocytes and macrophages (Table 5.1), soluble mediators of pain signalling were not 
examined. Further investigation into this area could examine the above neuropathic pain-
associated cytokine and chemokine release that could potentially influence neuralgia 
experienced in herpes zoster and PHN (598, 648). 
Additionally, investigation into conditions such as hemophagocytic lymphohistiocytosis 
(HLH) may provide a potential mechanism for the chronic inflammation experienced during 
PHN. HLH is characterised by exaggerated activation of T cells, NK cells, and macrophages 
and is most commonly triggered by herpesvirus infection, in particular, HSV-1, EBV, and 
HCMV (649-653). HLH, and similar conditions such as ‘drug reaction with eosinophilia and 
systemic symptoms’ (DRESS), are associated with chronic activation of these immune cells 
and sustained tissue infiltration which facilitates a persistently high release of inflammatory 
cytokines including IL-6, IL-18, and TNF (653, 654). Moreover, the mechanisms of HLH 
activation include direct infection of immune cells, alteration of host macrophage scavenger 
receptors, modulation of host cytokine and signalling pathways, and modulation of 
apoptosis (reviewed in 655). The susceptibility of macrophages to VZV infection, in 
combination with VZV infection of T cells and NK cells (23, 34, 40), may provide a potential 
mechanism for the underlying chronic inflammation contributing to neuropathic pain 
associated with herpes zoster and PHN.  
6.4. Concluding Statement 
VZV is ubiquitous in almost all communities, as are all members of the human herpesvirus 
family (2). Infection with VZV has been demonstrated to involve extensive modulation of the 
host immune system, including subversion of immune recognition and impairment of 
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immune cell responses (41). These capabilities are predicated upon the susceptibility of 
multiple immune cells to VZV infection. In comparison to the interactions of VZV within the 
adaptive immune system, we have a limited understanding of how VZV infects and 
modulates cells of the innate immune system. This current study represents the most in-
depth and comprehensive analysis to date of human monocytes and macrophages in the 
context of VZV, and describes the susceptibility of these cells to productive VZV infection. 
This study also uncovered multiple novel strategies employed by VZV to modulate 
monocytes and macrophages, the implications of which may provide insight into the 
pathogenesis of VZV. Monocytes and macrophages are represented in almost all tissues 
and are integral to the host response to infection (508). These cells are capable of potent 
inflammatory and anti-inflammatory responses that define the activation and suppression 
of a broad range of immune cells (402, 447, 507). The susceptibility of monocytes and 
macrophages to VZV infection therefore represents their control by the virus, and by 
extension, the control of immune cells responsive to them. Thus VZV is able to broadly and 
extensively subvert the immune system by shaping the host response and providing an 
environment suitable for the continued survival and persistence of VZV within the host. Our 
increased knowledge of these interactions allows for enhanced understanding of VZV 
pathogenesis, and understanding of herpesviruses as a whole, and leads to better informed 
decisions in regards to combatting disease.   
Chapter Seven
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